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CHAPTER I 
INTRODUCTION 

INTRODUCTION 
RNA tumor viruses constitute a group of widely spread 
animal viruses that share several important properties the 
most characteristic of which is the intimate relationship 
between their RNA genome and the chromosomal DNA of their 
hosts. There is no doubt that this relationship is the basis 
of their capacity to induce tumors. Although these facts were 
not understood before 1970, RNA tumor viruses have been im-
portant tools in the study of oncology practically during the 
whole course of the present century. Nevertheless, decades long, 
strains of leukemia and sarcoma virus of the chicken were the only 
known representatives of the group. They were initially dis-
covered in chicken tumors by Ellerman (1) and Rous (2). The 
next virus was mouse mammary tumor virus isolated by Bittner 
(3), followed by several murine leukemia virus strains isolated 
by Gross (4), Graffi (5), Friend (6), Rauscher (7) and Moloney 
(8). At present, it is well documented that different types of 
RNA tumor viruses can cause leukemias (tumors of hemopoietic 
origin), sarcomas (tumors of connective tissue) or carcinomas 
(tumors of epithelial origin) in susceptible host organisms. 
RNA tumor viruses bear their genetic information in a 
single-stranded RNA molecule, which upon infection is converted 
into a double-stranded circular DNA provirus by the RNA-de-
pendent DNA polymerase or reverse transcriptase, an enzyme com-
plexed with the viral RNA genome. In a next step, the circular 
proviral DNA is integrated in the host nuclear DNA. Subsequent 
transcription of these integrated sequences and translation of 
the newly synthesized virus-specific RNA give rise to the poly-
peptides encoded by the viral genome. The newly formed con-
stituents of the viron assemble at the plasma membrane in core 
particles, which bud through this membrane, thus acquiring a 
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lipid membrane (envelope) bearing cellular and virus-specific 
proteins. 
The study of the experimental model of tumor induction 
by RNA tumor viruses became more interesting when endogenous 
RNA tumor viruses became known. In contrast to the exogenous 
RNA tumor viruses, the endogenous viruses are integrated in 
the germ line of an animal. As a consequence, each cell of the 
animal contains the information for the endogenous virus in 
its chromosomes probably including gene(s) responsible for 
tumor induction. Not only have endogenous RNA tumor viruses 
been isolated from a number of well studied species, sensitive 
hybridization studies have also provided evidence for the 
presence of endogenous RNA tumor viruses in the germ line of 
a much wider variety of birds and mammals, including man (see 
the review by Aaronson and Stephenson (9, 10)). These data 
strengthen the oncogene theory of Huebner and Todaro (11) 
which proposes that in their DNA all cells would contain the 
information for the complete genome of an RNA tumor virus 
("virogene"), including an "oncogene" which is responsible for 
most tumors. The expression of these genes is thought to be 
controlled by cellular regulatory functions and escape from 
this control could lead to tumor growth and release of virus. 
On the other hand, Temin's protovirus hypothesis (12) assumes 
that RNA tumor viruses would have evolved by mutation and 
recombination from normal cellular genes that are involved 
in the transfer of information from DNA to RNA and back into 
DNA by reverse transcription. In the opinion of Temin, such 
undogmatic transfer of information could occur normally 
during cell differentiation. Although it is not possible at 
present to prove or reject either hypothesis, the frequent 
activation of complete viral genomes from normal cells favors 
the oncogene theory. On the other hand, the generation of 
murine sarcoma viruses by recombination of viral RNA and 
normal cellular RNA (see chapter II) indicates that certain 
processes hypothesized in Temin's theory could indeed be 
involved in the genesis of RNA tumor viruses. It should also 
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be noted that the oncogene hypothesis and the protovirus 
hypothesis are not completely mutually exclusive. 
The aim of the present work was to provide insight in 
the expression of the genome of Rauscher murine leukemia 
virus (R-MuLV). Therefore, we studied the synthesis of virus-
specific structural polypeptides in R-MuLV infected cells. 
We showed that the virus-specific internal and envelope 
polypeptides of R-MuLV are cleaved from separate precursor 
polypeptides, and we contributed to the elucidation of their 
processing schemes. Moreover, we identified two different 
virus-specific messengers (mRNAs) for these polypeptides in 
protein synthesizing systems. Part of oui investigations are 
a continuation of the studies published recently by Gielkens 
(13) and are parallel with studies on the translation of 
RNA from virions performed by Salden (14). For a better 
understanding of the experimental work presented here, a 
model for the gene expression of the structural polypeptides 
of R-MuLV is printed on the inside backcover of this thesis; 
in the next section, we will present ai· introduction to some 
important features of RNA tumor viruses and a preface 
to the papers. Moreover, we have added a separate survey 
on the murine sarcoma viruses (chapter II). There was much 
progress in that area lately but unlike the leukemia 
viruses the subject was not covered in recent reviews. We 
hope that the type of experiments described in this thesis 
for R-MuLV may soon be performed with sarcoma viruses as 
an approach towards a better understanding of their oncogenic 
potential. 
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THE STRUCTURE OF THE RNA TUMOR VIRUSES 
Electron microscopic studies of thin-sections of RNA 
tumor viruses have shown that these viruses possess an electron 
dense core situated eccentrically in type-B particles (mouse 
mammary tumor virus) or centrically in type-C particles 
(leukemia and sarcoma viruses) within a surrounding envelope 
with a unit membrane structure. Intracellularly, immature 
type-Α particles could be recognized in different stages of 
virion assembly (15). Nermut et al. (16) have studied the fine 
structure of murine leukemia viruses by freeze drying and 
freeze etching. Their observations indicated that the core 
surface of the virion consists of a regular pattern of subunits 
on the outside and a smooth membrane underlying these subunits. 
The internal component of the core, the nucleoid, is a fila­
mentous structure with helical symmetry, which probably con­
tains the viral RNA. The virion core is surrounded by a 
roughly spherical membrane covered with knobs, which are 
weakly bound to the membrane. The knobs are probably molecules 
of the envelope glycoproteins. 
The chemical composition of the RNA tumor viruses is as 
follows: 1% RNA, 60-70% protein, 20-30% lipid and 2% carbo­
hydrate (15). Some properties of the best studied components, 
the viral RNA and the viral proteins, will be discussed in the 
following sections. 
THE GENOME OF THE RNA TUMOR VIRUSES 
The genome of the RNA tumor viruses is a very character­
istic single-stranded RNA molecule, which sediments in neutral 
sucrose gradients at 60-70 S. This S-value was thought to 
correspond to a molecular weight of 10-12 χ 10 (15, 17-20). 
In addition to this high molecular weight RNA, several minor 
RNA species of smaller size (4-7S) can be isolated from 
virions. Denaturation of 60-70 S RNA by heat or dimethyIsulf-
oxide dissociates the high molecular weight RNA into 30-40 S 
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subunits and smaller RNA species (4-7 S). Until recently 
60-7 0 S viral RNA was thought to be a complex of three to four 
30-40 S subunits,linked together by hydrogen bonds. The associa­
tion of the subunits is thought to occur during and directly 
after the assemblage of the virion because it was observed by 
Cheung et al. (21) that RNA isolated from virions harvested 
every 5 minutes sedimented at 50-60 S with a shoulder at 30-40 
S, whereas virus harvested at hourly intervals contained 60-70 
5 RNA only. Additional results were obtained by Canaani (22), 
who showed that m rapid harvest virus the 30-40 S subunits 
were converted into 60-70 S RNA by incubation of the virus at 
40 . By means of Polyacrylamide gel electrophoresis in sodium 
dodecyl sulfate (SDS-PAGE), the molecular weight of the viral 
RNA subunits was estimated to be 3 χ 10 (19). This result is 
in keeping with electronmicroscopic length measurements (23-
25). For 60-70 S viral RNA, Delius et al. (24) reported a 
length corresponding to a molecular weight of approximately 
6 χ 10 dalton. Similar values were reported by Riggin et al. 
(26, 27) who analyzed the 60-70 S viral RNA of murine leukemia 
virus by Polyacrylamide gel electrophoresis and by equilibrium 
sedimentation at various ionic-strengths. The latter method 
yields estimates of the molecular weights that are independent 
of the conformation of the RNA. From these results, it was 
finally concluded that the 60-70 S viral RNA consists of two 
30-40 S subunits. Electron microscopic studies on partially 
denatured 60-70 S RNA whose S'ends were marked with SV40 DNA 
circles gave further insight in the structure of the viral 
genome (28-31). These experiments showed that the viral RNA 
of several RNA tumor viruses consists of two subunits joined 
together at their 5'ends in a configuration called the dimer 
linkage structure. Moreover, both monomers contained a loop 
structure close to the middle of each molecule. 
Although these studies have contributed to our knowledge 
of the viral RNA genome, they do not reveal its genetic com­
plexity. The genetic complexity of the viral genome would 
correspond with a 30-40 S subunit if the two subunits of the 
60-70 S RNA are identical (diploid genome) and with the com-
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píete 60-70 S RNA if the subunits are different (haploid 
genome). Studies on RNA-DNA hybridization kinetics indicated 
a complexity of 8-9 χ 10 dalton for the viral genome (32, 33) 
which favors a haploid genome. However, similar studies by 
Baluda et al. (34) revealed a complexity of 3 χ 10 dalton 
corresponding to a diploid genome. This latter result was con­
vincingly confirmed by the analysis of unique oligo-nucleotides 
produced after digestion of 60-70 S RNA by nbonuclease T. 
(35-37). The conclusion that the 60-70 S viral genome consists 
of two identical subunits of 3 χ 10 dalton implies that it 
can code for approximately 300,000 dalton of protein. Once 
this was established, Baltimore (38) tentatively proposed four 
genetic functions constituting most of the genome: gag for the 
precursor polypeptide of the ma-jor internal polypeptide p30 
(and other internal polypeptides), pol for the RNA-dependent 
DNA polymerase, env for the protein moiety of the envelope 
glycoprotein (and other envelope polypeptides) and one for 
cell transformation. He discussed these genetic functions as 
if they were genes. Later progress has justified this early 
simplification. The gene products of gag, pol and env are 
identified in all classes of the RNA tumor viruses. The one-
gene of the avian and murine sarcoma viruses is recognized 
by mutants (39, 40), whereas the one-gene of all other RNA 
tumor viruses should still be considered as hypothetical. 
The 30-40 S viral RNA subunits share several character­
istics with eukaryotic mRNAs: they possess a cap structure 
(7m G 5 ppp5 GmpCp) at their 5'end (41-43), a poly-A track of 
about 200 nucleotides at their 3'end (42, 44-49) and several 
methylated adenosines (42, 50). Partial sequence analysis 
showed that the first 25 nucleotides of the S'end do not con­
tain an AUG initiation codon (43). 
THE GENE-ORDER OF THE RNA TUMOR VIRUSES 
Relatively small but significant size differences (about 
10-25%) were observed m the molecular weight of the 30-40 S 
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subunits isolated from uncloned Rous sarcoma virus (RSV) (51). 
Two size classes with molecular weight of 2.9 χ 10 and 
2.2 χ 10 (based on Polyacrylamide gel electrophoresis in the 
presence of formamide) were distinguished and they were called 
a and b subunit, respectively (51, 52). Λ continuation of these 
studies showed that cloned RSV contained no b subunits, whereas 
transformation defective (td) RSV or uncloned avian leukosis 
virus (ALV) lacked a subunits (53, 54). These results indicated 
that the a subunit represents the genome of the non defective 
(nd) sarcoma virus and that the b subunit is derived from the 
defective virus, which is always present in uncloned RSV stocks. 
After high multiplicity passage with cloned RSV (i.e. with 
virions containing a subunits exclusively) the progeny virus 
again contains a and b subunits (54) (apparently some cells in 
the culture used to clone RSV produce virions with either a 
or b subunits, otherwise cloned RSV with subunits of one type 
could not have been obtained). When, however, cell cultures 
are made to produce RSV by transfection with integrated pro-
viral DNA from a cloned transformed cell-line (producing 
virions which contain type a subunits), no cultures producing 
td RSV (with b subunits) were obtained (55). The explanation 
is that type b subunits somehow may segregate from type a sub-
units at some stage between the penetration of the viral RNA 
and the transcription of the newly formed provirus (54, 55). 
Hybridization studies by Lai et al• (56) and by Neiman et al. 
(57) demonstrated that the genome of td RSV is almost com­
pletely homologous to the nd RSV genome except for a sequence 
of about 10-13% of the nd RSV genome, probably responsible for 
cell transformation. This observation was clearly confirmed 
and extended by the comparison of unique RNase Τ -oligonucleo­
tides obtained from 60-70 S RNA of nd RSV and td RSV (56, 58). 
The deleted sequence was identified by the absence of two 
spots m the RNase T.-oligonucleotide pattern of td RSV-RNA. 
The T.-oligonucleotides were mapped relative to the 3' poly(A) 
track of the 30-40 S subunit; in this physical map the sarcoma-
specific sequence (one- or sre-gene) lies between approximately 
700 and 2000 nucleotides from the 3'end (58, 59). Similar 
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studies on an RSV mutant defective for eην-functions and on 
recombinants of nd RSV with several ALV strains harboring 
markers for the env-, pol- and gag-gene elucidated the follow­
ing complete gene-order of the avian nd sarcoma virus genome 
(59-62): 
5'- gag- pol- env- one- poly(A)- 3' 
A small "heteropolymeric" region of unknown function was found 
adjacent to the 3' poly(A) track of the genome of all avian 
RNA tumor viruses investigated (58, 59, 61, 62). 
Although direct evidence is still lacking, it is usually 
assumed that the gene-order of the murine leukemia viruses is 
identical to the gene-order shown above. There are no experi­
mental data m conflict with this assumption. In fact it is 
indirectly supported by translation experiments with avian and 
murine virus-specific (m)RNA (see chapters Viand Vlland 63-70). 
Moreover, a universal gene-order would account nicely for many 
similarities among important groups of RNA tumor viruses. 
THE GENE-PRODUCTS OF THE MURINE RNA TUMOR VIRUSES 
The isolation of deletion mutants or temperature sensitive 
(ts) mutants with impaired expression of reverse transcriptase 
(39, 71-73), transformation properties (39, 40) or envelope 
proteins (59), as well as the translation of viral RNA (64-70) 
and the strong type-specific antigenic determinants of the 
major env-gene product (74) constitute overwhelming evidence 
for the fact that the gag-, £o_l- and env-genes of the RNA tumor 
viruses as well as the one-gene of the sarcoma viruses are in­
deed viral genes. The gag- and env-genes are divided into sub-
genes that contain the information for the mature viral poly­
peptides. The processing into subgene-products is a post-trans-
lational event. It is the subject of our experimental work 
described in chapters III, IV and V. In the following sections, 
we present a catalogue of the mature (sub)gene-products. We 
confine ourselves to polypeptides of R-MuLV, occasionally 
mentioning polypeptides of other RNA tumor viruses for com-
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parison. This catalogue is preceded by an explanation of the 
current nomenclature for the structural polypeptides. Virtually 
nothing is known of the native viral proteins and of the bio­
logical function of individual structural polypeptides. There­
fore, our catalogue contains almost exclusively physico-
chemical and serological data. There Js one exception: the 
position of the mam glycoprotein on the surface of the virion, 
the fact that it determines the interference groups to which 
the virus belongs and the neutralizing activity of antisera 
directed against it (74) make clear that the mam glycoprotein 
is involved in the penetration of the virus in the susceptible 
host cell; however, also in this case, molecular details of 
that process are still lacking. For other reviews on the gene 
products of RNA tumor viruses see references 13, 75-77. 
THE NOMENCLATURE OF THE STRUCTURAL POLYPEPTIDES OF THE RNA 
TUMOR VIRUSES 
Before 1974, the readability of the literature on the 
structural polypeptides of the RNA tumor viruses was seriously 
hampered by the existence of no less than five nomenclatures 
for the avian and six for the murine viruses (15). By the time 
that so much progress was made that the results of different 
laboratories could be compared, the leading authorities in the 
field (78) agreed upon a simple and universal nomenclature 
that was happily accepted by all RNA tumor virologists. Accord­
ing to this convention the structural polypeptides of the RNA 
tumor viruses should be designated ρ (protein) or gp (glyco­
protein) followed by their apparent molecular weight in kilo-
daltons. For use in this nomenclature, the molecular weights 
of the smaller components (10,000-30,000 daltons) are to be 
estimated by gel filtration in the presence of guanidmium 
chloride (GuHCl), whereas the molecular weights of the compo­
nents larger than 30,000 daltons should be based on SDS-PAGE. 
It should be noted that the nomenclature ignores the anomalous 
mobilities of glycoproteins during SDS-PAGE. Additional in-
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formation concerning the location of a structural polypeptide 
can be added m parentheses (C for core, E for envelope, N for 
nucleoprotein). This nomenclature has facilitated the communi­
cation on the structural polypeptides of RNA tumor viruses. 
However, the designation of viral polypeptides is largely 
based on their molecular weights and, therefore, the symbols 
for unrelated polypeptides with similar molecular weights look 
alike (for instance pl5 and pl5(E) of R-MuLV) or analogous 
polypeptides with different molecular weights are designated 
differently (for instance pl5 of R-MuLV and pl2 of F-MuLV). 
Therefore, we think that in the near future the authorities 
will reconvene to set up a still better nomenclature based on 
the fact that all structural polypeptides are subgene-products 
belonging to either gag or env and on the expectation that 
complete subgene maps of gag and env will soon be available 
for important groups of RNA tumor viruses. In view of the 
great homology among RNA tumor viruses there is probably a 
high degree of conformity of genetic maps and of the functions 
of the subgene-products. Such conformity should be apparent 
from a new nomenclature. 
GAG-GENE POLYPEPTIDES OF R-MuLV 
Studies on the synthesis of virus-specific polypeptides 
in R-MuLV infected cells have shown that рЗО, pl5, pl2 and plO 
are all derived from a common gag-precursor polypeptide (79-
88, chapter III-V). Similar experiments had already shown that 
p27, pl9, pl5 and pl2 of avian myeloblastosis virus (AMV) are 
also derived from a common gag-precursor polypeptide (89, 90). 
p30 
The major structural protein of the viral core is рЗО (91). It 
carries interspecies antigenic determinants (shared by viruses 
of different species), group-specific antigenic determinants 
(shared by viruses of one species) and type-specific antigenic 
determinants (unique for an individual virus strain) (74, 78). 
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The extended immunological homology of p30 isolated from a 
variety of RNA tumor viruses has been confirmed by the analysis 
of their tryptic peptides (92), ammo acid compositions (93) 
and the sequence of their first 24 N-terminal amino acids (94). 
Moreover, these studies also demonstrated small type-specific 
differences. Murine p30 is not expressed on the virion envelope 
surface (75, 96-98). However, complement-dependent cytotoxic 
reactions of anti-рЗО serum were observed with Mo-MuLV infected 
cells (95) and with a single murine cell line producing large 
quantities of F-MuLV (97). The latter result is m agreement 
with immunoelectron microscopic studies (98). We tend to 
believe that m these studies a gag-precursor polypeptide is 
recognized rather than p30 itself (see chapter III and IV; 99). 
Ell 
The type- or subgroup specific polypeptide pi5 of R-MuLV is 
identical to the FMR (Friend, Moloney, Rauscher-MuLV) cell 
surface antigen: it cross reacts immunologically with F-MuLV 
and to a lesser extent with Mo-MuLV. In mice infected with 
leukemia viruses the FMR antigen induces cytotoxic antibodies 
which can be absorbed with disrupted virions, but not with 
intact virus-particles. Therefore, pl5 is probably located 
inside the virion, as well as on the surface of infected cells 
(74, 75). Again, in this case we suspect that the antigenic 
determinants of pl5 within a gag-precursor polypeptide are 
recognized on the cell surface. pl5 of R-MuLV is probably 
analogous to pl2 of F-MuLV; the latter polypeptide showed 
immunological cross reactions with R-MuLV and Mo-MuLV but not 
with Gross-MuLV (100). Moreover, it was shown to be present on 
the surface of F-MuLV infected cells (97, 98), and in disrupted 
F-MuLV (97) but not on the envelope of budding virions (98). 
On the other hand. Bolognesi et al. (91) have shown that a 
F-MuLV polypeptide which migrates during SDS-PAGE as pi2 is 
present on the envelope surface. This polypeptide is not 
characterized serologically and, in our opinion, may represent 
a small env-subgene-product. It is useful to keep in mind that 
pl5 of R-MuLV does not contain methionine (13, 101) and, there-
21 
fore, is never seen m studies using S-methionine. 
pl2 
R-MuLV polypeptide pl2 carries mainly type-specific antigenic 
determinants (75, 102-104) and appeared to be very useful in 
the classification of endogenous murine leukemia viruses (105). 
The type-specific nature of pl2 was confirmed by tryptic pep-
tide analysis (92). The location of this polypeptide is not 
certain. Sen et al. (106) have shown that a phosphoprotem 
(pl2) of R-MuLV binds specifically to its homologous 70 S and 
35 S viral RNA. This observation suggests that like the other 
gag-gene products pl2 is located within the virion core. How-
ever, this suggestion needs further experimental confirmation. 
R-MuLV-pl2 is probably not identical to pi2 of F-MuLV for the 
reasons discussed m the preceding paragraph. 
plO 
The smallest known structural polypeptide of R-MuLV is plO. 
Analyses of tryptic peptides have revealed a strong homology 
between plO of R-MuLV, Mo-MuLV and G-MuLV (92). This observa-
tion is consistent with the strong group-specific antigenic 
determinants of plO isolated from R-MuLV and Mo-MuLV (104). 
plO of R-MuLV is probably also identical or very similar to 
plO of F-MuLV (100). It is located in the virion core in 
strong association with the viral RNA (91). Like some other 
proteins that bind to nucleic acids, plO is a strongly basic 
polypeptide. F-MuLV plO is not expressed on the cell surface 
of infected cells, except that it is recognized serologically 
in a single high producer cell-line (97, 98); again, we pre-
sume, as a part of a gag-precursor polypeptide. It should be 
mentioned here that Parks et al• (107, 108) have observed 
serological cross reactions between the plO and pl2 polypep-
tides isolated from Ki-MuLV or from Mo-MuLV. The cross-reaction 
between plO and pl2 of Mo-MuLV is in conflict with the observa-
tion of Barbacid et al. (104) that these polypeptides do not 
share antigenic determinants. Moreover, it can be concluded 
from the serological characterization of flo-MuLV p30, pl5, pl2 
22 
and plO, that these polypeptides are analogous to the corres-
ponding polypeptides of R-MuLV discussed above (85, 104). It 
is not easy to identify plO in SDS-PAGE gels. There are two 
reasons why we probably did not observe it in our studies: 
our anti-R-MuLV serum probably does not recognize plO and plO 
is eluted from Polyacrylamide gels with dimethylsulfoxide 
during the Bonner and Laskey procedure for scintillation 
autoradiography (170). 
Gag-precursor polypeptides in virions 
We have found gag-pr65 and probably gag-pr75 polypeptides in 
R-MuLV preparations (chapter IV). Similar results were ob-
tained by Jamjoom et al. (82) with R-MuLV and by Oskarsson et 
al. (109) with a feline leukemia pseudo-type of Moloney sarcoma 
virus. We have noticed that once present in virions, gag-pr65 
is no longer processed (chapter IV). Jamjoom et al. (110) 
believe that the viral RNA catalyses the processing of the 
gag-precursor and that gag-pr65 is present in a small fraction 
of the virions that lack viral RNA. 
ENV-GENE POLYPEPTIDES OF R-MuLV 
Not only the gag-gene but also the env-gene is divided 
into subgenes. It has been shown that the viral polypeptides 
gp69/71, gp45, pl5(E) and pl2(E) are derived from a common 
env-gene precursor polypeptide (79, 81, 83, 84, 86-88, 111, 
112, chapters IV and V ) . In contrast to the gag-precursor poly-
peptides, the env-precursor polypeptide itself is never seen 
m virions (unpublished results and 110). 
gp69/7l· 
The major glycoprotein of R-MuLV is gp69/71. It harbours 
type-, group- and mterspecies-specific antigenic determinants, 
which are probably specified by the protein moiety of the mole-
cule (86, 113). Polypeptide gp69/71 is located on the cell 
surface of infected cells and on the virion envelope surface 
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(74-76, 96, 114). Strand and August (115) have shown that 
gp69/71 consists of two immunologically related molecules. 
Tryptic peptide analysis of lodmated purified gp69 and gp71 
have confirmed their close structural relationship (112). 
Antisera against gp69/71 possess a strong neutralizing activity 
for virus infection (74). The cell surface antigen GIX which 
is expressed on the thymocytes of some strains of mice probably 
represents a type-specific antigenic determinant of gp69/71 
(74) . 
g p 4 5 
Several workers have identified a second glycoprotein with a 
molecular weight of approximately 45,000 (77, 101, 112, 116). 
Immunoprecipitation with anti-gp69/71 serum of gp45 from R-MuLV 
isolates and from spontaneously degraded gp69/71 preparations 
indicated that gp45 is derived from gp69/71 (112). This ob-
servation was confirmed by tryptic peptide analysis of gp69/71 
and gp45. Moreover, by limited proteolytic digestion it was 
shown that gp69/71 could be converted into gp45 and a 32,000 
dalton polypeptide, which overlaps with gp45 (112). 
pl5(E) 
A new virion polypeptide pl5(E) with interspecies-specific 
antigenic determinants has been identified in several strains 
of murine leukemia viruses (101, 117). Ikeda et al. (101) have 
shown that it elutes during GuHCl gel filtration of R-MuLV 
polypeptides in the void volume, and that pl5(E) is immuno-
logically and biochemically different from pl5. pl5(E) is 
located in the virion envelope (96, 118), but was not recog-
nized in complement-dependent cytotoxic reactions or in immuno-
electron microscopic studies as a constituent of the virion 
envelope or the cell surface (97, 98). Schwar¿ et al (98) 
suggested that pl5(E) is covered by the major virion glyco-
protein gp69/71 and possibly functions as an anchor for the 
gp69/71 knobs. Leamnson et al. (119) showed that gp69/71 of 
Mo-MuLV is linked by disulfide bonds to a polypeptide with a 
molecular weight of approximately 15,000, which migrates just 
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behind pl5 and pl2 during SDS-PAGE (probably identical to 
pl5(E)). A similar association of pl5(E) and gp69/71 was ob­
served by Witte and Weissman (120) and confirmed the observa­
tions of Ikeda et al. (101) and van Zaane et al. (87, chapter 
IV) that pl5(E) and gp69/71 are strongly associated. Disulfide 
bridges between the avian glycoproteins gp85 and gp37 had been 
reported earlier (121). 
pl2(E) 
Polypeptide pl2(E) represents another new viral polypeptide, 
which was first recognized by Arcement et al. (83). Pulse-chase 
experiments and chymotryptic peptide analysis have shown that 
pl2(E) is a cleavage product from env-pr82 or pl5(E) (84, 87, 
chapter IV). pl2(E) was found in purified envelope preparations 
of R-MuLV (96). 
RNA-DEPENDENT DNA POLYMERASE 
The RNA-dependent DNA polymerase (or reverse transcriptase) 
was identified m RNA tumor virus preparations independently by 
T e m m and Mizutam (122) and by Baltimore (123) m 1970. 
Already in 1964, Temm had put forward his DNA provirus hypo­
thesis, which demanded the existence of a reverse transcriptase 
(124). Extensive reviews on the characteristics of this enzyme 
have been published (15, 125; see also 126 and 128). Reverse 
transcriptase from avian RNA tumor viruses consists of two sub-
units of approximately 60,000 and 100,000 daltons, designated 
α and ß respectively (15). The smaller α subunit is derived 
from the 3 subunit (129, 130). Both the α subunit and the aß 
holoenzyme possess three enzymatic activities: an RNA-dependent 
DNA polymerase, a DNA-dependent DNA polymerase, and an RNase Η 
activity (i.e. the capacity to degrade the RNA strand in an 
RNA-DNA hybrid) (126, 128, 131). The holoenzyme αβ has a 
stronger affinity for its template than the η subunit (126, 
127). Very recently, Tsiapalis (171) demonstrated that a small 
acidic phosphoprotein isolated from avian RNA-dependent DNA 
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polymerase preparations stimulated the reverse transcriptase 
activity of avian, murine and simian RNA tumor viruses with 
exogenous templates (see also 172). Dephospnorylation of this 
protein resulted in the complete loss of its stimulatory 
activity. The significance of this discovery is not yet clear. 
In contrast to the avian enzyme, the murine reverse trans-
criptase contains only one subunit with a molecular weight of 
about 70,000. It has the same enzymatic activities as the 
avian enzyme (15, 128). Both the avian and the murine enzyme 
are located within the viral core, probably associated with 
the viral RNA (91, 132, 135). 
THE UNKNOWN ONC-GENE PRODUCT 
The one- or sre-gene of the avian and murine sarcoma 
viruses is recognized by mutants defective for transformation 
(39, 40). Evidence for a comparable gene in the genome of the 
other RNA tumor viruses is still lacking. The main phenotypic 
expression of the one-gene is the induction of tumor growth 
in sarcoma virus infected animals and the loss of contact in-
hibition in cell cultures infected with these viruses. In 
addition, in infected cells other characteristics of trans-
formed cells can be observed: e.g. alterations in morphology, 
capacity to grow in agar or at low serum concentrations, 
altered agglutinating ability with lectins like concanavaline 
A, expression of tunor-specific sarface antigens or tumor-
specific transplantation antigens (15). At least three diffe-
rent one-genes of avian and murine RNA tumor viruses can be 
distinguished: the one-genes of Kirsten sarcoma virus, Moloney 
sarcoma virus and Rous sarcoma virus (see chapter II). In 
hybridization experiments each of them was recognized as part 
of the genome of the homologous normal host cell. A protein 
encoded by the one-gene of sarcoma viruses has not been identi-
fied and its role m tumor induction remains unclear. 
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REPLICATION OF THE VIRAL GENOME 
Upon infection with an RNA tumor virus, the core of the 
virion penetrates into the cytoplasm of the cell and the viral 
RNA is converted by the reverse transcriptase into a double-
stranded DNA provirus of approximately 6 χ 10 dalton (15, 
136). The synthesis of the proviral DNA starts with the addi­
tion of mononucleotides at the 3'OH end of a specific 4 S RNA 
primer molecule (137-139). tRNA was identified as the primer 
for the cDNA synthesis in vitro using RNA templates isolated 
from avian viruses (140-144),whereas tRNA*3 serves as a primer 
in reactions with RNA templates of murine leukemia viruses 
(139, 145). The 4 S primer molecule is bound at 100-200 nucleo­
tides from the 5'-terminal end of the 30-40 S viral RNA sub-
unit (43, 139, 146-148). In addition, internal primers might 
be operative during DNA synthesis in vitro (43). cDNA prepared 
in vitro consists mainly of small DNA species (approximately 
4 S) and the most abundant one is called "strong stop cDNA" 
(43, 139) which is complementary to the S'-terminal end of 
the 30-40 S RNA subunit (43, 148). Collet and Faras (148) 
showed that the strong stop cDNA hybridized also to the 3' end 
of the AMV RNA subunits. This observation is in accordance 
with the identification of an RNase T.-oligonucleotide of 
Mo-MuLV RNA which is present at the 5' end as well as at the 
3' end of the 30-40 S subunit (149). Therefore, it seems 
likely that the 3' and 5' termini of 30-40 S RNA contain homo­
logous sequences, which could be involved m circularization 
of the replication intermediate. This mechanism would enable 
the synthesis of a full length DNA genome, despite the localiza­
tion of the primer molecule near the 5' end of the viral RNA 
subunit. During the synthesis of ds proviral DNA in vivo, 
several replication intermediates could be recognized: super-
coiled circular ds DNA (form I), non-closed circular ds DNA 
(form II) and linear ds DNA (form III) (136, 150-152). The 
molecular weight of the ds proviral DNA never exceeded 6 χ 10 
(136), which is consistent with the molecular weight of the 
single stranded RNA genome (3 χ 10 dalton). Form I and form 
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III viral DNA were infectious and gave rise to infectious 
progeny (152). Hybridization analysis specific for either the 
(+)strand DNA or the (-)strand DNA showed that the (-)strand 
is of genome length, whereas the (+)strand comprises small 
DNA species of 0.5 χ 10 1.0 χ 10 dalton (153). The meaning 
of this result is not yet clear. Early after infection, un-
mtegrated proviral DNA could be detected m the cytoplasm 
and in enucleated cells, whereas later after infection almost 
all proviral DNA was found in the nucleus (136, 154, 155), 
where it becomes integrated in the host-cell genome (156). 
GENE EXPRESSION OF R-MuLV; 
INTRODUCTION TO THE PAPERS 
Once the proviral DNA of an RNA tumor virus is integrated 
in the host cell genome, transcription of the genome into RNA 
and its subsequent translation into proteins generates the 
new constituents of progeny virus. We studied the expression 
of the viral genome: i. by following the synthesis of virus-
specific polypeptides during pulse-chase experiments with 
JLS-V9 cells persistently infected with R-MuLV (chapters III, 
IV and V) and n.by the translation of virus-specific RNA pre­
parations isolated from these cells (chapters VI and VII). In 
both types of experiments, the synthesis of virus-specific 
products is accompanied by the synthesis of a large excess of 
cellular proteins. Therefore, we applied a sensitive two-step 
immunoprecipitation procedure with antisera raised against 
R-MuLV or its purified polypeptides to select the virus-
specific products. In the first step, a small amount of anti-
R-MuLV serum was added to the virus-specific polypeptides 
formed in infected cells or protein synthesizing systems upon 
the addition of radioactive precursors. Subsequently, the 
soluble immuno-complexes were precipitated by the addition of 
a pre-titrated amount of the appropriate anti-immunoglobulin 
serum. The immunoprecipitates were dissolved and subjected to 
SDS-PAGE followed by autoradiography to visualize the virus-
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specific polypeptides. A schematic representation of our re-
sults is printed on the inside backcover of this thesis. 
Chapter III: Virus-specific precursor polypeptides m cells 
infected with Rauscher leukemia virus. 
D. van Zaane, A.L.J. Gielkens, M.J.A. Dekker-Michielsen and 
H.P.J. Bloemers. 
Virology 67, 544-552 (1975). 
The strategy outlined in the previous paragraph was 
followed in this study to examine the synthesis of virus-
specific polypeptides in R-MuLV infected JLS-V9 cells. The 
cells were pulse-labeled with radioactive ammo acids and 
after immunoprecipitation with anti-R-MuLV serum, we detected 
two high molecular weight products which might be precursor 
polypeptides of mature virion polypeptides. However, when the 
radioactivity was chased by the addition of an excess of un-
labeled amino acids to the cell cultures, the putative pre-
cursor molecules disappeared but only one mature virion poly-
peptide was detected in the cell lysate. On the other hand, 
several mature virion polypeptides were identified upon in-
cubation of the lysate of pulse-labeled cells in vitro. These 
observations suggested that the high molecular weight poly-
peptides are precursors of mature virion polypeptides, and 
that some of the cleavage products are lost from the cell 
during the chase period, probably as constituents of newly 
assembled virions. The virus-specific precursor polypeptides 
were too small to represent the translation product of the 
entire R-MuLV genome with its coding capacity of about 300,000 
dalton of protein. Such giant precursor polypeptides were 
found in cells infected with picornaviruses (157, 158), which 
possess an RNA genome of similar size as the RNA tumor viruses 
do. We attempted but failed to identify giant precursor poly-
peptides in R-MuLV infected cells grown in the presence of 
inhibitors of proteolysis. This failure, of course does not ex-
clude the existence of giant R-MuLV specific precursor poly-
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peptides. 
Chapter IV: Virus-specific precursor polypeptides in cells 
infected with Rauscher leukemia virus: synthesis, identifica-
tion and processing. 
D. van Zaane, M.J.A. Dekker-Michielsen and H.P.J. Bloemers. 
Virology 75, 113-129 (1976). 
The major difficulty encountered m our previous study 
was the failure to demonstrate a clear conversion of virus-
specific precursor polypeptides into mature virion polypeptides 
during pulse-chase experiments. We ascribed this failure to 
the rapid release of newly formed viral polypeptides into 
budding virions. To enable the detection of both intracellular 
and extracellular virus-specific polypeptides, we lysed the 
cells in the chase medium containing the newly assembled 
virions. Now, a clear conversion of virus-specific precursor 
polypeptides into mature virion polypeptides was observed. 
Immunoprecipitation experiments with polyvalent and mono-
specific antisera and the analysis of chymotryptic peptides 
of virus-specific products enabled the identification of 
separate virus-specific precursors of the internal and envelope 
virion polypeptides. 
Chapter V: Precursor polypeptides of Rauscher murine leukemia 
virus plO, pl2 and pl2(E) (unpublished results). 
As an extension of our studies documented in the chapters 
III and IV, we here present the identification of virus-specific 
precursors of the R-MuLV polypeptides plO, pl2 and pl2(E); 
these relations were not clarified by us previously. Although 
Barbacid et al. (85) had demonstrated before that plO and pl2 
(as well as p30 and pl5) of R-MuLV are derived from a 65,000 
dalton polypeptide, the techniques used by them did not resolve 
gag-pr75 from gag-pr65. For this reason we studied the rela-
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tionship of both gag-precursor polypeptides to plO and pl2. 
Moreover, we showed that pl2(E) (in our previous work desig-
nated pl2) is identical to pl2(E) identified by Naso et al. 
(84) as a cleavage product of the env-precursor polypeptide 
and pl5(E). 
In summary, from the results presented in chapters III, 
IV and V, we conclude that the envelope polypeptides of R-MuLV 
(gp69/71, pl5(E) and pl2(E)) are derived from two almost iden-
tical and glycosylated polypeptides (env-pr82) which probably 
are synthesized separately from the precursor polypeptides 
(gag-pr75 and gag-pr65) of the internal virion polypeptides 
(p30, pl5, pl2 and plO). These results are in good agreement 
with those obtained by other groups (79, 80, 82-86, 88) and 
they are discussed in chapters III, IV and V. It should be 
noted here, that the synthesis of reverse transcriptase escaped 
detection in our studies since a mono-specific antiserum 
against this polypeptide was not available. The significance 
of the translation of the viral genome into large precursor 
polypeptides rather than into mature virion polypeptides may 
be that " m this way polyfunctional messengers can be trans-
lated by the eukaryotic protein synthesizing machinery which 
apparently is not suited for the translation of polycistronic 
messengers" (chapter III). Our results on the translation of 
virus-specific mRNAs presented in Chapters VI and VII support 
this conclusion. In addition, precursor polypeptides may 
help to keep together the viral polypeptides that should stay 
together during assembly of the virion (morphogenetic cleavage, 
159). The latter assumption would agree with our observation 
that the processing of virus-specific precursor polypeptides 
probably takes place at the plasma membrane just before or 
during the assembly of the virion (chapters III and IV). 
31 
Chapter VI: Synthesis of Rauscher murine leukemia virus-
specific polypeptides in vitro 
A.L.J. Gielkens, D. van Zaane, H.P.J. Bloemers and 
H. Bloemendal. 
Proc. Nat. Acad. Sci. USA 73, 356-360 (1976). 
Hybridization studies by Gielkens et al. (160) and others 
(161-164) have identified virus-specific mRNA species of genome 
length (35 S) and smaller sizes (22 S and 14 S) in association 
with polyribosomes isolated from cells infected with RNA tumor 
viruses. To provide evidence for their functional role in the 
synthesis of virus-specific polypeptides, we studied the 
translation of virus-specific RNA preparations isolated from 
R-MuLV infected JLS-V9 cells. Thus, we observed the synthesis 
of several virus-specific high molecular weight polypeptides. 
In order to identify the mRNA species encoding these poly-
peptides, we fractionated poly(A)-tagged RNA isolated from in-
fected cells according to size in a denaturing sucrose gradient 
and, subsequently, we translated each RNA fraction from the 
gradient in a rabbit reticulocyte lysate. It was shown that 
the virus-specific mRNAs of different size classes could code 
for different virus-specific products. These products were 
precipitated with anti-R-MuLV serum; some but not all of them 
comigrated during SDS-PAGE with authentic virus-specific poly-
peptides isolated from infected cells.However, these results 
did not yet allow a reliable identification of the translation 
products with virus-specific polypeptides. 
Chapter VII: Identification of Rauscher murine leukemia virus-
specific mRNAs for the synthesis of gag- and env-gene products. 
D. van Zaane, A.L.J. Gielkens, W.G. Hesselink and 
H.P.J. Bloemers. 
Proc. Nat. Acad. Sci. USA 74 (5) (1977) in press. 
To identify the virus-specific mRNAs isolated from in-
fected cells, we translated poly(A)-tagged RNA fractionated 
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according to size m oocytes of Xenopus laevis and subsequently 
analyzed the virus-specific products by immunoprecipitation 
with polyvalent and mono-specific antisera. In these experi-
ments, it appeared that oocytes were able to glycosylate and 
to process virus-specific products. The 35 S and 22 S virus-
specific mRNAs studied m our previous work were shown to re-
present the messengers for the synthesis of gag- and env-gene 
products, respectively. A similar result was obtained by 
Pawson (63) with virus-specific mRNA isolated from RSV in-
fected cells. This analogy and the established gene-order of 
the avian RNA tumor viruses argue for the following composition 
of the mRNAs for the structural polypeptides of the RNA tumor 
viruses: 
5'-gag-pol-env-onc-poly(A)-3' (gag-mRNA) 
5'-env-onc-poly(A)-3' (env-mRNA) 
In agreement with these results, Salden et al. in our 
group (14, 65-68) and others (64, 69, 70) found that the 35 S 
RNA isolated from virions mediated the synthesis of gag-gene 
products. Some of these studies (68, 69) demonstrated the 
synthesis of virus-specific products whicn could represent the 
product of the gag-gene and an adjacent gene, probably formed 
by a read-through mechanism. It is unknown whether these large 
precursor polypeptides play a role in the replication of the 
virus. 
Hybridization studies by Bishop et al. (165) identified 
also virus-specific 35 S and 24 S RNA species in RSV xnfected 
permissive cells. However, their data demonstrated that the 
24 S fraction harbored both 3' and 5' termini of the 35 S 
subunit in addition to env- and src-specific sequences. It is 
unknown whether the 5' terminal and of the genome in this 
fraction is represented by an RNA species different from the 
env-mRNA described above, or by the env-mRNA itself. In the 
cytoplasm of RSV transformed non-permissive cells, only 24 S 
RNA was found containing gag and src sequences, whereas the 
nucleus contained both 35 S and 24 S RNA. The meaning of this 
result is not yet understood. 
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In summary, we conclude that the virus-specific gag-mRNA 
and probably the env-mRNA contain open cistrons at their 5' end 
which are accessible to translation, and closed internal cis-
trons which are inactive. Similar inactive internal cistrons 
have been reported for virus-specific mRNA of Semliki forest 
virus (166), Brome mosaic virus (167), Tabacco mosaic virus 
(168) and polyoma virus (169). Moreover, our data seem to pre-
clude the translation of the 35 S RNA into one giant precursor 
polypeptide representing all genes of an RNA tumor virus as an 
essential step in virus replication. 
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CHAPTER II 
THE GENOME OF THE MURINE SARCOMA VIRUSES 

THE GENOME OF THE MURINE SARCOMA VIRUSES 
In this chapter, we present a brief review on the mole-
cular biology of the murine sarcoma viruses and the closely 
related Abelson leukemia virus. In contrast to the leukemia 
viruses, sarcoma viruses transform fibroblasts in tissue cul-
ture and induce sarcomas when injected into mice (1). Abelson 
leukemia virus is a virus with exceptional properties: it in-
duces leukemia in mice but resembles sarcoma viruses in all 
other aspects (1, 2 and cf. 3). It is discussed in this 
chapter as if it were a sarcoma virus. Murine sarcoma viruses 
evolved by a rare recombination of the genetic information 
represented by murine leukemia virus RNA and normal cellular 
RNA, which is probably responsible for their transforming 
properties. The cell derived sequences of the genome of Moloney 
sarcoma virus were detected by hybridization in the chromo-
somal DNA of various mammals (4, 5). Apparently, these sequen-
ces are well conserved, suggesting that they are essential for 
survival. A similar transformation-specific sequence was iden-
tified for the non-defective avian sarcoma viruses (6, 7). 
Sarcoma viruses and leukemia viruses are not completely 
separate entities: the segregation of avian leukemia virus from 
cloned Rous sarcoma virus was already discussed in the previous 
chapter; another typical relationship exists between murine 
sarcoma and leukemia viruses m that the sarcoma viruses are 
defective and for their replicatioi, depend on leukemia viruses 
as helpers to supply missing gene products (1). They can be 
rescued from transformed non-producer (NP) cells by superin-
fection with type-C viruses, yielding a mixture of helper virus 
and pseudo-type sarcoma virus (i.e. a sarcoma virus genome 
encapsidated m helper virus polypeptides). Murine sarcoma 
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viruses are not readily found in naturally occurring sarcomas. 
In stead, they were isolated after passage of murine leukemia 
virus in rats or mice. Thus, the Harvey sarcoma virus (Ha-SV) 
was found in a leukemia virus stock obtained after passage of 
Moloney leukemia virus (Mo-MuLV) in Chester Beatty rats (8) 
and similarly the Kirsten sarcoma virus (Ki-SV) was isolated 
after passage of mouse erythroblastosis virus (MEV) in a Wistar 
Fürth rat (9). The helper virus associated with Ki-SV was de-
signated Kirsten leukemia virus (Ki-MuLV) and is probably 
identical to MEV (9, 10). Fibroblast transforming viruses were 
also obtained after passage of Mo-MuLV m Balb/c mice: the 
Moloney sarcoma virus (Mo-SV) was isolated from a rhabdomyo-
sarcoma that grew in an infected mouse (11), and the Abelson 
leukemia virus (Ab-LV) was found in the Mo-MuLV preparation 
obtained from an infected prednisolone-treated Balb/c mouse 
(2). A few other sarcoma viruses (e.g. one murine (12), and 
two feline viruses (13, 14)) were isolated from naturally 
occurring sarcomas but these viruses are not yet well charac-
terized. Some authors claimed the isolation of helper inde-
pendent sarcoma viruses (15, 16) but later studies showed that 
these isolates contained helper leukemia virus in low amounts 
(17) or m aggregates with the sarcoma virus (18). 
The relation between the transforming replication defec-
tive sarcoma viruses and the leukemia viruses used for their 
isolation has been studied extensively by sensitive hybridiza-
tion methods. Initially, the inability to isolate sarcoma virus 
RNA completely free of helper virus RNA was a severe obstacle. 
Most studies were performed with cDNA synthesized in an endo-
genous RNA-dependent DNA polymerase reaction of leukemia virus 
or of sarcoma virus-helper ігиь mixtures, the latter yielding 
a single-stranded probe complementary to both viral RNAs. These 
probes were hybridized with cellular RNA isolated from pro­
ducer cells (shedding pseudo-type sarcoma virus and leukemia 
virus) or from transformed non-producer cells (selected from 
cultures infected with sarcoma virus at a low multiplicity of 
infection). From these studies only qualitative conclusions on 
the homology between the sarcoma virus and the leukemia virus 
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genome could be obtained because: !_. it was often unknown 
which sequences were represented in the cDNA probe; n the 
transcription of the provirus is under host-control and, there­
fore, the sarcoma virus-specific intracellular RNA may not be 
representative for the complete integrated sarcoma virus 
genome; and ш .complete hybridization of cDNA with the homo­
logous RNA or proviral DNA was not always obtained. Clear and 
quantitative estimations of the homology can be obtained by 
determining the protection against RNase digestion of labeled 
viral RNA after hybridization with an excess of cDNA probe, 
that contains sequences complementary to its entire template 
RNA (see for instance 19-21). 
THE GENOMES OF KIRSTEN AND HARVEY SARCOMA VIRUS 
Benvemste and Scolnick (22) demonstrated that approxi­
mately 50-60% of the cDNA prepared from Ki-MuLV or Ki-SV(Ki-MuLV) 
hybridized with the cytoplasmic RNA isolated from Ki-SV trans­
formed NP rat cells, whereas there was no hybridization with 
RNA isolated from uninfected rat or mouse cells. From these 
results, they concluded that the Ki-MuLV-cDNA is partly homo­
logous to the RNA found in NP cells. They could not exclude, 
however, that the homologous RNA represented RNA of an endo­
genous rat leukemia virus (RaLV) or cellular RNA induced by 
the Ki-SV infection. A continuation of this study with cDNA 
prepared from Ki-SV(Ki-MuLV) with an excess of Ki-SV showed 
that in addition to the sequences homologous to Ki-MuLV, sarcoma 
virus-specific sequences were present in the RNA from NP cells 
(23). Data obtained by Roy-Burman and Klement (10) confirmed 
the existence of homologous and heterologous sequences in the 
Ki-SV and Ki-MuLV genome. A similar result was obtained by 
Maisel et al. (24) who compared the Τ -oligonucleotide patterns 
of Ki-SV and Ki-MuLV RNA. The sarcoma virus-specific sequences 
were stable on virus passage and seemed to be homologous to 
the genome of RaLV. This virus was induced by bromodeoxyuridme 
(BrdU) from Fischer normal rat kidney (NRK) cells and its RNA 
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showed no homology to Ki-MuLV-RNA (23). However, a more ex-
tended comparison with other closely related RaLV's and Ki-SV 
cDNA probes made specific for sarcoma virus sequences by ab-
sorption with Ki-MuLV-RNA showed that the sarcoma virus-speci-
fic sequences in the BrdU induced RaLV preparation represented 
(non RaLV) rat cellular RNA encapsidated by RaLV (25, 26). 
The same information is present in the chromosomal DNA of all 
rat cell lines investigated, and is transcribed in some of 
these lines, while other lines can be induced with BrdU to 
transcribe it (25, 26). Goldberg et al. (27) showed that 
type-C viral RNA can be rescued from infected but not virus-
producing cells only by encapsidation with type-C helper virus 
and not with type-B virus (mouse mammary tumor virus) or type-D 
virus (Mason-Pfizer monkey virus). Therefore, it was concluded 
that the sarcoma virus-specific rat cell RNA found in RaLV 
(and m other type-C virus preparations grown in some rat 
cells) is structurally related to type-C RNA, allowing its en-
capsidation by type-C viruses and its reverse transcription 
into cDNA (26, 28). The sarcoma virus-specific RNA in unin-
fected rat cells although present in polyribosomes is not 
translated into protein that is detectable in radioimmunoassays 
for rat viral pl2 and p30 (28). This observation is in agree-
ment with the total lack of homology between rat leukemia 
virus and sarcoma virus-specific rat cellular RNA (28). More-
over, Scolnick et al. (28) showed that encapsidated sarcoma 
virus-specific rat cellular RNA was unable to infect and to 
transform rat or mouse cells. Anderson and Roobms (29) pre-
pared a cDNA, which was made specific for the rat cellular RNA 
sequences encapsidated by helper type-C virus. They showed 
that about 50% of these rat sequences are represented m Ki-SV 
viral RNA, covalently bound to the Ki-MuLV specific sequences 
and that this cDNA is not homologous to RaLV specific RNA. 
In conclusion, the results suggest that the first step in 
the generation of a sarcoma virus involves the encapsidation 
of sarcoma virus-specific rat cellular RNA in helper virus 
particles, which upon recombiantion with leukemia viral RNA 
forms a stable but helper dependent sarcoma virus (28, 29). 
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Scolnick et al. (30) found indications that some additional 
rat sequences not identical with the sarcona-specific rat 
cellular RNA would be involved in this process. 
The Harvey sarcoma virus genome is similar to the genome 
of Ki-SV. It contains Mo-MuLV specific sequences covalently 
bound to at least a part of the rat-specific sequences found 
m Ki-SV (19, 23, 31). 
THE SIZE OF THE Ki-SV AND Ha-SV GENOME 
Sedimentation analysis or Polyacrylamide gel electropho­
resis of RNA isolated from Ha-SV or Ki-SV preparations and 
from producer and non-producer cells, followed by hybridization 
with leukemia or sarcoma virus-specific cDNA, revealed two RNA 
species: a 35 S RNA (3 χ 10 dalton), representing exclusively 
the helper virus-specific RNA and a 30 S RNA (2.3 χ IO6 dalton) 
with both helper- and sarcoma virus-specific sequences (19, 
24, 29, 32, 33). The same sizes of RNA (35 S and 30 S) were 
present in RaLV grown m NRK cells (34). Both virus-specific 
RNA species were also observed in virus producing rat cells, 
whereas virus-free rat cells contained 30 S RNA only. This 
30 S RNA hybridized with a Ki-SV-specific cDNA probe only, in 
contrast to the 35 S RNA which hybridized with a RaLV-specific 
probe only. These observations are consistent with the earlier 
conclusion that the Kirsten and Harvey sarcoma virus were 
generatod by recombination of the genetic information repre­
sented by a leukemia virus 35 S RNA and rat 30 S RNA harboring 
the sarcoma virus-specific sequences of Ki-SV and Ha-SV. In a 
quantitative study employing the RNase protection assay, 
Maizol et al. (19) found that 33% of the Ha-SV 30 S RNA is 
sarcoma virus-specific and 67% is Mo-MuLV-specific. Scolnick 
and Parks (31) reported a ытііаг percentage of sarcoma virus-
specific sequences in Ha-SV and Ki-SV RNA. However the cDNA 
probe they used could protect only 75% of its template RNA. 
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THE EXPRESSION OF LEUKEMIA VIRUS REGION(S) OF ThE GENOME OF 
Ki-SV AND Ha-SV 
The leukemia virus-specific sequences of the 30 S RNA of 
Ki-SV and those of Ha-SV contain common sequences with a few mis-
matched regions (20). The Mo-MuLV-specific region of Ha-SV RNA 
is not expressed in Ha-SV transformed NP cells as immunoreac-
tive viral structural proteins p30, pl5, pl2, plO or gp70 (35). 
In contrast, Bilello et al. (36) isolated Ki-SV transformed 
non-producer NRK clones which expressed gp69/71 in the absence 
of p30 and pl5, while other clones did not express one of 
these viral proteins. In later studies the viral envelope 
protein of Ki-SV gp69/71 clones was characterized by the 
interference properties of the transformed cells (37, 38) and 
it appeared that the gp69/71 was of ecotropic MuLV origin. Its 
antigenic determinants could also be detected intracellularly 
(after pulse-labelmg) m an env-pr90 precursor polypeptide 
(37, 38), which is probably analogous to env-pr82 found in 
R-MuLV infected cells (chapter III, IV and V ) . Therefore, we 
presume that the Ki-SV gp69/71 clone also contains pl5(E) in 
addition to gp69/71. 
TWO STRAINS OF MOLONEY SARCOMA VIRUS 
Two types of Mo-SV transforired non-producer cell-lines 
free of helper virus have been obtained. One type of cell-lines 
does not produce known structural viral proteins (Mo-SVp 
infected cells) and was isolated after injection of Mo-SV(Mo-
-MuLV) into a hamster. The other type of cell-lines was ob-
tained from cell cultures infected with Mo-SV(Mo-MuLV) and 
found to express p30 of Mo-MuLV (Mo-SV S L infected cells) 
(3, references in 3). Both Mo-SV strains rely for their repli-
cation on helper leukemia viruses which provide the envelope 
protein (39) and - at least in the case of Mo-SV S L - the 
reverse transcriptase (40, 41). It was shown by Bassin et al. 
(42) and by Aaronson et al (43) that the S L transformed 
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cell-lines produce small amounts of non-infectious type-C like 
particles. 
THE SIZE OF THE Mo-SV GENOME 
From Mo-SVp transformed NP hamster cells fused with an 
R-MuLV producing mouse cell,Tsuchida et al. (44) isolated in­
fectious Mo-SVp (R-MuLV) with a 500-fold excess of sarcoma 
virus. RNA from this virus sedimentated at 60 S, while R-MuLV 
RNA sedimented at 70 S. Upon denaturation, Mo-SV RNA dissocia­
ted into 30 S subunits, in stead of 35 S, the size of RNA 
subunits of R-MuLV. Hybridization of cDNA prepared from Mo-SV 
(MuLV) with cellular RNA isolated from the original NP cell 
line or from the producer hybrid cell line showed that a homo­
logous virus-specific 30 S RNA species could be detected in 
both cell lines (44). In a related study, Tsuchida and Green 
(45) identified a Mo-SV specific 26-28 S RNA species in five 
mouse cell-lines transformed by Mo-SV (the S L or ρ charac­
ter of these cell-lines was not reported by the authors). 
Mo-MuLV AND SARCOMA VIRUS-SPECIFIC SEQUENCES IN THE GENOME OF 
Mo-SV AND Ab-LV 
The relation between Mo-SV and its helper virus has been 
studied extensively in hybridization experiments. In some of 
them Ab-LV was investigated as well. Since both viruses were 
discovered after passage of Mo-MuLV in Balb/c mice, we will 
discuss them together. The experimental evidence mentioned in 
this section, implies that Mo-SV and probably Ab-LV were gene­
rated by recombination of Mo-MuLV and mouse cellular RNA in 
a process similar to the generation of Ki-SV and Ha-SV. 
Scolnick et al. (3) prepared three non-overlapping cDNA 
probes specific for different regions of Mo-SV S L and 
Mo-MuLV RNA (cDNA , cDNA , cDNA, . ) . The cDNA of 
sarc common leuk sarc 
Mo-SV S L RNA hybridized for approximately 50% with RNA iso-
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lated from NP cells transformed by Mo-SVp or Mo-SV S L . No 
hybridization of cDNA was observed with RNA from Ab-LV or 
-' sarc 
Ha-SV transformed NP cells or with RNA from cells producing 
N-tropic MuLV or xenotropic endogenous Balb/c virus. Hybridiza­
tion of cDNA prepared from Mo-MuLV with some of the RNA pre­
parations mentioned above revealed 48% homology with Mo-SV 
S L~ RNA, 33% homology with Mo-SVp" RNA, 33% homology with 
Ab-LV RNA and 21% homology with Ha-SV RNA. (As discussed m a 
previous section, homologies measured in this way are quali­
tative rather than quantitative). Hybridization with cDNA 
^ •' common 
and cDNA., revealed that the Mo-MuLV sequences of Mo-SV S + L -leuk ^ 
RNA are larger than and completely overlap the Mo-MuLV se­
quences of Ab-LV and Ha-SV. In the same study it was found 
that RNA isolated from Mo-SVp NP cells contained a small 
Mo-MuLV-specific region not homologous to Mo-SV S L RNA (3). 
Similar, but nore quantitative data were obtained by 
Frankel et al. (20). They hybridized an excess of cDNA , 
cDNA and cDNA-, , to lodmated high molecular weight RNA 
common leuk_ ^ 
isolated from Mo-SV S +L (Mo-MuLV) (with a 3-fold excess of 
Mo-SV) and the fraction resistent to RNase T. digestion was 
determined. Thus, it was shown that (after correction for the 
presence of Mo-MuLV) 25% of the Mo-SV RNA was homologous to 
cDNA , wnile the remainder represented the Mo-SV RNA 
sarc 
region homologous to Mo-MuLV. This common RNA region repre­
sented about half of the Mo-MuLV RNA. These experiments also 
confirmed that the cDNA revealed little homology to Ki-SV 
sarc ^ 
and Ha-SV, and that the region corresponding to cDNA was 
_
 J
 jr- r common 
larger in Mo-SV S +L RNA than m Ha-SV RNA (see also 3). 
Moreover, the sarc-specific sequences were found in normal 
mouse DNA (4, 5, 20) and represented a well conserved sequence 
in the cellular genome whose rate of divergence is similar to 
that of the globm genes, but much lower than that of the com­
mon region of Mo-SV and Mo-MuLV. This observation suggests 
that cellular sequences homologous to cDNA may be essential 
sarc 
for survival (5). 
Dina et al. (21) reported experiments with a cell-line 
infected with the original Чо-SV(Mo-MuLV) isolate of Dr. Moloney 
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(11, 16, 17). In agreenent with the results presented above, 
they isolated a 30 S sarcoma virus-specific RNA (6000 nucleo-
tides, 46) from Mo-SV(Mo-MuLV) with a thirty-fold excess of 
Mo-SV; the viral RNA consisted of about 70% (4200 nucleotides) 
of Mo-4uLV-specific sequences and 30% (1800 nucleotides) of 
sarcoma-specific sequences. The T.-oligonucleotide patterns 
obtained from Mo-SV and Mo-MuLV RNA confirmed the existence 
of sarcoma specific-regions, leukemia specific-sequences and 
sequences common to both viruses (21). In addition, hybridiza-
tion data obtained with cDNA probes made specific for different 
regions of the Mo-MuLV genome present in Mo-SV S L or Mo-SVp 
transformed NP cells revealed the existence of a Mo-MuLV se-
quence common to all Mo-MuLV related transforming viruses 
(joint region) (35). It is tempting to speculate that this 
region is involved in the integration of the transforming 
viral genome and that the small heteropolymeric region close 
to the 3' end of the genome of the avian RNA tumor viruses 
(47-50) represents its avian counterpart. 
No doubt, further hybridization studies with specific 
cDNA probes will soon reveal the localization of Mo-MuLV and 
sarcoma virus-specific sequences on a physical cleavage map of 
the linear Mo-SV proviral DNA which was established very re-
cently by Canaani et al. (51). 
THE EXPRESSION OF LEUKEMIA VIRUS REGION(S) OF THE GENOME OF 
Mo-SV AND Ab-LV 
Studies on the expression of Mo-MuLV viral proteins in NP 
cells transformed by several Mo-MuLV related sarcoma viruses 
showed that the envelope glycoprotein is not expressed in 
these cells (35, 52). Mo-SV S L transformed NP cells express 
the gag-related polypeptides p30, pl5, pl2 (52) and a pr60 
precursor polypeptide of Mo-MuLV p30 (53) but not plO (52), 
whereas none of the structural polypeptides were found in NP 
cells transformed by Mo-SVp~ or Ha-SV (35, 52). Parks et al. 
(35) demonstrated that in Ab-LV transformed NP cells Moloney 
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pl5, pl2 and plO were expressed and that in Mo-SV S L trans­
formed NP cells plO was expressed in addition to p30, pl5 and 
pl2; however, it should be noted that these authors have 
claimed that Moloney plO and pl2 are identical (54), which is 
in contrast to the observations of Barbacid et al. (52, 55) 
who could clearly distinguish a type-specific pl2 and a group-
specific plO polypeptide in Mo-MuLV preparations. Since Parks 
et al• (54) detected mainly type-specific antigenic determi­
nants in their pl0/pl2 radio-immunoassay, we suspect that the 
pl0/pl2 they described actually represents pl2, and that 
neither Mo-SV S L nor the Ab-LV transformed NP cells express 
Mo-MuLV plO. 
THE SUBGENE ORDER WITHIN THE GAG-GENE 
The differential expression of viral polypeptides in a 
set of NP cell-lines allows the construction of genetic maps. 
Thus, Barbacid et al. (52) concluded from their results on the 
expression of Mo-MuLV specific polypeptides m transformed NP 
cells and leukemia virus infected cells, that the arrangement 
of the gag-subgenes is as follows: 
(5' ) - p l 5 - p l 2 - p 3 0 - p l 0 - ( 3 ^ ) 
This arrangement is at variance with the conclusion of Parks 
et al. (35) (5'-p3 0-pl2-pl5-sarс-3'). However, the latter 
sequence is not compatible with a single initiation site for 
the translation of the gag-gene sequences (chapter III, IV and 
V). Moreover, the strong genetic linkage between the sarc-gene 
and pl5 observed in the studies discussed above (35, 52) can 
also be explained by the arrangement (5')-pl5-pl2-p30-sarc-(3') 
since the 3'- and 5'-terminal genes of RNA tumor viruses are 
closely linked in the circular proviral DNA. 
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SUMMARY 
In conclusion, the murine sarcoma viruses and the Abelson 
leukemia virus share several characteristics: 
1. they are able to transform fibroblasts in vitro, and are 
oncogenic m vivo; 
2. they are replication defective, and can be rescued from 
non-producer cells by helper leukemia virus yielding pseudo-
type virus; 
3. their genome consits of a 30 S subunit (approximately 6000 
nucleotides) which contains a leukemia virus-specific region 
apparently covalently bound to a sequence derived from nor-
mal rat cells (a 30 S RNA species) or normal mouse cells. 
(The size of the Ab-LV RNA has not yet been investigated). 
It should be noted that an RNA species similar to the 30 S 
sarcoma-specific RNA found in normal rat cells has not yet 
been identified in normal mouse cells. Moreover, the sarcoma-
specific sequences m the RNA of Ki-SV, Mo-SV, the avian RSV 
and the non-Mo-MuLV virus sequences of Ab-LV are not homolo-
gous (3, 5-7, 20). (The sarcoma-specific sequences of Ha-SV 
RNA are closely related to those of Ki-SV RNA). The expression 
of sarcoma-specific RNA in normal rat tissues and in rat tumors 
was studied by Frankel et al. (20). Elevated levels were found 
in many tumors and in some normal tissues. Apparently, the 
sarcoma viruses and the Abelson leukemia virus are vehicles 
of sequences that are involved in malignant transformation but 
possibly also in unknown processes in normal cells. Therefore, 
they are important tools in the study of oncology. 
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CHAPTER III 
VIRUS-SPECIFIC PRECURSOR POLYPEPTIDES IN CELLS INFECTED WITH 
RAUSCHER LEUKEMIA VIRUS 
The nomenclature of R-MuLV polypeptides used in this chapter is 
different from the present nomenclature (see chapter I) R-MuLV 
polypeptides designated here pi5, ρ 12a and pi2b are identical with 
pi5(E), pi5 and pi2(E). respectively, of the present nomenclature 
UROIOGT 67, 544-652 (1975) 
Virus-Specific Precursor Polypeptides m Cells Infected with 
Rauscher Leukemia Virus 
D. VAN ZAANE, A. L. J. GIELKENS, M. J A. DEKKER-MICHIELSEN, 
AND H P. J. BLOEMERS 
Department of Biochemistry, University of Nijmegen, Geert Grooteplein Noord 21, Nijmegen, The 
Netherland'· 
Accepted Ma\ 29 1975 
Viru*, specific protein svnthesis in JLS V9 cells inlected with Rauscher leukemia virus 
(R MuLV) was studied bv an immunoprecipitation technique One low irolcculai weight 
virion protein (pl5) could be detected intraccllularK and two nonvinon polypeptides with 
molecular weights ol 82,000 and 65 000 respectively These high molecular weight 
polypeptides were converted into the virion proteins pi() p i ) and p l ib . as shown by 
incubation ol the cell Ivsate The results suggest that the conversion look place on 
membrane structures, it was not inhibited bv three ditferent protease inhibitors However 
growth of cells in the presence of the arginine analog canavamne prevented 
formation ol the 65,000 dalton polypeptide and the pió virion polypeptide From our 
observations it is concluded that the 82,000 and 65 000 dalton polypeptides are precursors 
of virion proteins 
INTRODUCTION 
The formation oí viral proteins by spe-
cific posttranslational cleavage oí large 
precursor polypeptides is described for a 
wide range ol animal viruses The signifi-
cance of this phenomenon may be that in 
this way polyfunctional messengers can be 
translated bv the eukarvotic protein syn-
thesi7ing machinerv which apparentlv is 
not suited ior the translation of polvcis-
tronic messengers Vogt and Eisenman 
(1973) identified at least one large precur-
sor molecule (76,000 daltons) and a smaller 
one (12,000 daltons) of avian myoblastosis 
virus tAMV) proteins However, precursor 
polypeptides were not detected bv Shan-
mugam et al. (1972) and Fleissner and 
Tress (197,4) sludving, respectively, cells 
producing Moloney sarcoma-leukemia 
virus (MSV'AMLV)) and cells transformed 
bv Rous sarcoma virus (RSV) The latter 
authors detected low molecular weight vi-
rion proteins onlv Proteins of picor-
naviruses like poliovirus and enceph-
alomvocarditis virus are svnthesized as one 
( »pvright© 147") b\ Academic Press Ine 
All riKhls of reproduclmn m a m form reserved 
precursor polypeptide (hat is cleaved dur-
ing translation or alter termination (.Jacob-
son and Baltimore. 1968, Butterworth et 
al , 1971). Some proteins of vaccinia virus 
(Moss and Rosenblum, 197.)), Sindbis 
virus (Snyder and Sreevalsan, 197.}), New-
castle disease virus (Samson and Fox, 
1973) and influen/a virus (La/arowit/. et 
al , 1971) are also formed bv the specific 
degradation of precursor polypeptides In 
this paper we present evidence lor the 
occurrence of two precursor polypeptides of 
high molecular weight of the Rauscher 
leukemia virus (R-MuLV) proteins, which 
were both tightlv membrane-bound The 
last processing steps take place just before 
or during the assembly of the virion 
MATKRIALS AND МКЛ HODS 
Materials 
L-[35S]methionine (sp act, 170 Ci/mmol) 
and l4C-labeled amino acid mixture (sp 
act, 57 mCi/matom) were obtained from 
the Radiochemical Centre, Amersham, 
England Rabbit anti-R MuLV serum was 
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a generous gift of Dr. Ph. C. Hageman, 
The Netherlands Cancer Institute, Am-
sterdam, The Netherlands. The anti-R-
MuLV serum was produced in a rabbit by 
a primary injection, in the footpads, of 160 
Mg R-MuLV in 1.0 ml phosphate-buffered 
saline mixed with 0.2 ml of Freund's ad-
juvans incomplete followed by intramus-
cular booster injections of the same 
amount of R-MuLV mixed with Freund's 
adjuvans complete. One week after each 
booster 20-30 ml of blood was collected 
and the serum was absorbed in vitro by 
stepwise addition of 20 mg of liver powder 
and 10 mg of spleen powder of normal 
mice, until the serum was negative in 
Ouchterlony analysis against normal 
mouse serum, liver and spleen homoge-
nate (125 mg/ml). An antiserum against 
R-MuLV was prepared in our laboratory 
in a similar way which gave the same re-
sults as described in this paper; however, 
this serum was absorbed with spleen-, 
liver-, and serum powder coupled to Seph-
arose 4b. Both sera did not precipitate plO 
and pl2a. 
Goat anti-rabbit immunoglobulin and 
rabbit anti-bovine-serum-albumin (anti-
BSA) serum were prepared according to 
standard procedures. 
Protease inhibitors and aminoacid ana-
logs were obtained from Sigma, St. Louis, 
Mo, except phenylmethanesulphonyl fluo-
ride, which was obtained from Merck, 
Darmstadt, Germany. 
Cells and Virus 
The JLS-V9 cell-line, derived from bone 
marrow cells of Balb/c mice (Chopra and 
Shibley. 1967) infected with and producing 
R-MuLV, was grown in Eagle's minimal 
essential medium completed with 10% calf 
serum. 
R-MuLV labeled with MC-amino acids 
was isolated as described by Duesberg 
(1966) from culture mèdium of monolayers 
labeled with the MC-amino acid mixture in 
labeling medium (Hanks' basic salt solu-
tion supplemented with 10% dialysed calf 
serum and amino acids except for the 
radioactive ones). 
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Cell Labeling and Fractionation 
Cells in logarithmic growth were starved 
for 10 min in labeling medium (see above). 
Labeling was started by changing the me-
dium to labeling medium with radioactive 
amino acid(s). When indicated, radioactiv-
ity was chased by growth in normal culture 
medium. Cells were harvested, washed 
three times with cold isotonic buffer (146 
mM NaCl, 35 mM Tris-HCl, pH 7.4) and 
lysed according to one of the following pro-
cedures. 
Method 1. Cells were swollen at 4° for 5 
min in 1.0 ml of hypotonic buffer (10 mM 
NaCl, 10 mM Tris-HCl. pH 7.4, 1.5 mM 
MgCl2) and lysed by addition of 1.0% 
Triton X-100, 0.5% deoxycholate (DOC) 
(final concentrations). The lysate was 
cleared by centrifugation at 220,000 g for 10 
min in a Ti 50 rotor of a Spinco L50 
centrifuge. The supernatant fraction was 
collected and the 220,000 g pellet was 
extracted with 1.0% Triton X-100, 0.5% 
DOC and 0.1% sodium dodecyl sulphate 
(SDS) in hypotonic buffer (see above) 
(0.1% SDS did not interfere with the 
immunoprecipitation). The extract was 
cleared as described above. The superna-
tant fraction and the cleared extract were 
used for immunoprecipitation. 
Method 2. Cells were swollen as in 
Method 1 and lysed by administration of 
1.0% Triton X-100, 0.5% DOC and 0.1% 
SDS (final concentrations). The lysate was 
cleared as described above and the super-
natant fraction was used for immuno-
precipitation. 
For in vitro processing of precursor poly-
peptides cells were lysed in 1.0 ml of 
hypotonic buffer with 20 strokes of a tight-
fitting Dounce homogenizer, and the ly-
sates were incubated at 37°. The lysates 
were chilled (4°) and treated as described 
in Method 1 or 2. 
Immunoprecipitation 
Proteins of R-MuLV labeled with 14C-
amino acids (3 дСі/тІ) and solubilized 
with 1.0% Triton X-100 and 0.5% DOC 
were directly precipitated in immuno­
precipitation buffer (10 mM sodium phos­
phate, pH 7.2, 0.9% NaCl supplemented 
546 VAN ZAANE ET AL. 
with the same amounts of detergents as in 
the test sample) by addition of' rabbit 
anti-R-MuLV and incubated for 16 hr at 
4°. In a pilot experiment the optimal 
concentration of rabbit anti-R-MuLV 
serum was determined. Likewise, for the 
indirect precipitation the optimal ratio of 
viral proteins, rabbit anti-R-MuLV serum 
and goat anti-rabbit-immunoglobulin se­
rum were determined. Subsequently, virion 
proteins in the test samples of cell lysates 
were indirectly precipitated after addition 
of 2 μΐ of rabbit anti-R-MuLV serum in 
immunoprecipitation buffer (supple­
mented with the same amounts of deter­
gents as in the cell lysate) by incubation for 
16 hr at 4°, followed by incubation with 50 
μ\ of goat anti-rabbit-immunoglobulin 
serum for 2 hr at 4°. As a blank, 1 μΐ of 
rabbit anti-BSA serum was added to the 
same volume of cell lysate. With both 
rabbit sera, precipitates containing 100 ßg 
of protein were obtained. The precipitates 
were collected by centrifugation for 5 min 
at 12,000 g, washed three times with im-
munoprecipitation buffer and, finally, dis-
solved in sample buffer (Laemmli, 1970), 
containing 6 M urea, by heating for 2 hr at 
37° and 2 min at 95°. 
Immunoprecipitates were analyzed by 
gel electrophoresis, PAGE (Laemmli, 
1970), on a slab gel constructed with a 
linear (6-18%) gradient of acrylamide. Gels 
were run at 25 mA until the bromophenol 
blue marker had reached the bottom of the 
gel. The gel was stained and dried, and the 
radioactive bands were visualized by auto-
radiography. Autoradiogram sections were 
scanned in a Gilford densitometer at 590 
nm in a number of experiments. 
RESULTS 
Analysis of Anti-R-MuLV Serum 
Soluble R-MuLV proteins labeled with 
uC-amino acids were directly immuno-
precipitated for 50-60% of input radioac-
tivity. The nonprecipitated virion polypep-
tides (40-50%) could not be precipitated by 
an additional amount of antiserum. 
SDS-PAGE analysis (Fig. 1) showed that 
the major virion polypeptides except plO 
and pl2a were precipitated by anti-R-
MuLV serum. The distribution of radioac-
;^^^ â * - g p 6 9 / 7 l 
gp35 
p30 
.pl5 là 
-pio 
A В 
FIG. 1. Autoradiogram of SDS-PAGE analysis of 
(A) immunoprecipitated and (Bl reference R-MuLV 
labeled with "C-amino acids. 
tivity in total and immunoprecipitated 
R-MuLV polypeptides labeled with 1 4C-
amino acids was approximately the same, 
except for the glycoproteins gp35 and 
gp 69/71 which were present in lower 
amounts in immunoprecipitates. The anti­
serum did not react in Ouchterlony analy­
sis with normal Balb/c mouse serum, 
spleen and liver homogenates (not shown). 
6 5 
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Virus-Specific Polypeptides in Pulse- and 
Pulse-Chase-Labeled Cells 
JLS-V9 cells, persistently infected with 
R-MuLV, were labeled with L-[35S]methio-
nine for several periods between 5 and 120 
min. Cells were lysed as described in Mate­
rials and Methods {Method 1). Virus-
specific polypeptides of the supernatant 
fractions were immunoprecipitated and 
analysed by SDS-PAGE and autoradiogra­
phy. Only after at least 30 min of labeling 
was one of the virion polypeptides, pl5, 
seen. Even immunoprecipitates of the 0.1% 
SDS extract of the material insoluble in 
1.0% Triton X-100 and 0.5% DOC {Method 
1) did not contain one of the other virion 
polypeptides. However, in all immuno­
precipitates two large nonvirion polypep­
tides with molecular weights of 82,000 and 
65,000 daltons are seen, the latter more 
pronounced in the SDS extract. Therefore, 
analysis of the SDS extract obtained after 
5, 10 and 60 min of in vivo labeling is shown 
in Fig. 2. In all precipitates an aspecific 
precipitation line is seen in the region of 
50,000 daltons. 
In the next experiment cells were pulse-
gp69/71-
.p82 
-p65 
gp35-
p 3 0 -
P15-
p12b-
-p15 
plO-
B D 
FIG. 2. JLS-V9 cells (5 « 10e) were labeled with 100 дСі of L-[ 3 S S ]methionine for 5, 10 and 60 min and lysed 
according to Method I. SDS-extracted virus-specific proteins were immunoprecipitated and analysed by 
SDS-PAGE and autoradiography. (A), R-MuLV, labeled with "C-amino acids; (B), aspecific immunoprecipi-
tate of 60-min-labeled cell extract; (C-Ε), specific immunoprecipitates of the SDS extracts of cells labeled for 5, 
10 and 60 mm. respectively. 
6 6 
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labeled for 15 min with L-[35S]methionine, 
and the radioactivity was chased for vari­
ous periods up to 20 hr The results (Fig 3) 
show a gradual decrease in the amount of 
the 82,000- and 65,000 dalton polypep 
tides, accompanied by the appearance of 
pl5 after 2 hr of chase. After 20 hr of growth 
in normal medium none of the antigens can 
be detected any longer, suggesting their 
assembly in new virions, this result also 
suggests that the antiserum used does not 
precipitate cellular proteins These obser­
vations indicate that the 82,000- and 
65,000-dalton polypeptides serve as precur­
sor polypeptides that are converted into 
virion proteins immediately before or even 
during the budding process The following 
experiments were designed in order to 
visualize the transition of radioactive label 
from the 82,000- and 65,000-dalton poly­
peptides into virion polypeptides In these 
experiments cells were pulse-labeled, but 
the "chase" was carried out in the cell 
lysate in order to prevent the loss of newly 
formed virion proteins in released virions 
In Vitro Processing of R-MuLV Precursor 
Proteins 
JLS-V9 cells were labeled with L-
[3 6S]methionine for 60 mm and lysed in 
a Dounce homogemzer Prior to addition of 
detergents, fractions were incubated for 0, 
30, 60 and 120 mm, and virus-specific 
proteins from the supernatant fraction and 
the extract (Method 1) were analysed after 
immunoprecipitation (Fig 4) Now proc­
essing of the precursor polypeptides could 
clearly be demonstrated by the appearance 
of p30 and by an increase in the amount of 
pl5 after in vitro incubation, accompanied 
by a decrease in radioactivity of the 82,000-
and 65,000-dalton polypeptides, the latter 
one being present in significantly higher 
amounts in the SDS extract (Fig 4) The 
processing could be demonstrated most 
clearly in the SDS-extract (Figs 4 G-L) 
The scanning patterns of the latter analysis 
are shown in Fig 5 
In Litro incubation for 18 hr resulted in 
an additional shift in radioactivity of p l5 
to pl2b (Fig 6) Therefore, these virion 
polypeptides may be related A small peak 
of material larger than 82,000 daltons is 
2 s 
9 3 6 9 CM 
FIG 3 JLS Э cells (5 χ 10*) were labeled for 15 
mm as described with 200 дСі of L ("S ¡methionine 
and radioactivity was chased for (A) 0 (B) 2, (C) 5 and 
(D) 20 hr R MuLV specific proteins were solubilized 
as described in Method 2 and immunoprecipitated 
(E) Aspecific immunoprecipitate of 15 mm labeled 
cells and (F) R MuLV labeled with "C ammo acids 
Autoradiograms of SDS PAGE analysis were scanned 
at 590 nm 
seen in Fig 6B The origin of this material 
is not clear, it shoud be noted that aspecific 
"background" precipitation is always more 
pronounced in fractions that have been 
incubated at 37° during a long period Our 
experiments indicate that the virion pro-
teins and the precursors, especially the 
65,000-dalton polypeptide, are associated 
with a 220,000 g pellet, which contains 
material insoluble in Triton X-100 and 
DOC In accordance with this conclusion 
an analysis of cell fractions obtained in the 
absence of detergents demonstrated the 
presence of a high amount of virus-specific 
proteins in the 35,000 g pellet (Table 1) 
Attempts to inhibit proteolysis with 
phenylmethanesulphonyl fluoride (1 mM), 
./V-a-p-tosyl L-lysine-chloromethyl ketone 
(0 1 mM) or L-l-tosylamide-2-phenylethyl-
chloromethyl ketone (0 1 mM) in vwo 
and phenylmethanesulphonyl fluoride (1 
mM) or soybean trypsin inhibitor (0 1 
mg/ml) m vitro had no effect However, 
of the amino acid analogs tested, p-fluoro-
phenylalanine, canavanine and azetidine-
2-carboxyhc acid, 3 3 mM each, only 
canavanine prevented in vwo formation of 
67 
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gp69/71-
-p82 
-P65 
g p 3 5 -
p 3 0 - -p30 
p l 2 a -
p l 2 b -
-p15 
plO-
0' 
в 
30' 
с 
60' 
D 
120' 
E 
120' 
F 
0' 
G 
30 
H 
60' 120' 0' 120' 
I J К L 
Fie. 4. JLS-V9 cells (5 χ IO7), labeled for 1 hr with 200 дСі of L-[3SS|methionine, were lysed in a Dounce 
homogenizer and incubated in vitro for the times indicated. Virus-specific proteins of the supernatant fraction 
{Method 1) were immunoprecipitated and analysed (B-E); (F), aspecific control. Detergent insoluble proteins 
were extracted with IM Triton X-100, 0.5% DOC and 0.1% SDS (Method I) and treated as above (G-J); (K) 
and (L), aspecific controls; (A) R-MuLV labeled with 14C-amino acids. 
the 65,000-dalton precursor and the 
virion protein pl5 (Fig. 7). The nature of 
the very slowly moving peak found after 
canavanine treatment (Fig. 7B) is obscure; 
this small peak was sometimes also de­
tected in cells not treated with canava­
nine, and it may represent material pres­
ent in a low amount or material with low 
antigenicity. Moreover, in vitro incuba­
tion of lysates from cells that were labeled 
in the presence of canavanine did not result 
in the formation of рЗОог pl5 (not shown). 
DISCUSSION 
The experiments presented indicate the 
synthesis of two large membrane-
68 
associated proteins with molecular weights 
of 82,000 and 65,000 in R-MuLV-infected 
cells as precursors of at least the virion 
proteins p30, pl5 and pl2b (Figs. 4-6), 
which is comparable to the synthesis of a 
76,000-dalton precursor in AMV-infected 
cells (Vogt and Eisenman, 1973). It re­
mains to be established by means of finger­
prints of tryptic digests whether the 65,000-
dalton polypeptide is derived from the 
82,00G-dalton precursor polypeptide. Such 
a relationship is suggested by the absence 
of a labeled 65,000-dalton polypeptide after 
growth of cells in the presence of canavan­
ine. A more detailed scheme of the process­
ing of the precursor polypeptides cannot be 
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F I G . 5. Densitometer scannings of autoradiogram 
shown in Figs 4A and G-L In vitro incubation times 
are indicated Moleculai weight markers were albu­
min (68,000 daltons), ovumalbumin (43,000 daltons), 
chymotrypsinogen A (25,000 daltons) and cytochrome 
с (12,000 daltons) 
presented at this time, since some process­
ing products may escape detection because 
they lack antigenic determinants or 
labeled methionine residues, or they may 
have a very rapid rate of turnover. 
Anyway, it is certain that the assembly 
of p30 into budding virions proceeds very 
rapidly after production of this protein, as 
indicated by the small intracellular pool at 
p30 (Figs. 2 and 3). On the other hand, the 
polypeptide pl5, which is probably related 
to pl2b (Fig. 6), apparently has a lower 
rate of turnover because it can be detected 
intracellularly. The glycoproteins gp35 and 
gp69/71 are sometimes seen in low 
amounts, which is consistent with the high 
rate of turnover described for these R-
MuLV proteins by Moroni (1972). 
The higher amount of virus-specific pro­
teins in the 35,000 g pellet (Table 1) and 
the strong association of these proteins 
with the membrane-rich fraction (Fig. 4) 
suggest that processing is an event that 
takes place at membranes. In agreement 
with these observations, the synthesis of 
virus-specific proteins proceeds in associa­
tion with membranes as shown by the 
kinetics of virus-specific polyribosome for­
mation, studied by hybridization tech­
niques (Fan and Baltimore, 1973; Vecchio 
et al, 1973; Gielkens et al, 1974; Shanmu-
gam et al., 1974). 
In contrast to our observations, both 
virus-specific precursor polypeptides and 
virion polypeptides could be detected in 
® 
® 
/J'VAH 
<D 
A J U J 
i. 5 6 7 8CM 
Fie. 6 JLS V9 cells (5 χ 10') were labeled for 1 hr 
with 200 μΟι of L-[3iS)methionine and lysed in a 
Bounce homogemzer Lysates were incubated at 37° 
for (A) 2 and (B) 16 hr and treated as described in 
Method 2 Soluble proteins were analysed by im-
munoprecipitation and SDS PAGE (C), Reference 
R MuLV labeled with "C-amino acids Autoradio­
gram sections were scanned at 330 nm 
69 
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TABLE 1 
DISTRIBUTION OF VIKI Ь SPKCIHC PROTKINS IN S I ΒΓΕΙ 11 LAR FRACTIONS FROM JLS-V9 С п u, PRODI CINC. R - M L L V 
Fractionation step 35,(Ю0й Supernatant fraction" 35,000 a Pellet-
Total cpm Percent of 
previoub step 
Total cpm Percent of 
previous step 
1 Total radioactivity 13x10« 100 
2 220,000^ Supernatant after extraction 9 1 < 10« 70 
with detergents' 
3 Immunoprecipitable from 2 3 6 ч 10' 0 4 
13 χ 10« 100 
2 9 χ IO« 22 
2 3 у 10s 7 9 
° 50 χ 10' cells were labeled for 1 hr with 200 цСі ol i,- [35S jmethionine The cells were lysed in the absence of 
detergents with a Dounce homogeni7er The Ivsate, which contained 26 у 10' cpm incorporated into protein, 
was divided into a 35.000g supernatant traction and a 35,000 g pellet by centrilugation for 10 mm at 35,000 g in 
a Ti 50 rotor 
' The 35,000 g supernatant fraction and pellet were extracted with 1 0% Triton X-100, 0 54 DOC and 0 IT-
SDS. and the extracts were cleared by centrifugation tor 10 mm at 220,000 g in a Ti 50 rotor 
J. 5 6 7 CM 
FIG. 7 JLS-V9 cells (10*) were labeled for 1 hr 
with 50 MCI of L- ["S )methionine in the absence (A) or 
in the presence (B) of 3 3 mjVf canavamne Cells were 
lysed according to Method 2 and lysates were 
analysed by immunoprecipitation and SDS-PAGE 
Autoradiogram sections were scanned at 590 nm 
cells infected with AMV (Vogt and Eisen­
man, 1973), whereas in MSV/(MLV)-
infected or RSV transformed cells only 
virion proteins were found (Shanmugam et 
al., 1972; Fleissner and Tress, 1973). It is 
unlikely that in these cells no precursors of 
low molecular weight virion proteins are 
70 
formed; therefore, there must be a differ­
ence in the kinetics of processing of virus-
specific proteins among several viruses 
and different cell-lines. 
Convincing evidence indicates that the 
genome size of oncornavirus RNA is only 3 
χ 10e (Quade et al., 1974; Billeter et al., 
1974; Beemon et ai, 1974). Since this 
genome is already known to code for a 
precursor polypeptide (76,000 daltons, gag), 
an envelope (70,000 daltons) gene product, 
the polymerase (60,000 daltons) and, pre­
sumably, an one gene product (Baltimore, 
1975), there is little space left for yet 
unidentified genes, for instance those for 
processing of precursor polypeptides. 
Therefore, the processing is likely to be cat­
alyzed by host enzymes and, consequently, 
different kinetics of the processing are host 
specific. 
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Noie added in proof Recent experiments resulted 
in the detection of a 72,000 dalton polypeptide after 
growth in the presence of canavamne This poly­
peptide and the 65,000-dalton polypeptide could be 
precipitated by a monospecific anti-p)0 serum, 
whereas the 82,000-dalton polypeptide was not pre­
cipitated by this serum Moreover, it was found that 
the latter polypeptide is glycosylated 
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CHAPTER IV 
VIRUS-SPECIFIC PRECURSOR POLYPEPTIDES IN CELLS INFECTED WITH 
RAUSCHER LEUKEMIA VIRUS: SYNTHESIS, IDENTIFICATION AND 
PROCESSING 
The nomenclature of R-MuL V polypeptides used in this chapter is 
different from the present nomenclature (see chapter I): R-MuL V 
polypeptide designated here pi2 is identical with p12(Ej of the present 
nomenclature. 
VIROLOGY 75, 113-129 (1976) 
Virus-Specific Precursor Polypeptides in Cells Infected with Rauscher 
Leukemia Virus: Synthesis, Identification, and Processing 
D. VAN ZAANE,1 M. J . A. DEKKER-MICHIELSEN, AND H. P. J. BLOEMERS 
Department of Biochemistry, University of Nijmegen, Geert Grooteplein Noord 21, 
Nijmegen, The Netherlands 
Accepted July 8, 1976 
The synthesis of virus-specific polypeptides in JLS-V9 and JLS-V5 cells infected with 
Rauscher leukemia virus (R-MuLV) was studied in pulse-chase experiments, followed by 
radioimmunoprecipitation analysis with polyvalent and monospecific antisera against 
R-MuLV proteins Two glycosylated polypeptides with molecular weights of about 82,000 
(елі;-рг82і were identified as precursors of the virion envelope polypeptides gp69/71 and 
pl5(E) On the other hand, virion polypeptides p30 and pl5 are derived from a 75,000-
(gag-pr75) and a 65,000-dalton {gag-prf>5) precursor polypeptide These precursor-prod­
uct relations were confirmed by analysis of chymotryptic digests of virion polypeptides 
and their precursors In the presence of the arginine analog canavamne two polypeptides 
with molecular weights of 82,000 and 72,000 (£ag-pr82 andgag-pT72, respectively) were 
synthesized instead of gag-prTS and gag-prSd Processing of precursor polypeptides is 
reduced in the presence of canavamne From these results, we conclude that£a#-pr82 is 
possibly the primary gag-gene product and is cleaved into gag-prlä These studies 
provided the following additional information: First, we established that immediately 
after cleavage of their precursors, gp69/71 is found on the outer surface of the cell and 
p30, pl5, and pl2 leave the cell as components of budding virions. Therefore, these 
polypeptides were detected intracellularly in very small amounts only Polypeptide 
pl5(E) was present within the cell as well as on its outer surface Second, despite a great 
similarity in virus-specific (precursor) polypeptides detected in JLS-V9 and JLS-V5 
cells, small differences in molecular weights of some of these polypeptides were observed 
after SDS-PAGE 
INTRODUCTION 
The synthesis of precursor polypeptides 
of oncornavirus polypeptides was first 
demonstrated for avian myeloblastosis vi-
rus (AMV) by Vogt and Eisenman (1973). 
Recently, this group described a detailed 
processing scheme of the AMV-specific 
precursor polypeptide (Vogt et al., 1975). 
In addition, Halpern et al. (1974) demon-
strated the synthesis of an incompletely 
glycosylated 70,000-dalton precursor poly-
peptide of the envelope glycoprotein gp85 
of Rous sarcoma virus. 
In cells infected with and producing 
Rauscher leukemia virus (R-MuLV), two 
unstable precursor polypeptides of virion 
1
 Author to whom requests for reprints should be 
addressed. 
proteins were detected (Van Zaane et al., 
1975). One of these precursors with molec-
ular weight of 65,000 (pr65) contained anti-
genic determinants of the major virion 
protein p30, whereas the other precursor 
polypeptide with molecular weight of 
82,000 (pr82) was not precipitated with 
monospecific anti-рЗО serum. In addition, 
it was shown that the latter precursor pol­
ypeptide could be labeled with D-[1-
'H ¡glucosamine. 
In contrast to our results, Naso et al. 
(1975) reported the synthesis of at least 
three unstable precursor candidates 
(140,000, 65,000, and 50,000 daltons) of R-
MuLV polypeptides in infected JLS-V16 
cells. However, more recent results of this 
group (Jamjoom et al., 1975; Arcement et 
al., 1976) are in good agreement with the 
Copyright © 1976 by Academic Press, Ine 
AU rights of reproduction in any form reserved 
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present work and our previous publication 
(Van Zaane et al., 1975) Consistent with 
our results are also the findings of Shapiro 
and Strand (1975); in normal rat kidney 
cells infected with R-MuLV, they identi­
fied a glycosylated 85,000-dalton precursor 
polypeptide and a 65,000-dalton precursor 
polypeptide with gp69/71 and p30 anti­
genic determinants, respectively In still 
another main group of the oncornaviruses, 
the B-type mouse mammary tumor virus, 
some polypeptides are derived from a gly­
cosylated 73,000-dalton precursor polypep­
tide (Dickson et al , 1975, Dickson et al , 
1976) 
The major problem encountered in our 
previous study (Van Zaane et al , 1975) 
was the failure to demonstrate a clear con­
version of precursor polypeptides into vir­
ion polypeptides in pulse-chase experi­
ments, probably because of the rapid 
release of some virion polypeptides (e g., 
p30) in budding virions, thus, they escaped 
from detection. In this paper, we used a 
modified pulse-chase and lysis procedure 
that enabled the detection of both intracel­
lular and extracellular virus-specific poly­
peptides. According to this new procedure, 
the cells were lysed in the chase medium 
which contained newly released virions 
Thus, using again JLS-V9 cells infected 
with R-MuLV, we identified two glycosyl­
ated virus-specific precursor polypeptides 
with molecular weights of about 82,000 
(егш-рг82) and two nonglycosylated virus-
specific precursor polypeptides of 75,000 
and 65,000 molecular weight (gag-pr75 
and gag-pr65) The prefixes gag- and env-
correspond with two of the four genes pro­
posed by Baltimore (1975) for the oncorna­
virus genome gag, env, pol, and one We 
showed by chymotryptic peptide analysis 
and radioimmunoprecipitation with mono­
specific antisera that the virion envelope 
proteins gp69/71 and pl5(E) are derived 
from the eni;-pr82 precursor polypeptides, 
whereas the virion proteins p30 and pl5 
are cleaved from precursor polypeptides 
gag-pr75 and gag-pr65 Similar results 
were obtained with JLS-V5 cells infected 
with R-MuLV 
Finally, our analysis of virion polypep­
tides confirmed the detection of pl5(E) by 
76 
Ikeda et al (1975) as a new virion polypep­
tide that is chemically and serologically 
different from pl5 
MATERIALS AND METHODS 
Materials l4C-labeled amino acid mix­
ture (sp act, 57 mCi/matom) and D-[1-
3H]glucosamine (sp act, 3 Ci/mmol) were 
obtained from the Radiochemical Centre, 
Amersham, England Canavamne was 
bought from Sigma, St Louis, Mo., and 
chymotrypsin was obtained from Wor-
thington, Freehold, N J 
Antisera (1) Rabbit anti-R-MuLV se­
rum was prepared as described previously 
(Van Zaane et al , 1975), and it was ab­
sorbed with normal Balb/c mouse tissue 
powder coupled to Sepharose 4b. 
(2) Rabbit anti-рЗО serum and rabbit 
anti-pl5(E), pl2 serum was prepared simi­
larly with R-MuLV polypeptides, isolated 
by gel filtration in 6 M guamdinium chlo­
ride (GuHCl) (fractions 61-68 and 11-35, 
respectively, Fig 1) These sera were not 
absorbed 
(3) Goat antisera against R-MuLV gp69/ 
71 and pl5 were a generous gift of M. 
Strand and J Τ August, Albert Einstein 
College of Medicine, Bronx, N.Y Charac­
teristics of these sera were described by 
Strand and August (1976) 
(4) Rabbit anti-bovine-serum-albumin 
serum, rabbit anti-goat immunoglobulin 
serum, and goat anti-rabbit immunoglob­
ulin serum were prepared by the immuni­
zation procedure described for rabbit anti-
R-MuLV serum 
Cells and virus The JLS-V9 cell-line, 
derived from bone marrow cells of Balb/c 
mice (Chopra and Shibley, 1967), and the 
JLS-V5 cell-line, derived from spleen and 
thymus of Balb/c mice (Wright and Las-
fargues, 1965) infected with and producing 
R-MuLV, were grown as monolayers in 
Eagle's minimal essential medium com­
pleted with 10% calf serum 
R-MuLV used for isolation of virion 
polypeptides by gel filtration in 6 M 
GuHCl and subsequent preparation of 
monospecific rabbit antisera was isolated 
from the culture medium of JLS-V9 cells, 
which were grown in Eagle's minimal es­
sential medium completed with 5% inacti-
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vated normal rabbit serum The use of 
rabbit serum prevented immunological re-
actions against copunfied serum proteins 
R-MuLV was concentrated by 6 M polyeth-
ylene-glycol precipitation and was purified 
as described by Duesberg and Robinson 
(1966) 
R-MuLV labeled with HC-amino acid 
mixture was prepared as described previ-
ously (Van Zaane et al , 1975), and R-
MuLV labeled with D-tl-'Hlglucosamine 
(15 /¿Ci/ml) was prepared similarly 
Cell labeling and lysis procedure Sub-
confluent monolayers of JLS-V9 or JLS-V5 
cells (25 cm-) were starved for 10 min in 
labeling medium lacking amino acids or 
glucose (Van Zaane et al , 1975) Subse-
quently, cells were labeled with "C-amino 
acid mixture or with D-fl-'Hlglucosamine 
for 15 and 30 mm, respectively When indi-
cated, radioactivity was chased by growth 
in 1 0 ml of normal medium supplemented 
with 1 mg of lacto-albumin hydrolysate 
per ml or with 25 mM D-glucosamine 
After pulses, cells were harvested by 
scraping them with a rubber policeman in 
2 0 ml of hypotonic bufler (Van Zaane et 
al , 1975), after chases, cells were scraped 
in the chase medium after addition of 1 0 
ml of hypotonic buffer Cells (containing at 
most 2 5 mg of cellular protein) (Lowry et 
al , 1951) were lysed by addition of 0 25 
volume of a concentrated buffer yielding 
final concentrations of 10 mM sodium 
phosphate, pH 7 2, 0 15 mM sodium chlo-
ride, 1 0% Triton X-100, 0 59c deoxycho-
late, and 0 1% sodium dodecyl sulphate 
(immunoprecipitation buffer) The lysate 
was cleared by centrifugation at 220,000 g 
for 10 mm in a Ti 50 rotor of a Spinco L50 
centrifuge The supernatant which con-
tained 80-90% of total radioactivity was 
used for immunoprecipitation of virus-spe-
cific polypeptides 
Radioimmunoprecipitation assay 
(RIP) Radioimmunoprecipitation of vi-
rus-specific polypeptides labeled with "C-
amino acid mixture was performed as de-
scribed previously (Van Zaane et al , 1975) 
with a minor modification before washing 
of immunoprecipitates, the immunopre-
cipitation mixture was layered on 0 2 ml of 
10% sucrose in immunoprecipitation 
buffer and was centrifuged for 5 mm at 
12,000 g Subsequently, precipitates were 
washed three times with immunoprecipi-
tation buffer Optimal ratios of virus-spe-
cific antigen in JLS-V9 and JLS-V5 lysates 
and rabbit anti-R-MuLV serum were de-
termined by means of immunoprecipita-
tion curves Similarly, optimal ratios for 
the anti-immunoglobulin sera were deter-
mined A typical RIP assay mixture con-
tained in 200 μ\ of immunoprecipitation 
buffer 15 μg of protein of JLS-V9 or JLS-
V5 lysates and 2 μ\ of anti-R-MuLV se­
rum Immunocomplexes were precipitated 
by addition of 50 μΐ of goat anti-rabbit 
immunoglobulin serum Analysis with 
monospecific antisera (1-5 μΐ) were per­
formed with the same amount of JLS-V9 or 
JLS-V5 lysate used for the RIP assay with 
anti-R-MuLV serum All precipitates con­
tained 50-100 μg of protein 
To precipitate sufficient radioactivity for 
analysis of virus-specific polypeptides in 
cells labeled with D-H-'HIglucosamine, 
much larger amountb of cell lysates were 
required Therefore, virus-specific poly­
peptides labeled with D-tl-'HJglucosamine 
were precipitated directly by addition of 
100 μΐ of rabbit anti-R-MuLV serum to 200 
μg of cellular protein in 500 μΐ of immuno­
precipitation buffer 
R-MuLV-specific antisera were charac­
terized by indirect RIP assay with R-
MuLV labeled with "C-amino acid mix­
ture and dissolved in immunoprecipitation 
buffer R-MuLV-insoluble material was 
removed by centrifugation for 5 mm at 
12,000 g 
In competitive RIP assays, R-MuLV 
polypeptides purified by gel filtration in 6 
M GuHCl were added to the assay mixture 
before the R-MuLV specific antiserum In­
direct immunoprecipitation was performed 
as described above 
Immunoprecipitates were dissolved in 
sample buffer (Laemmli, 1970) supple­
mented with 6 M urea, and virus-specific 
polypeptides were analyzed by SDS-PAGE 
as described by Gielkens et al (1976) Ra­
dioactivity was visualized by scintillation 
autoradiography (Bonner and Laskey, 
1974) 
Fractionation of R-MuLV polypeptides 
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A R-MuLV preparation (10 mg of protein) 
was mixed with IO"* cpm of R-MuLV la­
beled with "C-amino acid mixture, and 
this mixture was dissolved in 8 M GuHCl, 
0.02 M sodium phosphate, pH 6.5, and 2% 
/3-mercaptoethanol by heating for 2 hr at 
56°. R-MuLV polypeptides were isolated by 
gel filtration on a Biogel A5m column (1.6 
χ 100 cm) as described by Nowinski et al. 
(1973). After elution, 50 μ\ of each fraction 
(1.0 ml) was counted in 5.0 ml of Aquasol 
in a Packard liquid scintillation counter. 
Pooled fractions were dialyzed as described 
by Green and Bolognesi (1974) and were 
lyophilized. 
Chymotryptic peptide analysis. For a 
further characterization of virus-specific 
polypeptides, immunoprecipitates or R-
MuLV preparations or eluates of slices of 
Polyacrylamide gels were digested in 50 
mM ammonium bicarbonate buffer, pH 
8.9, with chymotrypsin (0.1 mg/ml). Chy­
motryptic peptides were analyzed by Ami-
nex A5 ion-exchange chromatography 
(0.4- χ 20-cm column) at 50° with the elu­
tion system described by Vogt et al. (1975). 
Fractions of 1.8 ml were collected and ra­
dioactivity was counted in 5.0 ml of Aqua-
sol as described above. ['Hlserine and 
['Hllysine, 2000 cpm each, were cochro-
matographed as markers. 
RESULTS 
R-MuLV Polypeptide Composition 
The polypeptide composition of R-MuLV 
has been studied by gel filtration in 6 M 
GuHCl and SDS-PAGE (reviewed by 
Nowinski et al., 1973; Bolognesi et al.. 
1974; Gielkens, 1976). By these techniques, 
six major polypeptides could be identified 
in R-MuLV: gp69/71, gp45, p30, pl5, pl2, 
and plO (nomenclature according to Au­
gust et al., 1974). In our experiments all 
polypeptides were detected with the excep­
tion of gp45, which was not visible after 
labeling of virion polypeptides with D-[1-
'HJglucosamine (Figs. 1, 2, and 3P). The 
virion polypeptide plO was present in a low 
and variable amount. An additional poly­
peptide with molecular weight of 65,000 
was observed in our R-MuLV prepara­
tions. This polypeptide comigrated with 
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pr65, described previously as a precursor of 
virion polypeptides (Van Zaane et al., 
1975), and was precipitated in RIP assays 
with monospecific anti-рЗО serum. The 
amount of pr65 in our R-MuLV prepara­
tions differed remarkably (see also Gielk­
ens, 1976). Recently, a new low molecular 
weight polypeptide of R-MuLV which was 
overlooked in earlier studies has been de­
scribed by Schafer et al. (1975), Ihle et al. 
(1975), and Ikeda et al. (1975). This poly­
peptide designated pl5(E) elutes in the 
void volume fraction during gel filtration 
in 6 M GuHCl and migrated slightly 
slower or with the same mobility as pl5 in 
SDS-PAGE analysis. It is chemically and 
serologically different from pl5 and ap­
peared to be a minor component in R-
MuLV preparations. In our previous study 
(Van Zaaneet al., 1975), we observed three 
polypeptides migrating during SDS-
PAGE in the 18,000-12,000 dalton region, 
previously designated by us as pl5, pl2a, 
and pl2b, but in this paper indicated by 
the nomenclature of Ikeda et al. (1975) as 
pl5(E), pl5, and pl2, respectively. This 
identification is based upon the following 
evidence: Fig. 1 shows the elution profile of 
R-MuLV polypeptides labeled with 'sc­
arnino acid mixture. The virion polypep­
tides gp69/71, p30, pl5, pl2, and plO eluted 
in the order of their molecular weights; 
however, it appeared from SDS-PAGE 
analysis that the void volume fraction 
(fraction numbers 1-10, Fig. 1) as well as 
the fractions 11-35 contained two low mo­
lecular weight polypeptides pl5(E) and 
pl2, which were previously designated as 
F I G . 1 Gel filtration in 6 M GuHCl of a mixture 
of 10 mg of R-MuLV and 10'' cpm of R-MuLV labeled 
with "C-amino acid mixture R-MuLV preparations 
were isolated from culture medium of JLS-V9 cells 
Details are described in the Materials and Methods 
section 
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pl5 and pl2b, respectively. The analysis of 
the column fractions is not presented here, 
but pl5(E) and pl2 can be seen in Fig. 2. 
In accordance with Ikeda et al. (1975), it 
was found in cooperation with Gielkens 
that pl5(E) was chemically different from 
pl5 because of different labeling character-
istics of these polypeptides with "C-amino 
acid mixture and L-|4'S|methionine 
(Gielkens, 1976). In addition, Fig. 2 shows 
that pl5 is serologically different from 
pl5(E) because only pl5 could be precipi-
tated with anti-pl5 serum, whereas pl5(E) 
was precipitated with antiserum raised 
against polypeptides eluting in fractions 
11-35 (Fig. 1). Although direct evidence 
was lacking, Ikeda eí al. (1975) concluded 
from their results and a related study of 
Ihle et al. ( 1975) that pl5(E) was located in 
the virion envelope. In this paper we will 
show that pl5(E) is located on the cell 
surface (Fig. 7) and, therefore, pl5(E) is 
probably a component of the virion enve-
lope. 
Analysis of Polyvalent and Monospecific 
Antisera 
The serological activity of antisera 
raised against R-MuLV polypeptides was 
tested by means of radioimmunoprecipita-
tion. Antisera were mixed with 2000 cpm 
of R-MuLV polypeptides labeled with "C-
amino acid mixture. Immunocomplexes 
were precipitated by addition of the appro-
priate antiimmunoglobulin serum, and vi-
rus-specific polypeptides were analyzed by 
SDS-PAGE and scintillation autoradiog-
raphy (Fig. 2). The anti-R-MuLV serum 
precipitated all major virion polypeptides, 
except plO which was present in low 
amounts in R-MuLV preparations (Fig. 2A 
and B). The antisera raised against gp69/ 
71, p30, and pl5 precipitated the corre-
sponding virion polypeptides (Fig. 2C-E). 
9P69/71-
pr65~ 
-9Ρ69/71 
-РГ65 
P30-
-P30 
pISCIgL^ . _ , _ £ . ^P15(E) 
-P15 
"P12 
EÌ 
FIG. 2. Characterization of polyvalent and monospecific antisera against R-MuLV polypeptides by 
radioimmunoprecipitation of soluble R-MuLV proteins labeled with "C-amino acid mixture as described in 
the Materials and Methods section. Immunoprecipitates were applied to SDS-PAGE and radioactivity was 
visualized by scintillation autoradiography. (Al Reference R-MuLV labeled with "C-amino acid mixture. 
Immunoprecipitation of virion polypeptides with: (B) anti-R-MuLV serum; (Cl anti-gp69/71 serum; (Dl anti-
p30 serum; (E) anti-pl5 serum; (F) anti-pl5(E), pl2 serum; (G) anti-BSA serum; (H) anti-R-MuLV serum. 
Analyses (F), (G), and (H) were performed on a separate gel with a different R-MuLV preparation. 
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Moreover, anti-gp69/71 serum precipitated 
pl5(E) and pl2 However, we concluded 
from competitive RIP assays with unla­
beled pl5(E) and pl2 (Fig 4G-0) that 
pl5(E) was strongly associated with gp69/ 
71, therefore, pl5(E) coprecipitates with 
gp69/71 This was indicated by the obser­
vation that precipitation of pl5(E) with 
anti-gp69/71 serum was not prevented by 
addition of excess unlabeled pl5(E) and 
pl2, isolated by gel filtration in 6 M 
GuHCl (Fig 1, void volume fraction), on 
the other hand, there is no doubt about the 
serological activity of the unlabeled pl5(E) 
and pl2 preparation, because it did com­
pete with radioactively labeled pl5(E) and 
pl2 in a RIP assay with anti-pl5(E), pl2 
serum Precipitation of the virion polypep­
tide pl2 with anti-gp69/71 serum was ob­
served in these experiments after longer 
exposure of autoradiograms (not shown) 
Its precipitation was not prevented by an 
excess of unlabeled pl5(E) and pl2 There­
fore, pl2 can also be found in association 
with gp69/71 
The anti-pl5(E), pl2 serum precipitated 
a small amount of gp69/71 in addition to 
pl5(E) and pl2 because of the association 
ofgp69/71 with pl5(E) and pl2 (Fig 2F) A 
similar association of pl5(E) and virion 
glycoproteins was observed by Ikeda et al 
(1975) 
Synthesis of Virus-Specific Polypeptides 
in JLS-V9 Cells 
Previous experiments (Van Zaane et al , 
1975) revealed the existence of a glycosyl­
ated 82,000-dalton polypeptide and a 
65,000-dalton polypeptide as precursors of 
R-MuLV proteins Conversion of these 
polypeptides into some of the virion poly­
peptides could be demonstrated by incuba­
tion of lysates of pulse-labeled cells only 
Therefore, it was concluded that newly 
formed virion polypeptides are rapidly re­
leased in budding varions Consequently, 
to avoid loss of chased radioactivity, we 
modified the pulse-chase conditions and 
the procedure for harvesting cells by scrap­
ing them with a rubber policeman in the 
chase medium This procedure enabled the 
detection in the RIP assay of both intracel­
lular and extracellular virus-specific poly­
peptides 
Figure 3 shows the results of a pulse-
chase experiment with JLS-V9 cells in­
fected with R-MuLV Cells were pulse-la­
beled for 15 mm with HC-amino acid mix­
ture, and immunoprecipitates of virus-spe­
cific polypeptides from the cell lysates with 
anti-R-MuLV serum were analyzed by 
SDS-PAGE and scintillation autoradiog­
raphy (Fig 3A-D) In addition to the pre­
viously described virus-specific polypep­
tides pr82 and pr65, a 75,000-dalton poly­
peptide was observed in pulse-labeled cells 
(Fig ЗА) Moreover, gels with high resolu­
tion showed that pr82 consisted of two 
polypeptides After chase periods of '/4, 2, 
and 8 hr with excess amino acids, a clear 
conversion of these virus-specific polypep­
tides into virion polypeptides gp69/71, p30, 
pl5(E), pl5, and pl2 could be demon­
strated (Fig 3B-E) The virion polypep­
tides were not synthesized de novo during 
the chase period because inhibition of pro­
tein synthesis by addition of cycloheximide 
(100 μg/ml) to the chase medium did not 
prevent the formation of virion polypep­
tides (not shown) Therefore, both pr82 
polypeptides, pr75 and pr65, are probably 
precursor polypeptides of virion proteins 
To discriminate between these precursors, 
a similar experiment was performed with 
monospecific anti-рЗО serum (Fig 3F-I) 
This serum precipitated pr75 and pr65 
from lysates of pulse-labeled cells and p30 
was precipitated after chase periods of 2-8 
hr, whereas pr75 and pr65 were gradually 
disappearing during the chase Conse­
quently, both pr75 and pr65 polypeptides 
contain antigenic determinants of virion 
p30 and are precursor polypeptides of p30 
In contrast to pr75 and pr65, both pr82 
polypeptides which could be labeled with 
D-ll-'HIglucosamine (Fig 3L) were not 
precipitated by anti-рЗО serum (Fig 3F-
1,0) After growth of pulse-labeled cells for 
2 to 8 hr in the presence of 25 mM D-
glucosamine, radioactivity was chased 
into the virion envelope glycoprotein gp69/ 
71 (Fig 3L-0) In addition, it should be 
noted that the virion envelope polypep­
tides gp69/71 and pl5(E) are formed more 
rapidly than the virion polypeptides рЗО, 
pl5, and pl2 These results argue for a 
precursor-product relation of the pr82 poly­
peptides with gp69/71 and pi5(E) The 
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Fro. 3. Suhmnflnont. тппоіаургч of JLS- colls (25 i-m2) were piil«e-lahpIo<l for 15 min with 100 μ€ί of 
"C-amino arid rriivtnrp and rad inactivity was chased for 0. 1/4. 2. or 8 hr as indicated in the figure (Α-D and 
F-K). Similarly, JI.S-V9 cells were labeled for 30 min with 250 дСі of n-ll-'HIglncosamine and radioactivity 
was chased for 0, 2, or 8 hr (L-Ol. Cells were scraped in hynntonic buffer (after pulses) or in the chase 
medium (after cha«es) and were lysed as described in the Materials and Methods section. Virus-specific 
polypeptides were analysed by SOS-PAGE and scintillation autoradiography after immunoprecipitation 
with: (Α-D) anti-R-MuLV serum; (F-l) anti-рЗО serum; (.1) and (K) anti-BSA serum; (L-N) anti-R-MuLV 
serum; (O) anti-рЗО serum. Reference R-MuLV labeled with (E), uC-amino acid mixture, or (P), D-(l-
1H ¡glucosamine. 
slight diffprpnce in elprtrophor^tic mobil-
ity of gpfi9/71 foTnpd after chases in the 
precence of 25 mW glucosamine (Fig. 3L-
N) and of gfp69/71 from isolated virions 
(Fig. 3P) can he due to an inhihition of 
glycosylation hy the high conrentration of 
p-glucosamine (Klenk ίΊ* a/., 1972). 
None of tbe polypeptides described could 
be precipitated in a control RIP assay with 
anti-BSA serum (Fig. 3-1 and K), but a 
50,ООП-dalton polypeptide migrating 
slightly faster than the immunoglobulin 
Η-chain was precipitated in variable 
amounts in all assays. From these results, 
we concluded that the 50.000-dalton poly­
peptide was precipitated asppcifically, at 
least partly. Migrating between this poly­
peptide and the p30 virion polypeptide, two 
to four minor components w^re observed 
which could also be precipitated with anti-
p30 serum (Fig. 3A-I). Therefore, they are 
prohahly intprmedia^es in the processing 
of pr75 and ргв5. 
In the high mnlepular weight region, 
gpvpral minor polypeptides migrating 
more slowly than pr82 wpre precipitatpd 
with anti-R-MuLV serum. The polypep­
tide migrating directly behind pr82 was 
also precipitated with anti-рЗО serum. 
This latter polypeptide was not precipi­
tated from lysates of cells pulse-labplpd for 
15 min, but was detected after chase pe­
riods only. Since addition of cycloheximide 
to the chase medium (see above) does not 
prevent formation of this polypeptide (not 
shown), it is not synthesized de novo dur­
ing tbe chase period. At present, the na­
ture of thpse high molecular weight poly­
peptides is unknown. We could speculate 
that they are possibly still larger prpcur-
sor-polypeptides or intermediates in their 
processing (Arcement et ni., 1976). 
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So far, these initial experiments suggest 
that the envelope polypeptides gp69/71 and 
pl5(E) are cleaved from the enu-pr82 poly­
peptides, whereas the virion polypeptides 
p30 and pl5 are derived from gag-prl5 and 
gag-pr65 (see also Fig. 11). For reasons of 
clarity, the prefixes enч and gag are added 
to the nomenclature of precursor polypep­
tides of virion envelope polypeptides and 
internal polypeptides, respectively. More 
detailed analyses with monospecific anti-
jera and ion-exchange chromatography of 
chymotryptic digests of virus-specific poly­
peptides will provide further evidence for 
the suggested precursor-product relations. 
Identification of Virus-Specific Precursor 
Polypeptides 
Radioimmunoprecipitation analysis of 
virus-specific polypeptides in JLS-V9 cells 
was performed with monospecific antisera 
(Fig. 4). The еп -рг82 polypeptides could 
be precipitated from lysates of pulse-la­
beled cells with anti-gp69/71 serum and 
anti-pl5(E), pl2 serum, whereas gag-pr75 
and gag-pr65 were precipitated with anti-
p30 serum and anti-pl5 serum (Fig. 4A-D, 
G). After a chase period of 8 hr, eni;-pr82 
and gp69/71 were precipitated with anti-
gp69/71 serum, and pl5 was precipitated 
with anti-pl5 serum (Fig. 4E and F). 
pl5(E) was also precipitated with anti-
gp69/71 serum due to its strong association 
with gp69/71 (Fig. 4G-0), as discussed 
above. The polypeptides migrating to the 
40,000- to 50,000-dalton region during 
SDS-PAGE (probably intermediates in 
the processing of gag-prlb and gag-pr&b) 
were precipitated with anti-рЗО serum, but 
not with anti-pl5 serum. 
pr82-
pr75-
9P69/71: 
pr65 
-pr82 
-gp69/71 
W ^ 1 " 
p15(EJ— 
p 1 5 — 
-p15(E) 
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А в 
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FIG 4. -Virus-specific polypeptides from JLS-V9 cells were identified by radioimmunoprecipitation with 
monospecific antisera and by competitive radioimmunoprecipitation with isolated R-MuLV polypeptides. 
Analyses were performed as described in the legend of Fig 3 with JLS-V9 cells which were labeled with ' 'C-
amino acid mixture, followed by a chase period of 0, 2, or 8 hr as indicated in the figure Immunoprecipita-
tion with: (A) anti-R-MuLV serum; (B) anti-gp69/71 serum; (C) anti-рЗО serum, (D) anti-pl5 serum; (E) anti-
gp69/71 serum; (F) anti-pl5 serum; (G) and (H) anti-pl5(E), pl2 serum; (I) and (J) anti-pl5(E), pl2 serum, 
in the presence of 25 μg of unlabeled ρ 15(E), ρ 12 (void volume fraction from Fig. 1), (K) and (L), anti-gp69/71 
serum; (M) and (N), anti-gp69/71 serum in the presence of 25 μg of pl5(E), pl2; (O), anti-BSA serum. 
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Chymotryptic Peptide Analysis of Virus-
Specific Precursor Polypeptides 
The chymotryptic peptides of £ag-pr75 
and gag-pr65 immunoprecipitated to-
gether from a lysate of JLS-V9 cells with 
anti-рЗО serum and the chymotryptic pep­
tides of R-MuLV proteins, both labeled 
with "C-amino acid mixture, were com­
pared by ion-exchange chromatography as 
described in the Materials and Methods 
section (Fig. 5). It should be noted that our 
R-MuLV preparations contained small 
amounts of gp69/71 and plO; therefore, the 
chymotryptic peptides obtained from these 
preparations (Fig. 5B) are characteristic 
for the low molecular weight polypeptides 
p30, pl5(E), pl5, and pl2. Despite the 
great complexity of the elution patterns 
obtained, the results presented in Fig. 5 
confirm the relation of the #ag-precursors 
pr75 and pr65 and some of the low molecu­
lar weight R-MuLV polypeptides (p30 and 
pl5). Similarly, we compared the chymo­
tryptic peptides of еш;-рг82, gp69/71, and 
pl5(E) eluted from slices of Polyacrylamide 
gels (Fig. 6). The virus-specific polypep­
tides were immunoprecipitated with anti-
R-MuLV serum from lysates of JLS-V9 
cells labeled with "C-amino acid mixture. 
'. I, 
FIG 5 (A) Chymotryptic peptides of gag-pr75 
and #a,¡»-pr65 immunoprecipitated with anti-рЗО se­
rum from lysates of JLS-V9 cells pulse-labeled with 
"C-amino acid mixture, and (B) chymotryptic pep­
tides of R-MuLV labeled with "C-amino acid mix­
ture were analyzed by ion-exchange chromatogra­
phy as described in the Materials and Methods sec­
tion I'Hlserme and ['Hjlysine were cochromato-
graphed as markers 
These analyses agree with the precursor-
product relation of env-pr82 and gp69/71 
described above. The differences of the elu­
tion patterns of chymotryptic peptides of 
env-pr82 and gp69/71 (a double peak in 
fractions 26-31 in Fig. 6A in comparison 
with a single peak in fractions 26-31 in 
Fig. 6B, and the absence in Fig. 6B of the 
peaks eluting in fractions 126-128 and 157-
159 of Fig. 6A) agree with the pattern ob­
tained after analysis of chymotryptic pep­
tides of pl5(E) (Fig. 6C). Cochromatogra-
phy of chymotryptic peptides of env-pr82 
and pl5(E) confirmed the identical elution 
behavior of the peaks 26-31, 126-128, and 
157-159 of Fig. 6A, and peaks 21-26, 130-
132, and 159-161 of Fig. 6C, respectively, 
as shown in Fig. 6D. Therefore, this obser­
vation gave further evidence for our con­
clusion discussed above that pl5(E) is also 
derived from <?лі.-рг82. Preliminary results 
with L-[r,S]methionine-labeled polypep-
F I G 6 Chymotryptic peptides of virus-specific 
polypeptides labeled with "C-amino acid mixture 
and eluted from Polyacrylamide gel slices were ana­
lysed as described in the legend of Fig 5 The col­
umn dimensions differed slightly from those of the 
column used lor the analyses presented in Fig 5 (A) 
em -pr82, (B) gp69/71, (C) pl5(Ei, (D) mixture of eni,-
pr82 and pl5(E) 
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tides confirmpd these conrlusions (to be 
published). 
Localization of Virus-Specific Polypep­
tides 
In contrast to our previous results, the 
virion glycoprotein ρρβ9/71 was detectpd in 
the present exp^rimpnts. This disrrepancy 
could he expiainpd by differences in the 
experimental procedure of harvesting 
cells. In the experiments dpscribed in this 
paper, cells were scraped with a police­
man, whereas previously cells were har-
vesfpd by treatment with trypsin. There­
fore, we compared both procedures after a 
pulse-labeling for 15 min with "C-amino 
acid mixture followed by a 2-hr chase pe­
riod. Virus-specific polypeptidps wpre pre­
cipitated with anti-R-MuLV serum and 
were analyzed as dpscribpd above. Figure 
7 shows that treatment with 0.3% trypsin 
for 5 min at 37° after removal of the chase 
mpdium resulted in a total loss of gp69/71 
and a reduction in the amount of рШЕ). 
Since removal of the chase medium prior 
to harvesting resulted in loss of small 
amounts only of gp69/71 and pl5(E) (Fig. 
7Cl. thp4e componpnts wpre not removed 
as constitupnts of npwly formed virions in 
the chase medium. In contrast, the 
amounts of p30, pl5, and pl2 wpre re­
duced, and thpse polypeptides could he 
precipitatpd with anti-R-MuLV serum 
from the removed chase medium (not 
shown). 
The rpsults confirm the rapid release of 
p30, pl5, and pl2 in budding virions after 
cleavage from thpir precursor polypeptides 
(Van Zaane et ni., 1975). Moreover, gp69/ 
71 could not he dpfpctpd intracellularly 
and was found at the outer surface of the 
cell immediately after cleavage from env-
pr82. Consequently, it is likely that the 
processing machinery is located at the 
pla«ma membrane. 
Influence of the Arginine Annlog Cona-
vanine on the Processing of Virus-
Specific Precursor Polypeptides 
Whpn the arginine analog canavanine 
was present during the synthesis of virus-
sppcific polypeptidps, a 72,ΟΠΟ-dalton poly­
peptide (gag-Y)rl2) was formed instead of 
84 
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F I G . 7. Suhrnnflnent mnnolayprs of JLS-V9 cells 
were labeled Гпг IS min with 100 дСі of "C-amino 
acid mixture and radioactivity was chased for 2 hr 
Cells were harvested hy scraping in the chase me­
dium (A) or after removal of the chase medium 
either by treatment with 2.0 ml of 0 .4% trypsin for 5 
min at 37° (B) or by scraping in isotonic buffer (Cl 
Cells were washed with 5 ml of isotonic buffer |(B) 
and (C) only] and were lysed as described in the 
Material and Methods section. Virus-specific poly­
peptides were analyzed by SDS-PAGE and scintilla­
tion autoradiography after immunoprecipitatinn 
with anti-R-MuLV serum 
^а^-ргбб. Under these circumstances, for­
mation of mature virion proteins was not 
observed (Van Zaane et al., 1975). A more 
dptailpd analysis of this phenompnnn is 
presented in Fig. 8. JLS-V9 cells were la-
belpd in the presence of 3.3 mM canavan­
ine with 14C-amino acid mixture or D-[1-
3H]glucosamine for 15 and 30 min, respec­
tively. Before labpling with D-[1-
^Hlglucosamine cells were grown for I hr 
in mpdium containing canavanine instead 
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FIG. 8. Subconfiuent munoiayers of JLS-V9 cells were labeled for 15 mm with 11)0 μϋι of "C-amino acid 
mixlure (B-D and F-l) or for 30 mm with 250 ^Ci of D-ll-'HIglucusamine (J-Ml in the piesence of 3.3 mM 
capavaiime as described in the Materials and Methods section. As a control, cells were labeled similarly 
with 14C-amiiio acid mixture in the absence of canavamne (A). Radioactivity was chased for 0, 2, or 8 hr as 
indicated in the figure, and virus-specific polypeptides Were analyzed as described in the legend of Fig. 3. 
Immunoprecipitatiun with; (Α-D) anti-R-MuLV serum; (F-H) anti-рЗО serum; (1) anti-BSA serum; (J-L) 
arai-R-MuLV serum; (M) anti-рЗО serum. Refeieuce R-MuLV labeled with (El, "C-amino acid mixture, or 
with (N), D-|l- : !Hlglucosamine. 
of' arginine to аьаше that the polypeptide 
chains which would be glycosylated during 
pulse-labeling contained canavanine. Fig­
ure 8 shows that no difference in the syn­
thesis of the e«i;-pr82 polypeptides was ob­
served. However, instead of gu¿;-pr75 and 
gag-pr65 two virus-specific polypeptides 
with molecular weights of 82,000 and 
72,000 {gug-TprH2 and gug-prl2i were de-
tected. This new 82,000-dalton polypep-
tide, gag-pr82, could be recognized after 
precipitation with mono»pecific anti-p30 
serum only (Fig. 8F-H), because it corni-
grates with the envelope-gene product е/го 
pr82, which was not precipitated with anti-
p30 serum (Fig. 8M). Moreover, the new 
^u^-pr82 and gag-pr72 could be precipi­
tated with anti-pl5 serum (not shown). 
We conclude that instead of gug-piTS 
and gug-pr65 two ^α^-gene specific prod­
ucts gug-pi-82 and gug-pr72 were synthe­
sized in the presence of canavanine which 
are about 7000 daitons higher in molecular 
weight and contain the same antigenic de­
terminants asgug-pilö andgug-prô5 (Fig-
li). The differences observed cannot be ex-
plained by different electrophoretic mobili-
ties ofgug-ρτΊ5 aiidgag-prG5 after incorpo­
ration of canavanine because other virus-
specific polypeptides migrate normally, 
and SDS-PAGE in the presence of 6 M 
urea gave identical results (SDS-PAGE in 
the presence of 6 M urea reduces anoma­
lous migration of polypeptides) (Van Der 
Ouderaaeí al., 1974). 
The processing rate oi vii us-specific pre-
cursor polypeptides synthesized in the 
presence of canavanine is reduced remark-
ably, a& shown in Fig. 8. However, when 
virus-specific precursor polypeptides syn-
thesized in the ausence of canavanine were 
processed in medium containing 3.3 mM 
canavanine, a reduction of their cleavage 
rate Was also observed (not shown). Al-
8 5 
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though the former result (Fig. 8) can be 
explained by incorporation of canavanine 
in precursor polypeptides (Jacobson and 
Baltimore, 1968), the latter result must be 
due to a direct inhibition by canavanine of 
proteolytic enzymes that catalyze conver­
sion of precursor polypeptides into virion 
proteins or to some indirect effect, e.g., a 
reduction by canavanine of the general 
metabolic activity of the cell. 
Synthesis of Virus-Specific Polypeptides 
in JLS-V5 Cells 
The cleavage of virus-specific polypep­
tides is probably catalyzed by host en­
zymes, because there is little space left on 
the viral genome (Baltimore, 1975) to code 
for proteolytic enzymes. Therefore, we 
studied the synthesis and processing of R-
MuLV-specific polypeptides in another 
cell-line infected with R-MuLV, the JLS-
V5 line. Figure 9 shows an experiment 
similar to the one presented in Fig. 3. JLS-
V5 cells were pulse-labeled with "C-amino 
acid mixture for 15 min (Fig. 9) or with D-
ll- :,H]glucosamine for 30 min (not shown), 
and radioactivity was chased for periods 
up to 8 hr. As was the case with JLS-V9 
cells, in JLS-V5 cells two glycosylated vi­
rus-specific precursors and two nonglyco-
sylated precursor polypeptides were iden­
tified, which could be converted into virion 
proteins. The glycosylated precursors 
{enu-pr82) could be precipitated with anti-
gp69/71 serum (not shown), whereas the 
other two precursor polypeptides (gag-
pr75 aT\dgag-pr65) contained antigenic de­
terminants of p30 (Fig. 9F-I) and pl5 (not 
shown). In addition a polypeptide migrat­
ing slightly slower than em;-pr82 was pre­
cipitated with anti-R-MuLV serum and 
anti-рЗО serum, however, only after short 
chase periods 0/4-2 hr). A similar polypep­
tide was observed in JLS-V9 cells (Fig. 3G 
and 8G). 
Despite the similarity of virus-specific 
polypeptides synthesized in JLS-V9 and 
JLS-V5 cells, small differences in molecu-
p p r r ? i : 9 P f e 
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FIG. 9. Subconfluent monoìayers of JLS-V5 cells were labeled for 15 min with 100 μΟι of "C-amino acid 
mixture, and radioactivity was chased as indicated in the figure. Virus-specific polypeptides were analyzed 
as described in the legend of Fig. 3. Immunoprecipitation with lA-Dl anti-R-MuLV serum; (F-I> anti-p30 
serum; (Jl anti-BSA serum. (El Reference R-MuLV grown in JLS-V9 cells and labeled with "C-amino acid 
mixture 
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lar weight of some polypeptides were ob-
served. These differences are visualized in 
Fig. 10. The low molecular weight poly-
peptides p30, pl5(E), pl5, and pl2, as well 
as the precursor polypeptide gag-pr65, 
have identical molecular weights in both 
cell-lines. The glycoprotein gp69/71, its 
precursor polypeptides (ent;-pr82), and 
gag-pr75 are different in molecular 
weight. To avoid confusion, the nomencla-
ture of virus-specific polypeptides of JLS-
V9 cells was used for virus-specific poly-
peptides of JLS-V5 cells. When necessary 
"V5" and "V9" in brackets will be added to 
this nomenclature. In the presence of can-
avanine, again a small shift in molecular 
weight (about 5000 daltons) of gag-pr75 
(V5) and ¿»a^-pr65 (V5) polypeptides was 
observed (Fig. 10F). These polypeptides, 
^ag-pr82 (V5) and^a^-pr72 (V5) were both 
precipitated with monospecific antisera 
p r 7 5 — • 
g p 6 9 / 7 i — 
prbb 
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-pr72 
FIG. 10. Electrophoretic mobilities in SDS-
PAGE of virus-specific polypeptides from JLS-V9 
(Αι and JLS-V5 (Bl cells, pulse-labeled for 15 min 
with 100 μΟι of "C-amino acid mixture. Virus-spe­
cific polypeptides were precipitated with anti-R-
MuLV serum. (C) and (D), the same as (A) and (B). 
respectively; however, pulse was followed by a chase 
period of 8 hr. (E) and (F), virus-specific polypep­
tides from JLS-V9 and JLS-V5 cells, respectively, 
immunoprecipitated with anti-рЗО serum after 
pulse-labeling with "C-amino acid mixture for 15 
min in the presence of 3.3 mM canavanine. 
against p30 (Fig. 10F) and pl5 (not 
shown). As in JLS-V9 cells, processing of 
precursor polypeptides was reduced when 
canavanine had been present in the me­
dium during their synthesis. Thega^-gene 
products ^a^-pr82 and gag-prl2 in JLS-V5 
cells observed after growth in the presence 
of canavanine migrate during SDS-PAGE 
with a mobility slightly different from that 
of the corresponding polypeptides from 
JLS-V9 cells (Fig. 10E and F). 
DISCUSSION 
The present study shows that in JLS-V9 
and JLS-V5 cells infected with R-MuLV 
the envelope virion polypeptides gp69/71 
and pl5(E) are derived from two precursor 
polypeptides of almost the same electro­
phoretic mobility in SDS-PAGE, corre­
sponding with an apparent molecular 
weight of 82,000; we designated these two 
precursor polypeptides as en^-pr82. On the 
other hand, the virion polypeptides p30 
and pl5 which are internal components of 
R-MuLV (Bolognesi βία/., 1973; Bolognesi 
et al., 1974) are derived from precursor 
polypeptides of 75,000 and 65,000 daltons, 
gag-prT5 and ^а^-рг65 (Fig. 11). This con­
clusion was based on pulse-chase kinetics 
of the synthesis of virus-specific polypep­
tides, RIP assays with monospecific anti-
sera, competitive RIP assays with unla­
beled R-MuLV polypeptides, and chymo-
tryptic peptide analysis of virus-specific 
polypeptides. 
The gag-Precursors 
The virus-specific gag-precursor poly­
peptides, gag-pr75 and gag-pr65, (Figs. 3 
and 4) are possibly intermediates in the 
processing of a still larger precursor, since 
after labeling in the presence of the argi­
nine analog canavanine a 82,000-dalton 
polypeptide is observed (Fig. 8) which 
shares antigenic determinants with p30 
and pl5. This polypeptide, gag-pr82, is not 
observed in the absence of canavanine, not 
even after pulses of 5 min; hence, it may be 
possible that in the absence of canavanine 
gag-pr82 is rapidly converted during or 
after its synthesis into the more stable 
intermediates gag-pvlb and gag-pr65. In 
the presence of canavani"^ the suggested 
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diieclly dei ι ν eu II υιη ollier inleiiiiediates 4U-5UkD 
The multiple virua-s^ccific pioducts with molecular 
weights between 40,ÜU0 and 5(1,000 * Ргесиюог 
pulypeptides, whicn wei e only detected alter synthe­
sis in tue presence ol 3 J nM Cdiiavainne 
сои еіьюп of' gu£-pr82 into gu^-pr75 is 
sUongly inhibited; in stead, #ug-pr72 is 
formed in a redctiun kinetically leaem-
blmg the appai ent conversion of gug-pi75 
into gag-prti5. Under normal conditions 
(i.e , in the abaence of canavanine), the 
65,OUO-dalton piecur»or is procesaud fur-
ther into the intermediates of 40,000-
50,000 daltons, which al&o contain p'oQ an-
tigenic deter mnidnts, bui antigenic deier-
niinants of pl5 were not observed (Fig 4) 
Since polypeptide pl5 can be recognized as 
part of gug-pr65 (Fig. 4), pl5 is риаыЫу 
cleaved from gug-prbb; p30 is der ived from 
the 40,000- to 50,000-dalton inter mediates 
(Figs. 3 and 4). The virion polypeptide plO 
Wets not detected by the antisera u&ed and 
is a minor component of R-MuLV prépara-
tions ibulaied from JLS-V5 and JLS-V9 
cells At the nioment, we do not know 
whether plO is also derived fr om gu£-pr82 
The etw-Pteiursors 
Both envelope polypeptides of the vir-
ion, gp69/71 and ρ1δ(Ε), are cleaved from 
68 
twoe/iU-pi82 polypeptides. In recent exper­
iments we found that the elution patterns 
of the chyrnotryptic peptides of pl5(E) and 
pl2 labeled with L-|'"'Sjrnethionine were 
identical (to ue published) Therefore, pl2 
rs also an euc-polypeptide. Differences in 
pulse-chase kinetics of the two егш-ргесиг-
sors e/if-pr82 were not observed There­
fore, it is not likely that the smaller· one is 
forrrred by cleavage from the lar gei' precur­
sor. Possibly, a difference in electropho-
retic mobility is due to a different carbohy­
drate content of the e/tt'-pi82 polypeptides. 
Alter rratrvely, the existence of two ent'-
gene products could be explained by the 
presence of two clo&ely related MuLV 
strains in JLS-V9 and JLS-V5 cells. In this 
context, it should be noted that Strand and 
August (1973) detected two glycoproteins 
gp69 and gp71 in R-MuLV preparations 
with similar antigenic determinants Our 
observations neither confirm nor exclude 
the preaence of two glycoproteins in R-
MuLV preparations. 
Although Bolognesi et al (1975) demun-
stidied recerrtly that the protein moiety of 
gp71 isolated from Friend leukeniia virus 
is serologically active in type- and group-
specific reactions, we did not detect a non-
glycosylated precursor oi'gp69/71. Halpern 
et al (1974) rdentified an incompletely gly­
cosylated 70,000-dalton piecuisor polypep­
tide of the glycoprotein gp85 ol avian Ruus 
sarcoma virus Likewise, the nascent 
chains of the е/гс-geiie product <?M>-pr82 
could be the primary substrate for glycusy-
lation 
The differences between the molecular 
weights of some of the vu us-specific poly­
peptides in JLS-V9 and JLS-V5 cells (Fig. 
10) can be explained by differences in R-
MuLV preparations used for infection of 
these cell-lirics or is caused by differences 
irr host-specific enzymes that catalyze pro­
teolytic cleavage and glycosylation of vi­
rus-specific polypeptides. 
From our observations, we conclude that 
the piucessing of virus-specific precuisor 
polypeptides and the assembly of virions 
take place simultaneously, since the cleav­
age of both em- and #ug-precui&or poly­
peptides appai ently occurs at the plasma 
membrane. Very illustrative, in this re-
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speet, was the observation that gp69/71 
can be detected on the outer surface of' the 
plasma membrane only, whereas the pre-
cui ьог еп -рт82 is found in the cell interior 
(Fig. 7), Neither pl2 nor the established 
gag-gene products p30 and pl5 were de­
tected intracellularly. Therefore, the 
cleavage of precursor polypeptides could be 
a rate-limiting step in virus production. 
We also observed the présence of some par-
tially cleaved gag-precurs>ors in R-MuLV 
preparations (Fig. 2). A similar result was 
obtained by Oskar&aon et al. (1975) with a 
feline saicoina virus and by Jarnjuom et al. 
(1975) with R-MuLV. Once trapped in viri-
ons, piecuisor polypeptides are no longer 
pioceoaed, since R-MuLV harvested every 
3 mm did not contain higher amounts of 
uiicleaved precursor polypeptides than vi-
rus that was harvested every 2 hr (unpub-
lished, Van Zaane). 
The leoults described in this paper and 
our previous paper (Van Zaane et al., 1975) 
aie in good agreement with the results of 
Shapiro and Strand (1975), who studied 
vii us-specific protein synthesis in normal 
rat kidney cells infected with R-MuLV. 
Recent results nom Jamjoom et al. (1975) 
and Arcement et al. (1976) with JLS-V16 
and JLS-V5 cells infected with R-MuLV 
agi ее with our íesults. 
The complexity of the viral genome of 
RNA tumorviruses is about 3 x 10e daltons 
(Quade et al., 1974; Billeter et al., 1974; 
Beemon et al., 1974) con esponding with 3 
χ 10'· daltons of protein. Baltimore (1975) 
proposed four genes for this genome (gag, 
env, pol, and one). If this genome were 
tranalated into one pi unary precursor pol­
ypeptide of about 3 χ 10"' daltons as was 
established for Picornavirus protein syn­
thesis (Jacobson and Baltimore, 1968; But-
terworth et al., 1971), one would expect 
that cleavage of this precursor product 
would produce four gene products in equi-
molar amounts. In our study, however, the 
enu-gene pioduct was detected in a higher 
amount than the gag-gene product (about 
2 and 1% of total protein syntheis in JLS-
V9 cells, respectively). These diffeiences 
were not due to rapid protein degrada­
tions, because piecuisor polypeptides were 
slowly procesaed in pulse-chase experi­
ments (Figs. 3 and 9). The po/-gene prod­
uct, reveise transcriptase, was not identi­
fied in the present study, although our 
anti-R-MuLV serum did strongly inhibit 
its enzymatic activity; anti-рЗО serum, on 
the other hand, did not influence the enzy­
matic activity (not shown). From these re­
sults we conclude that the gag- and env-
gene products are not synthesized coordi-
natively. This agrees with the observa­
tions of Bilello et al. (1974) and Aaronson 
et al. (1975) on the differential expression 
of oncornavirus polypeptides. In hybridiza­
tion studies of virus-specific mRNAs iso­
lated from polyribosomes of JLS-V9 cells, 
three mRNA species were identified 
(Gielkens et al., 1974) which could be 
tian&lated into virus-specific polypeptides 
(Gielkens et al., 1976). Translation of viral 
RNA isolated from RSV, AMV, and R-
MuLV reoulted only in the synthesis of 
gag-gene products in cell-free protein-syn-
thesizmg systems (Von Der Helm and 
Duesberg, 1975; Salden and Bloemendal, 
1976; Salden et al., 1976b) and oocytes of 
Xenopus laevis (Salden et al., 1976a). A 
more detailed analysis with monospecific 
antisera of the virus-specific polypeptides 
synthesized in these systems coded for by 
viral RNA and mRNA isolated from in­
fected cells will give further information 
on this aspect of the replication cycle of 
oncornavuuses. 
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INTRODUCTION 
There is abundant evidence that the structural polypeptides 
of Rauscher murine leukemia virus (R-MuLV) are derived by pro-
teolytic cleavage from precursor polypeptides. These polypep-
tides could be detected in pulse-labeled infected cells by 
immunoprecipitation with polyvalent and mono-specific antisera 
followed by SDS-PAGE and autoradiography. Thus, it was shown 
that two related virus-specific polypeptides with molecular 
weights of about 75,000 and 65,000 (gag-pr75 and gag-pr65) are 
precursors of the gag-protems p30 (1-5) and pl5 (4, 5 ) , where-
as the env-proteins gp69/71, pl5(E) and pl2(E) (previously 
designated pl2) (4 or chapter IV) are derived from two related 
precursor polypeptides with an almost identical molecular 
weight of approximately 82,000 (env-pr82) (3-6). 
Stephenson et al. (7) and Barbacid et al. (8) studied the 
synthesis of virus-specific polypeptides in cells infected 
with ts-mutants of R-MuLV by a different approach. They showed 
that at the non-permissive temperature a 65,000 dalton poly-
peptide has been accumulated which carried the antigenic deter-
minants of p30, pl5, pl2 and plO. Polypeptide pl2 found in 
these studies is not identical to pl2 detected in our previous 
experiments (4 or chapter IV), since our anti-serum against 
pl5(E) and pl2 did not precipitate the gag-precursor polypep-
tides. Meanwnile, Naso et al. (6) reportea the discovery of an 
additional R-MuLV polypeptide pl2(E) which is derived from 
the env-precursor polypeptide and is structurally related to 
pl5(E). The results presented in this chapter showed that pl2 
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detected in our previous study (4 or chapter IV) and now 
designated pl2(E) is identical with pl2(E) described by Naso 
et al. (6). Moreover, we found that pl2 and plO sequences are 
prosent in gag-pr65 as well as in gag-pr7 5, a precursor poly­
peptide not resolved from gag-pr65 by the techniques used by 
Barbacid et al. (8). A Summary of our results is shown on the 
inside backcover of this thesis. 
MATERIALS AND METHODS 
Antisera 
1. The preparation of anti-R-MuLV serum and anti-pl5(E), pl2(E) 
serum (previously designated anti-pl5(E),pl2 serum) is 
described in chapter IV. We showed that the latter serum 
was directed against pl5(E) and pl2(E) only; however, small 
amounts of gp69/71 were coprecipitated, because of a strong 
association of gp69/71 with pl5(E) and pl2(E) (chapter IV). 
2. Anti-pl2 (R-MuLV) serum was obtained by the courtesy of 
Dr. J. Gruber, Viral Oncology Program, National Cancer 
Institute, U.S.A. It was absorbed with purified p30 of 
R-MuLV (courtesy Dr. J. Brouwer, Dept. of Pathology, Leiden, 
The Netherlands) to remove contaminating anti-рЗО activity. 
3. Anti-plO (AKR) serum was a generous gift of Dr. J.N. Ihle, 
Frederick Cancer Research Center, Frederick, Md, U.S.A.). 
ír§¿i§_aD¿_Yi£y§§§ 
The JLS-V9 cell line derived from bone marrow cells of Balb/c 
mice infected with and producing R-MuLV was grown in Eagle's 
basal minimal essential medium supplemented with 10% calf 
serum (15). Moloney murine leukemia virus (Mo-MuLV) used in 
competitive radioimmunoprecipitation assays was a gift of 
Dr. A.J.M. Berns. 
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Methods 
The experiments were performed as described in the Materials 
and Methods section of chapter IV. Details will be given in the 
legends to the figures. 
RESULTS AND DISCUSSION 
In fig. 1 we present the analysis of virus-specific products 
pr82-
pr75-
pr65-
Ρ MMWM в·1* 4ВЦМІ 
D 
Fig. 1. Radioimmunoprecipitation analysis of R-MuLV precursor 
polypeptides in infected JLS-V9 cells. _ 
Subconfluent monolayers of JI.S-V9 cells (25 cm ) were labeled 
for 15 min with 50 uCi of 14C-amino acid mixture (sp act, 57 
mCi/matom, The Radiochemical Centre Amersham, England) and the 
virus-specific polypeptides were precipitated indirectly from 
the cell lysate with anti-R-MuLV serum (A), anti-рЗО serum (B), 
anti-pl2 serum (C) or anti-plO serum (D). Immunoprecipitates 
were analyzed by SDS-PAGE and scintillation autoradiography 
(9). Experimental details are described in the Materials and 
Methods section of chapter IV. 
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immunoprecipitated with anti-plO serum or anti-pl2 serum from 
a lysate of R-MuLV infected JLS-V9 colls which were pulse-
14 labeled for 15 m m with C-ammo acid mixture. The results 
showed that both gag-pr75 and gag-pr65 were recognized by the 
antisera raised against plO or pl2, whereas env-pr82 was not 
precipitated by these antisera. However, after we chased the 
radioactivity by growth of the pulse-labeled cells in the 
presence of an excess of unlabeled amino acids, we could not 
detect any of the mature virion polypeptides by immunoprecipita-
tion with anti-plO serum or anti-pl2 serum (not shown). In our 
previous study (chapter IV), we showed that the virion poly-
peptides gp69/71, p30, pl5(E), pl5 and pl2(E) (designated pl2 
in chapter IV) were precipitated by the corresponding anti-
scra in experiments similar to the ones described above; 
therefore, the anti-plO serum and the anti-pl2 serum were 
not contaminated with antibodies against one of these viral 
polypeptides. Our failure to detect plO and pl2 in our experi-
ments needed further analysis. Preliminary results indicated 
that plO is eluted with dimethylsulfoxide from the Polyacryl-
amide gels during the Bonner and Laskey (9) procedure for scin-
tillation autoradiography because plO could be detected with 
anti-plO serum after iminunoprecipitation from labeled R-MuLV 
preparations followed by conventional autoradiography of the 
electropherograms. In this experiment, again none of the other 
virus-specific polypeptides was precipitated with the anti-
plO serum. The results are not shown nere, because the amount 
of radioactivity in plO was too low for a photographic re-
production of the original autoradiogram. From tnese observa-
tions we concluded that the anti-plO serum is indeed mono-
specific for plO. Two additional observations indicated that 
the anti-plO serum and the anti-pl2 serum are directed against 
plO ard pl2, respectively: 
i_) the anti-plO serum was obtained after injection into a 
rabbit of plO isolated from AKR virus. Since plO of murine 
RNA tumor viruses carries strong group-specific antigenic de-
terminants (see chapter I), we expected and actually found 
that antiserum against AKR pi 0 could react with plO of R-MuLV 
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and its precursor polypeptides. Ir agreement with this obser­
vation, fig. 2 shov/s that, the precipitation of gag-pr75 and 
-pr82 
-pr75 
-pr65 
В С D E F G 
Fig. 2. Competitive radioimmunoprecipitation analysis of R-MuLV 
precursor polypeptides in infected JLS-V9 cells. 
The experiment was performed as described in the legend of 
Fig. 1. The virus-specific polypeptides were precipitated from 
the cell lysate with anti-pl2 serum (Л-С), anti-nlO serum (D-F) 
or anti-R-MuLV serum (G) in tne absence (Л, D and G) or in the 
presence of 1 ijg (B and F) or 5 ι g (С and F) of disrupted 
Mo-MuLV. 
gag-pr65 with anti-plO serum was prevented by the addition of 
1-5 g of competing Mo-MuLV protein to the assay mixture. 
ii.polypeptide pl2 is the sole 2^2 - r el a t ed product with mainly 
type-specific antigenic determinants (chapter I). In accordance 
with this immunological characteristic, we found that the ac-
dition of Mo-MuLV proteins to the immuncprecipitation mixture 
could not prevent the precipitation of gag-pr75 and gag-pr65 
with anti-pl2 serum (îig. 2). From these results, we concluded 
that both gag-pr65 and gag-pr75 contain antigenic determinants 
of plO and pl2 and, therefore, both polypeptides are precursor 
polypeptides of plO and pl2. It should be noted here that the 
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polypeptides, tor the isolation of precursor polypeptides subconfluent 
2 
monclayers of JLS-V9 cells (75 cm ) were labeled for 30 nin with 200 )iCi 
35 
of L- ' S)methionine (ьр. act, 250 Ci/nmo] , The Ra-iiochemical Centre, 
Amersham, England) and the virus-specific polypeptides were immunoprecipi-
tatea airectly rfith anti-R-MuLV serum from the cell lysate. Immunoprecipi-
tdtes here subjected to SDS-PAGS ana the radioactive bands were located 
by autoradiography and wore cut from the dried gel. Virion polypeptides 
were isolated similarly from cells which were labeled for 90 m m followed 
by a chase of 7 hr with an excess of unlabeled amino acids. Appropriate 
gol fractions were mincod and swollen in 2.0 ml of digestior buffer 
(50 mM ammonium bicarbonate, pH 8.9, 200 uÇt bovine gammaglobulin/ml) and 
were incubated at 37 for 20 hr with 0.1 mg chyirotrypsin (Worthingtor, 
Freehold, N.J.) per ml. Chynotryptic peptides were analyzed by Aminex A5 
(Bio-raa Laooratones Richmond, Calif ) ion exchange chromatography 
(0.4 χ 20 cm column) at 50 with tne elut^on system descnoed by Vogt sí 
al. (14). tractions of 1.8 ml were collected and radioactivity was counted 
with 5.0 irl of Aquasol (NEN, Boston, Mass.). Η-serine and H-lysine, 
2,00C cprr each, were cochromatographed as irarkers. Material eiuting η 
fractions 1-15 were considered to be unabsorbed pépticos. 
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gel filtration proccdare used by the group of Stephenson and 
Aaronson (7, 8) did not resolve gag-pr75 and gag-pr6 5 and that 
the C-termmal position of plO within the gag-precursor poly­
peptide (8) made it possible to suppose that plO was released 
during the transition of gag-pr75 to gag-pr65. Our experiments 
excluded tnat possibility. 
In our previous study (4), we showed that an antiserum raised 
against pl5(E) and pl2(E) (previously designated anti-pl5(E), 
pl2 serum, but now called anti-pl5(E),pl2(E) serum) precipi­
tated the env-pr82 polypeptides, but not the gag-precursor 
polypeptides. Chymotryptic peptide analysis of env-pr82 and 
pl5(E) showed that at least pl5(E) is derived from env-pr82. 
To extent this observation and to identify the precursor 
polypeptide of pl2(E), we analyzed the chymotryptic digests 
of virus-specific (precursor) polypeptides by ion exchange 
chromatography as described in the legend of Fig. 3. Simple 
but typical elution patterns were obtained by the combination 
of L-( S) methionine as the sole radioactive amino acid for 
the labeling of the polypeptides and chymotrypsm as the 
proteolytic enzyme. 
The analysis of the chymotryptic digests of env-pr82, 
gp69/71, pl5(E) and pl2(E) is presented m Fig. 3, whereas 
a similar analysis is presented m Fig. 4 for gag-pr75, 
gag-pr65, p30 and for a mixture of intermediates in the pro­
cessing of the gag-precursors with molecular weights between 
40,000 and 50,000. These analyses clearly demonstrated that 
pl2(E) is derived fron env-pr82 and is closely related to 
pl5(E) (Fig. ЗА, С and D) but not to gag-pr65 as shown in 
Fig. 4B,· therefore, pl2(E) is identical to pl2(E) described 
by Naso et al. (6 ) and is different from gag-pl2. The 
following additional two observations are in accordance with 
the conclusion that pl2(E) has sequences in common with 
pl5(E): i_, both pl2(E) and pl5(E) clearly showed snontaneous 
aggregation because they elutod in the void volume during gel 
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filtration of R-MuLV polypeptides in the presence of guani-
dinium cnlonde (4); 11,processing in vitro m lysates of in­
fected colls showed a conversion of pl5(E) into pl2(E) (2, ir 
this paper pl5(E) and pl2(E) were designated pl5 and pl2b, 
respectively). This is m agreement with our observation tnat 
in pulse-chase expennents pl2(E) appeared later than pl5(E) 
(4) . 
In addition, the analyses presented in Fig. 3 confirmed 
our previous conclusion (4) that gp69/71 and pl5(E) are derived 
fron env-pr82 (Fig. ЗА, В and С). It should be noted, that 
the present results neither prove nor exclude an overlap 
between pl5(E) and gp69/71, as was suggested by Shapiro et al. 
(5) and Naso et al. (6). Also in agreement with our previous 
results (2, 4), Fig. 4 shows that p30 has sequences in common 
with gag-pr65 and tne processing intermediates with molecular 
weights between 40,000 and 50,000 (Fig. 4B, С and D). Precursor 
polypeptide gag-pr75 was isolated in low amounts and was con­
taminated with env-pr82. Nevertheless a few chymotryptic pep­
tides characteristic for gag-pr65 could be recognized m the 
elution pattern of gag-pr75 chymotryptic peptides (Fig. 4A). 
The minor differences in the elution patterns of p30 and gag-
pr65 suggested that during processing proteolytic cleavage 
occurs in a ( S)metnionine labeled chymotryptic peptide. A 
similar analysis of chymotryptic peptides of pl5, pl2 and plO 
was not possible because plO and pl5 were not labeled with 
3 5 L-( S)methionine (10, 11), and mature pl2 was not detected 
in our studies. 
The results presented here are in agreement with tne ob­
servation of otner laboratories (3, 6, 10) that the murine 
RNA tumor viruses have a more complex polypeptide composition 
than was generally belioved one year ago. This implication 
is also supported by the independent evidence on the existence 
of two 12,000 dalton oolypeptides in murine leukemia virus 
(12). The accepted nomenclature of RNA tumor virus polypep­
tides (13) allows the addition of the letters (E), (C) or (N) 
to indicate a morphological rather than a genetic property, 
namely the association with the envelope, the core or the 
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nucleic acid of the virion, tortunately, the association of 
pl5(C) and ρ12(Ξ) with the virion envelope and with the env-gene 
appeared to coincide, since pure envelopes of R-MuLV were shown 
to contain as the only virus-specific polypeptides gp69/71, 
pl5(E) and pl2(E) (W.J.M. Van de Ven, to be published). 
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Synthesis of Rauscher murine leukemia virus-specific polypeptides 
in vitro 
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ABSTRACT The biosynthesis of specific polypeptides di­
rected by purified viral messenger RNA from JLS V9 cells in­
fected with Rauscher leukemia virus has been studied in a 
rabbit reticulocyte lysate The 35$ viral mR\A gives rise to 
two major products of 65.000 and 72,000 molecular weight 
The synthesis of specific polypeptides was also investigated 
in lysales derived from infected cells The main products 
were poKpeptides with molecular weights of 65 000, 76,000, 
and 82,000, and were preferentially made in association with 
membranes The relative content of the virus-specific poly­
peptide of 65,000 molecular weight, synthesized in a cell free 
system supplemented with purified polvnhosomes, is consid­
era bJ\ higher for membrane-bound polvnhosomes 
Mature proteins of RNA tumor viruses are formed b\ specif­
ic cleavage of large precursor polvpeptides In avian leukosis 
and sarcoma virus infected cells the biosvnthcsis of a pre­
cursor [molecular weight (Vf
r
) 76 000J of the internal virion 
antigens and an incompleteK glycosvlated precursor (V/
r 
70 000) of the major viral glycoprotein (gpfi1?) has been dem 
onstrated (1 2) likewise two newl\ ssnthesized intracellu 
lar precursor pol ν peptides were detected m cells infected 
with Rauscher leukemia virus (R MuLV ) (3 4) One poly­
peptide (Vi,- 65 000) is probabK the precursor of the low 
molecular weight virion proteins while the other (Vf
r 
85 000) is the precursor of the viral glvcoprottm (4) The 
virus specific messengers involved in the synthesis of these 
polypeptides have been identified The major virus specific 
mRNA in productively infected cells is 35S R W but evi 
dente for virus specific R\TA of smaller si/e (20-22 S) has 
been found 1,5-7) The latter mRNA appeared to be prefer 
entially associated with membrane bound poly nhosomc s (6 
7) 
We have studied the svnthesis of R MuL \ specific polv­
peptides in fractionated crude cell free Ivsates and m cell 
free systems supplemented with purified free and mem 
bra ne bound polyribosomes Moreover v\e examined the 
biosynthesis of virus specific polypeptides in a rabbit reticu 
locyte Ksate supplemented with pok(A.1 rich m R \ A frac­
tionated according to size Fvidence was obtained that virus 
specific products are preferentialK svnthisi/ed in associa 
tion with membranes Moreover it could be demonstrated 
that addition of 15S m R \ \ or 20 22S mRNA to a retículo 
су te lysate results in the synthesis of specific рок peptides 
МАТЬ RIALS A N D M E T H O D S 
Cells and Virus The JLS \ 9 cell line derived from bone 
marrow cells of Balb с mice infected with and producing 
Abhrewations R Mul V Raust her leuUmia wrm Vi
r
 molecular 
wtight \aDodSO4 sodium dodtcvl sulfate 
* Present addriss Department of Virology Central Vetcnnarv In 
stitule lelvslad The Net ht rlands 
* To whom requests for reprints should he addressed 
R MuLV' was grown in Fagle s basal minimal essential me­
dium supplemented with ΙΟ^ί calf serum (8) Lal>ehng of 
these cells and the preparation of cell extracts for immu 
noprecipitation was described \Ί) 
Preparation of Cytoplasmic Extracts and Polyribo­
somes For the isolation of cvtoplasmic extracts I 5 ml of 
cells was к sed in 2 volumes of hypotonic buffer (10 mM 
Tris-He 1 pH 7 5 15 mM kCl 1 5 mM magnesium acetate, 
and 2 mM dithmthreitol) bv 30 strokes of a tight fitting 
Dounce homogemzer Nuclei were removed by centrifuga 
tion at 125 X g for 5 mm Three milliliters of the superna­
tant was separated into a c\toplasniic supernatant and pellet 
by centnfugation at 20 000 X g for b mm in a Ti 50 rotor 
(Spincol The membrane rich 20 000 X g pellet fraction was 
suspended in 1 ml of h\ potóme buffer A nbosomal superna-
tant was prepared from the 20 000 X g supernatant by cen-
tnfugation at 220 000 X g for 2 hr m a Ti 50 rotor Polyribo-
somes used in the cell free system were isolated as described 
(9) except that sodium deoxy chola te and Nonidet P-40 
(Shell) solubihzed membrane fractions were clarified by 
centnfugation at 12 000 X g for 5 mm Total polyribosomes 
used for the isolation of ohgotdT^ cellulose purified mRNA 
were prepared from cells к sed by treatment with a mixture 
of sodium deoxy chola te and Nonidet Ρ 10 as described (7) 
Isolation and Fractionation of mRNA Pok(A)-contain 
mg mRNA of total polyribosomes was isolited by affinity 
chromatography on ohgoidT) cellulose Four mg of total po­
lyribosomes were dissociated in buffer A '10 m\i Tns-HCl 
p H 7 4 SOOmMNaCl 1 mM f DT \ and \% sodium dode 
evi sulfate (NaDodSO-i)! at 37 for 5 mm and applied to a 
2 ml oligo(dTj cellulose column in buffer A After the nh-
gotdT) cellulose was washed with buffer A and buffer В (10 
mM Tris-HC I pH 7 4 100 mM NaC 1 I mM l· D ГА and 0 2% 
NaDodSO-O until all nonabsorbed RNA was removed 
polv(A) containing RNA was eluted with buffer С (10 mM 
Tris HCl pH 7 4) 
Immunoprecipitation and Polyacrylamide Gel Fleetro-
phoresis To the cell free ine ubition mixtures immunopre 
cipitation buffer LO m M phosphate pH 7 2 OQ17? NaC 1 1^ 
Triton \ 100 0 5рг sodium cleowcholate and 0 lcc NaDod 
SOji was added and the resulting solution was clarified bv 
centnfugation at 220 000 X g for 10 min in a Ti 50 rotor 
Virus specific products in the supernatant were directly or 
indirtctk precipitated b\ addition of rabbit antiserum 
against R MuLV as described П) Precipítales were collect 
ed by centnfugation through a layer of 10cc sucrose ^weight 
volume) in immunoprecipitation buffer and washed 3 times 
with this buffer The resulting precipitates were dissoktd in 
sample buffer (10) containing β M urea b\ heating at 95 
for 2 mm Immunoprecipitates were anak/ed bv electro­
phoresis on 7-18^ pokacrvlamide gradient slab gels with 
the Tris glycine buffer system ylO) After electrophoresis the 
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Fio. 1. NaDodSO.4 polvacrylamide gel electrophoresis of the 
virus specific polypeptides synthesized in vitro in fractionated cell 
extracts. A standard reaction mixture contained (in a final volume 
of 25 μΙ) In mM Tris-HCI pH 7.5. 2 5 m \ l magnesium acetate, 75 
mM KCl. 70 mM potassium acetate. 1 mM dithiothreitol. 4 μΙ of 
energv and amino-acid mixture [final concentrations after dilution 
in the complete reaction mixture 1 mM ATP. 0.2 mM (ITP. 10 
mM creatine phosphate. 0.2 mg/ml of creatine kinase. 19 unlabeled 
amino acids in the concentrations described (13), 200 μΓι/ηιΙ of 
[ ' S |methionine (specific activity 170 Ci X mmol" '. Radiochemical 
Centre. Amersham)]. 3 μΙ (75 μg) of crude initiation factor from 
rabbit reticulocytes (14) Crude cell fractions. S100, and 10 μg of 
pH 5 enzymes (15) from infected cells were added as indicated 
below Incubation was performed at Ю0 for 150 min. Virus-specific 
polypeptides were precipitated by the direct method from reaction 
mixtures supplemented with (a) 15 μΐ of 125 X ^ supernatant : (b) 
15 μ) of the 20.000 X g supernatant: (c) 5 μΙ of the suspended 
20.000 X/? pellet: (d) as (c) with 10 μΐ of SlOO; (e) as (c) with-i μ! of 
pH 5 enzymes: (f) immunoprecipitate of virus-specific polvpep 
tides synthesized from extracts of cells pulse labeled m rivo fol­
lowed by processing'm oitro (3); (g) polypeptides aspecifically pre 
cipitated (3) with antiserum against bovine serum albumin from 
the reaction mixture supplemented with the 125 X g supernatant 
gel was stained, treated with 22 2% 2.5-diphenylnxazole 
(PRO) in dimethyl sulfoxide {weight Ч о і и т е ) (11). and 
dried on Whatman 3 MM filter paper, the radioactive bands 
were visualized hy autoradiography 
RESULTS 
Virus-specific Polypeptides Synthesized in Fractionat­
ed Cell Extracts. Hybridization experiments had demon­
strated that the relative amount of virus-specific mRNA is 
four to six times higher in membrane-bound polyribosomes 
than in free polyribosomes (7. 12) In accordance with these 
observations we expected and actually found a similar distri­
bution of newK synthesized virus-specific polypeptides lx--
tween a cytoplasmic 20.000 X g pellet and supernatant frac­
tion after incubation of these fractions in vitro. O i l s were 
К sed in hypotonic buffer and nuclei were removed by low 
speed centnfugalion The supernatant was fractionated by 
centnfugation at 20,000 X g into a pellet (membrane frac­
tion) and a supernatant fluid (membrane-free fraction) 
These crude fractions were tested for their protein-svnthe-
si/ing activit\ and the virus-specific products were directU 
precipitated with antiserum against R-MuLV Immunopre-
cipitation was always performed on equal amounts of 
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FlC. 2. Analysis of the virus-specific polypeptides synthesized 
by isolated polyribosomal fractions The cell free system contained 
(in a final volume of 25 μΙ) 12 μΙ of SlOO from rabbit reticulocytes. 
0.6 А2вапт unit of polyribosomes, 4 μΙ of energy and amino acid 
mixture as described in the legend of Fig. 1. and 20 mM .V'-2-hy-
droxvethylpiperazine-.V'^-ethanesulfonic acid (Hepes) pH 7 5. 2 
mM magnesium acetate. 60 mM KCl. 80 mM potassium acetate. 
and 1 mM dithiothreitol Cell free incubation was performed at 
2ß0 for 150 min. Indirect immunoprecipitate of polypeptides syn-
thesized m ι i to (a) using antiserum against bovine serum albumin. 
(b) using antiserum against R Mul.V: te) Η Mul.V labeled with 
['^Claminoacids (3). Indirect immunoprecipitation of VITUS specif 
ic polypeptides synthesized in the cell free system supplemented 
with (d) polyribosomes associated with the 125 X л1 pellet, (e) free 
polyribosomes, (f) membrane bound polyribosomes; (g). (h), and 
(i) same as id), (e). and (f) except thai 200 μΜ ammo acid analo 
gues (p fluorophenylalanme. canavanine. and azetidine 2-carbox 
ylic acidi were present in the incubation mixture 
| ^Sjmethionme incorporated into pol\ peptides 
Analysis of the immunoprecipitates In Polyacrylamide gel 
electrophoresis showed that three major vims-specific poly­
peptides were synthesized in the membrane-rich 125 X g su­
pernatant (Fig la) and the 20.000 X g pellet fractions (Fig 
1c) The molecular weights of these R-Mul.V specific poly­
peptides were 65,000. 76.000. and 82.000 in vwo only two 
major precursor polypeptides were newly synthesized, pp65 
and ppS2 (Fig If) (molecular weights of 65.000 and 82.000. 
respectively) Incubation of the 20.000 X g pellet fraction in 
the presence or absence of S100 or pM 5 enzymes from in­
fected cells resulted in the same set of polypeptides (Fig 1c. 
d. and e) Minor amounts of poly peptides with molecular 
weights between 30,000 and 60.000 are visible (Fig la, с d, 
and e). which could not be precipitated with antiserum to 
bovine serum albumin These minor products presumably 
arise by premature termination of translation or proteolytic 
cleavage of the high moletuiar-weight polypeptides \ dil 
ferenl result was obtained when the membrane-free 20.000 
X g supernatant was Incubated in vitro Three to five limes 
less virus-specific polypeptides were present in the immu­
noprecipitate of this fraction as compared w ilh the 20 (KK) X 
g pellet Ciel analysis of the immunoprecipitate of the incu­
bation mixture with added 20.000 X g supernatant showed 
that a poKpeptide with an apparent molecular weight ol 
65.000 is the- onK virus-specific product synthesized (Fig 
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FlG. .Ή. Gradient analysis of virus-specific RNA from tola! po­
lyribosomes before and after oIigo(dT)-cellulose chromatography. 
RNA from each fraction was precipitated with ethanol, after addi 
tion of 20 μg of 28S RNA from reticulocyte ribosomes as carrier. 
T h e relative amount of virus-specific RNA in each fraction was de­
termined by hybridization with R-MuI.V complementary DNA 
(4). (A) Phenol extracted RNA from total polyribosomes (4) was 
applied to a 15.30 2% (wt/vol) isokinetic glycerol gradient in T N E 
(10 mM Tns-HCI pH 7.4. 100 mM NaCI. and 1 mM EDTA) and 
centnfuged at Ì5.000 rpm for 13 hr in a Spinco SVV41 rotor at 0°; 
(B) same as (A), except that the RNA was denatured in 10 mM 
Tris-HCI pH 7 4 and 0.5% KaDodSOj at 50° for 5 min; (Γ) analysis 
of RNA purified on an oligo(dT) cellulose column PoIy(A)-con-
tammg RNA (80 μg) was treated with 85% formamide in 10 mM 
Tris-HCI pH 7 4 at 37° for 5 mm and loaded onto a 5-22.7% {wt/ 
vol) isokinetic sucrose gradient in T N E containing 50% ivoì/voì) 
formamide Tubes were spun in a Spinco SW41 rotor at 41.000 
rpm for 15 hr at 5°. 
l b ) . A m o n g the p r o d u c t s svnlhes ized in vitro t h e vir ion pro-
teins p-30 and p i 5 a r e not d e t e c t e d , wh i l e t h e \ a r e p resen t in 
m i n o r a m o u n t s in t he ext rac ts of cells pu lse- labe led m vivo 
(Fig If) (3) In t he e x p e r i m e n t s p resen ted , t rans la t ion fn 
vitro was p e r f o r m e d at its o p t i m a l t e m p e r a t u r e of 3 0 It 
was. howeve r , not inves t iga ted w h e t h e r this t e m p e r a t u r e is 
o p t i m a l for process ing of t he p recurso r p o l y p e p t i d e 
Vi rus -Spec i f i c P o l y p e p t i d e s S y n t h e s i z e d by F r e e a n d 
M e m b r a n e - B o u n d P o l y r i b o s o m e s . T h e e x p e r i m e n t s d e -
scr ibed a b o v e ind ica te that t he synthesis of R-MuLV-spec i f i c 
po lypep t ide s was possible in c r u d e cell ex t rac t s W e d e c i d e d 
to e x a m i n e w h e t h e r t rans la t ion m e d i a t e d b \ pur i f ied f ree 
a n d m e m b r a n e - b o u n d po ly r ibosomes resul ted in t he biosyn-
thesis of t h e s a m e set of specific po l \ p e p t i d e s Po l \ r ibosomes 
isolated f rom di f fe ren t cell f ract ions w e r e i n c u b a t e d in t he 
subce l lu la r sys tem in t he p re sence of Ы 0 0 f rom rabbi t ret ic­
ulocytes C o m p a r i s o n of t h e gel analysis of t h e i m m u n o p r e -
c i p i t a t e d p r o d u c t s s>nti iesized bv t h e s e p o l y r i b o s o m e s ( F i g 
2d, e. a n d f) w i t h those s y n t h e s i z e d in t h e c r u d e c y t o p l a s m i c 
ex t rac t s (Fig. l a ) shows t h a t t h e 8 2 . 0 0 0 a n d 76.000 MT poly­
p e p t i d e s p r e s u m a b l y w e r e not s y n t h e s i z e d b\ t h e isolated 
po lyr ibosomes T h e major p r o d u c t s synthes ized by t h e puri­
fied p o l y r i b o s o m e s originally present in t h e 125 X g pellet 
(Fig 2d) a n d t h e m e m b r a n e - b o u n d p o l y r i b o s o m e s ( F i g 2f) 
w e r e p o l y p e p t i d e s w i t h m o l e c u l a r w e i g h t s of 65,000 e n d 
45.000 T h i s la t ter p o l y p e p t i d e was present in m u c h smal ler 
a m o u n t s in t h e in vitro p r o d u c t s of t h e 20 .000 X g pel let 
f ract ion (Fig 1c) M i n o r p r o d u c t s w e r e several p o l y p e p t i d e s 
in t h e reg ion of 3 0 . 0 0 0 - 6 0 . 0 0 0 MT a n d a p o l y p e p t i d e of 
74,000 M
r
 (F ig 2d a n d f) T h e la t ter m o l e c u l a r weight va lue 
has b e e n ass igned s ince t h e mobil i ty of this p o l y p e p t i d e is 
consis tent ly s o m e w h a t faster t h a n t h a t of t h e 76,000 V/
r 
b a n d F r e e p o l y r i b o s o m e s synthes ize mainly o n e p o l y p e p ­
t i d e w h i c h c o m i g r a t e s wi th p p 6 5 ( F i g 2 b a n d e) After long­
er e x p o s u r e t i m e s also a faint b a n d of M
r
 74 .000 was visible 
on t h e a u t o r a d i o g r a m (not s h o w n ) F o r c o m p a r i s o n , t h e pro­
tein p a t t e r n of [ 14C a m i n o - a c i d - l a b e l e d R - M u L V is also 
s h o w n (Fig 2c) T h e most s t r ik ing f e a t u r e is t h e o c c u r r e n c e 
in t h e y i ras p r e p a r a t i o n of a poly p e p t i d e c o i n c i d i n g w ith t h e 
p u t a t i v e p r e c u r s o r p o l y p e p t i d e of 65 .000 M , T h e ra t io of 
t h e p e r c e n t a g e s of virus-specif ic p o l y p e p t i d e s of f ree a n d 
m e m b r a n e - b o u n d p o l y r i b o s o m e s was a p p r o x i m a t e l y t h e 
s a m e as t h a t b e t w e e n t h e m e m b r a n e - r i c h c y t o p l a s m i c pellet 
f ract ion a n d m e m b r a n e - f r e e s u p e r n a t a n t fluid H o w e v e r , 
q u a l i t a t i v e d i f fe rences in ind iv idua] p o l y p e p t i d e s b e t w e e n 
t h e var ious f ract ions d o exist A d d i t i o n of a m m o - a c i d analo­
g u e s ( p - f i u o r o p h e n y l a l a m n e , c a n a v a n m e . a n d azet id ine-2-
carboxyl ic ac id) to t h e cell-free sys tem d i d not result in t h e 
synthes is of h i g h e r - m o l e c u l a r - w e i g h t p o l y p e p t i d e s by these 
p o l y r i b o s o m e s ( F i g 2g. h. a n d i) 
T r a n s l a t i o n of O l i g o ( d T ) - C e l l u I o s e P u r i f i e d m R N A . Pre­
vious r e p o r t s d e m o n s t r a t e d that virus-specific R N A was 
p r e s e n t in p o l y r i b o s o m e s f r o m cells in fec ted w i t h 
M S V ( M L V ) a n d R - M u L V (6. 7) Virus-specific 35S m R N A 
2B·---
( 
' 5 6 7 θ 9 10 11 12 13 И 15 16 17 18 
Fifi 4 NaDodSO., Polyacrylamide gei autoradiogram ol the polypeptides synthesized ¡η litro by polv(A)containing RNA. fractionated 
accordine to si7e RNA from each traction of the gradient, shown in Fig. 3C, was dissolved in 50 μ\ of distilled water, ("ell free synthesis was 
perlormed in a final volume of 25 μ\ containing î μ\ of test solution. 12 μΙ of rabbit reticulocyte lysate. 4 μΐ of energy and amino acid mixture 
as ¡n legend of Fig. 1. and 2 mM magnesium acetate. fi5 mM KCl. and fiO mM potassium acetate. Reaction mixtures were incubated at 26° 
for 150 mm Numbers 5 to 1" refer to the fractions of the gradient {1 ) Polypeptides synthesized in the lysate. without exogenous RNA: (5 to 
/7) with RNA from the fractions indicated: i!H) with 10S lens mRNA 
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F i o S NaDodSO* polvacrvUmide slab gel апаі і^ч of the virus specific polypeptides svnthesi7ed b\ the fractionated m R N A Polypep 
tides svnthe4i7ed in the cell free system programmed with RNA from each fraction as described in legend of l· ig 1 were subjected to indi 
reet immunnprecipitation using an antiserum against R Mul V Likewise an asnecific immiinopreripitation was performed on the poh pep 
tides synthesized in the lásate without exogenous RNA (J to 17) Virus specific products synthesized under direction of each fnct ion of the 
gradient (IS) po)>peptKles svnthesi/ed in ι u о (as in Fig 1) {19) aspecific control 
was the prédominant RN Л species present in free pol\ribo 
somes On the other hand membrane bound pnKrilvi^mes 
contained in addition to 'VsS R\A also smaller R\ \ mole 
rules with sedimentation coefficients of about 14 S and 
20-22 S respectiveh First we were interested in the trans 
lation products coded for b\ the 35S mRNA Further we 
wanted to examine whether or not the 20-22S and MS 
RNAs art functional messengers evidence that these RNAs 
can be translated in specific poKpeptides provides valuable 
information about tht relation between this mRNA and the 
35S mRNA For this purpose it was necessarv to prevent any 
aggregation of mRNA during fractionation on $іісгоч· gradi­
ents Ί herefore the effect of heat denaturation or form-
amide treatment (the latter result not shown but almost 
identical to that of heat treatment) of poKnbosomal R\A in 
sucrose gradients was studied It appeared that denaturation 
of the R N \ resulted in a shift of virus specific RNA from 
the 354 to the 22S and MS region (Fig ЗА and B) Fig 3C 
illustrates the profile of virus specific poIy(A) rich mRNA 
after gradient cenlnfugahon in the presence of 509Ρ form-
amide The hvbridi/ation profile of this gradient is almost 
identical to that shown m Fig 3B except that the RNA pun 
fied on oligo(d*l Vcellulose contains less material sediment-
ing in the MS region Fractions from the formamide gradi­
ent were trans'ated in a reticulocvte system and the resulting 
pol\peptides were analvzed on a p o h a c n l a m d e slab gel 
The analvsis showed that there was no aggregai'on of the 
bulk of the mRNA in the gradient as there existed a good 
correlation between the moltiular weight of the products 
synthesized and the S vaine of the mRNA in each fraction 
( t i g 4) 
After immunoprecipitation by the indirect method sever 
al distinct polvpeptides could be detected (Fig 5) The 35S 
mRN'^ synthesizes two prec ipitable pol\peptides with mo­
lecular weights of fñ 000 and 72 00() ι big 5 I5Ì of which 
the first comigrated with the 65 000 V/r pol\peptide (ppb5) 
synthesized in ULO ^Fig 6a b and c) RNA present in the 
20-22S region gives rise to a product of M r 69 000 ( b g 5 
10) which is not synthesized in t no (big 6d and e) Messen 
ge г RNA present in the MS region directs the svnthtsis of 
low molecular weight poh peptides of about Ì0 000 and 
15 000 \fr (Fig 5 h) In a control experiment immunopreci 
pitation was carried out on polypeptides synthesized bv the 
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endogenous reticulocyte svstem One polypeptide with a 
molecular weight of 32 000 was precipitated by the R-
Mul V antiserum which was present en variable amounts in 
all Immunopretipitales (Fig 5) Native or denatured R 
Mul V 60S RN A directed the sv nthesis of the same polypep-
tides (Wr 65 000 and 72 000) as were coded for by the 35S 
mRNA (16) 
DISCISSION 
After labeling in u t o of R MuLV infected cells with га 
dioactive ammo acids two newly synthesized virus specific 
polypeptides were identified (3 4) A precursor poly peptide 
of M
r
 65 000 was precipitated with a monospecific antise­
rum against p^O while antiserum against the glycoprotein 
gp69/71 revealed a second high molecular-weight polypep 
82k-
65k-
a b с d e 
FlC. 6 Comparison of in wfro and in i n o synthesized virus 
specific polypeptides bv co electгоріюгечч on a NaDod'iC^ poly 
acrylamide slab pel (a) Immunoprecipitale of polypeptides syn 
thesi/ed in atro by mRNA from Irnctmn I T (l· ig 4) ih) t o electro 
phoresis of the Immunopret ipit at es of pol> peptide s syntheM/ed in 
ι к a and by the mRNA J rom frac hon 1 tin ι if го (с) and ie) immu 
noprctfpitate of polypeptides svnihew/ed /i itin ià) co elettro 
phoresis of the immunoprccipitales of polypeptides svmhesi/ed in 
m η and bv mRNA from frac hon 1(1 in ι lírtj 
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Table 1. R-MuLV-specific polypeptides* synthesized 
in vitro 
Fraction used 
for 
translation 
125 X g supernatant 
20,000 X li pellet 
20,000 X g supernatant 
Free polyribosomes 
Membrane-bound 
polyribosomes 
H S m R N A 
20-22S mRNA 
35SmRNA 
35S viral RNA 
Major 
products 
(Λ/, χ 10 J) 
65, 76, 82 
6 5 , 7 6 , 8 2 
65 
65 
45,65 
10, 15, 30 
70 
65,72 
65,72 
Minor 
products 
<iW
r
 X 10') 
30-60 
30-60 
30-60 
* Polypeptides synthesized m i-iro: major, Mr 82,000 and 65,000; 
minor, ,Vf
r
 74.000, 70.000. 28,000. and 16,000. 
tide of M, 85,000 (4), probably identical with polypeptide 
pp82 described in this paper. Recently we were able to dem­
onstrate that pp82 is glycosylated, since [3H]glucosamine 
was incorporated into this polypeptide in vivo. A second 
polypeptide, glycosylated in vivo, with a molecular weight 
of approximately 72,000 was also detected (unpublished ob­
servations). 
In this study, we present evidence that crude cell-free ex­
tracts of R-MuLV infected cells are capable of directing the 
synthesis of virus-specific products in triiro (compare Table 
1). All cytoplasmic fractions synthesize pp65, which is also 
detectable in vivo. However, only the membrane-rich frac­
tions synthesize the glycoprotein pp82 and a polypeptide 
with a molecular weight of about 76,000. The latter poly­
peptide either may be not completely glycosylated or repre­
sents one of the first processing products of pp82 to the viral 
glycoprotein gp69/71. Addition of purified free and mem­
brane-bound polyribosomes to a cell-free system results in 
the synthesis of pp65, while no synthesis of the glycoprotein 
pp82 was detected Moreover, a polypeptide of M
r
 74,000 
was present in minor amounts in the immunoprecipitale of 
the in üifro incubations programmed with membrane-
bound polyribosomes. From Fig. 2b it can be seen that a 
polypeptide of identical molecular weight is also present as a 
faint band in the in vivo products. 
It has been reported that mRNA isolated from mem-
brane-bound polyribosomes of cells infected with vesicular 
stomatis virus synthesizes almost exclusively a polypeptide of 
Mr 63,000 in tHtTO, which is most probably a nonglycosylat-
ed form of the viral glycoprotein (17). Therefore, it might 
well be (hat the 74,000 M r polypeptide is a partly glycosy-
lated or nonglycosylated precursor of the viral glycoprotein. 
However, the results indicate that the ratio of the amounts 
of the 65,000 and 74,000 Mr polypeptides synthesized in 
vitro does not correspond to that of pp65 and pp82 in uit». 
The reason for this may be that either the protein moiety of 
the glycoprotein is less antigenic or that association with 
membranes is a prerequisite for its corred synthesis. That 
membranes are involved in the synthesis of virus-specific po-
lypeptides is evident from the more general observation that 
they are synthesized in relative high amounts in membrane-
rich fractions or by polyribosomes isolated from these frac-
tions. The earlier finding of our group (7) and others (12) 
that the relative content of virus-specific RNA, as measured 
by hybridization, is four to ten times less on free polyribo-
somes than on membrane-bound polyribosomes supports 
these results Analysis of the cell-free products coded for by 
R-MuLV specific mRNA, fractionated according to size, 
shows that at least 22S and 35S mRNA can direct the synthe-
sis of specific products. In addition, it appeared that native 
or denatured R-MuLV 60S RNA gives rise to the same high-
molecular-wcight polypeptides (pp65 and M, 72,000) as 35S 
mRNA isolated from polyribosomes. However, a polypep-
tide of XfT 70,000, which is synthesized after addition of 
20-22S mRNA to the cell-free system, is not delectable in 
the cell-free products directed by the viral RNA. It should 
be mentioned that we also found a number of minor bands 
in the high molecular weight range. At present, however, no 
evidence can be provided that these components are virus-
specific and correspond to the high molecular weight poly-
peptides reported by the group of Arlinghaus (18,! 19). Since 
more complete data are still lacking, we can only speculate 
about the nature of the products synthesized by the different 
mRNA fractions. In conclusion we may state that a polypep-
tide of M r 65,000, which is most probably the precursor of 
the lower-molecular-weight virion proteins, is synthesized 
by all fractions tested, except 14S and 20-22S mRNA. Fur-
ther characterizations with monospecific antisera and the 
availability of sufficient labeled material for tryptic peptide 
analysis will be necessary to show the authenticity of the 
products synthesized and their interrelationship. 
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ABSTRACT 
Poly-A tagged mRNA isolated from cells infected with 
Rauscher murine leukemia virus (R-MuLV) was fractionated accor-
ding to size by centrifugation in a denaturing sucrose gradient 
Each RNA fraction was injected into oocytes of Xenopus laevis 
and the virus-specific products were analyzed by immunoprecipi-
tation with polyvalent and monospecific antisera against R-MuLV 
polypeptides, followed by gel electrophoresis and scintillation 
autoradiography. It was shown that a 35S mRNA species directs 
the synthesis of a precursor of the internal or group-specific 
antigens of the virion (the gag-gene products). A 22S mRNA 
species directs the synthesis of two viral envelope polypep-
tides and their precursor polypeptide (env-gene products). The 
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results indicate that the Ç[a2- and env-related polypeptides of 
R-MuLV are synthesized uncoordmately and provide evidence for 
open and closed cistrons on the virus-specific mRNAs. 
INTRODUCTION 
The structural polypeptides of the murine leukemia viruses 
and, presumably, also those of all other RNA tumor viruses are 
subgene products derived from the primary translation products 
(precursor polypeptides) of the 232- and the env-gene (for a 
review see ref. 1). In our studies with JLS-V9 cells, infected 
with Rauscher murine leukemia virus (R-MuLV), we have identi-
fied a glycosylated polypeptide with a molecular weight of 
82,000 (env-pr82) as the precursor of two polypeptides of the 
viral envelope, gp69/71 and pl5(E) (2, 3). The polypeptide 
pl2(E) (designated pl2 in ref. 3) shares chymotryptic peptides 
with pl5(E); therefore pl2(E) is also derived from the env-
precursor polypeptide (our unpublished results and ref. 4). In 
the same studies (2, 3), we recognized two mutually related 
polypeptides with molecular weight of 75,000 (called gag-pr75) 
and 65,000 (called gag-pr65) as the precursors of the internal 
virion polypeptides p30 and pl5. Recently, Barbacid et_al. (5) 
demonstrated that the two other internal polypeptides, pl2 and 
plO, are also derived from the precursor of p30 and pl5. All 
these data are consistent with those reported by several other 
authors (4, 6-9). 
The existence of virus-specific mRNA species of different 
size classes (10) suggests that the synthesis of gag- and env-
precursor polypeptides is programmed by different mRNA's 
rather than by one polycistronic mRNA In agreement with this 
suggestion, it was shown that each virus-specific mRNA species 
mediated the synthesis of its own virus-specific product(s) in 
a rabbit reticulocyte cell free system (11). Of the two virus-
specific products formed in this system under the direction of 
the 35S mRNA fraction, one comgrated during sodium dodecyl 
sulfate (NaDodSO.) Polyacrylamide gel electrophoresis with the 
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gag-pr65 mentioned above, the other one with gag-pr72, a gag-
related polypeptide found in infected cells in the presence of 
the arginine analog canavanme (3). Similar products were 
found in various protein synthesizing systems programmed with 
RNA isolated from virions of RNA tumor viruses and identified 
as gag-related products (12-17). In none of these experiments 
with virion RNA, however, env-related products could be de-
tected . 
In addition to these results obtained with genome size 
virus-specific RNA (35S) (whether isolated from virions or as 
poly-A tagged mRNA from infected cells), two observations 
described in our previous study are notewortny ±. the 22S 
mRNA fraction isolated from cells infected with R-MuLV mediated 
the synthesis of a virus-specific 70,000 dalton polypeptide in 
a cell free system from reticulocytes (11), a polypeptide of 
the same size as the env-related product formed in infected 
cells when glycosylation is inhibited (9 and W.J.M. van de Ven, 
unpublished); ii. in an endogenous cell free system derived 
from cells infected with R-MuLV, free polyribosomes containing 
35S RNA as the main virus-specific mRNA produced gag-products 
only whereas the membrane-bound polyribosomes gave rise to 
both gag- and env-products and contained 22S virus-specific 
mRNA in addition to the 35S RNA (11). These results prompted 
us to localize the gag- and env-messenger activity among the 
heterologous virus-specific mRNA's. 
MATERIALS AND METHODS 
Ceìì5_ED^_YìEy§ 
The JLS-V9 cell line derived from bone marrow cells of 
Balb/c mice infected with ard producing R-MuLV was grown in 
Eagle's Dasal minimal essential medium supplemented with 10% 
calf serum (18). Labeling of JLS-V9 cells and preparation of 
cell lysates for immunoprecipitation was described elsewhere 
(3) . 
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Isolation_of_ро1угіЬозотез 
For the preparation of total polyribosomes, cells were 
treated and subsequently harvested as described before (11). 
After the cells (2-3 ml) were washed and swollen m hypotonic 
buffer (11), they were disrupted by ten strokes of a Dounce 
homogenizer (B pestle) in 12 ml of lysis buffer (50 mM Tns-HCl 
pH 7.4, 5 mM Mg(Ac) 2, 150 mM KAc, 1% (v/v) Nonidet Ρ 40, 0.5% 
(w/v) sodium deoxycholate,2 mM dithiothreitol and 100 pg/ml of 
an RNAase inhibitor from bovine eye-lens purified on DEAE 
cellulose - courtesy Dr. II. Bloemendal - ) . Nuclei and cell 
debris were removed by centnfugation for 4 min at 20,000 rpm 
in a Ti50 rotor (Beckmann). The supernatant was layered onto 
1.0 ml of 2 M sucrose in 20 mM Tns-HCl pH 7.4, 120 mM KAc, 
5 mM Mg(Ac)_ and 2 mM dithiothreitol, and polyribosomes were 
collected by centnf ugation for 2.5 h at 56,000 rpm in an SW 56 
rotor (Beckmann). 
ï52iSÈi°D_§D^_Ê£§£ti°D§£i20_2f_ШБ^ 
Isolation of poly-A tagged mRNA from total polyribosomes 
was performed by affinity chromatography on oligo(dT)-cellulose 
according to the procedure described before (11) with the fol­
lowing modifications: polyribosomes were incubated in buffer A 
for 10 min at 37 with 0.5 mg/mi pronase (RNAase-free) and 
NaDodSO. was omitted from column buffer B. mRNA was fractionated 4 
according to size by centnf ugation m a denaturing sucrose 
gradient as described in the legend to Tig. 1. 
Antisera 
Antisera raised against R-MuLV polypeptides and used for 
immunoprecipitation were described elsewhere (3). We observed 
no cross-reactivity among the monospecific antisera used in 
this study; a slight co-precipitation, however, of gp69/71, 
pl5(E) and pl2(E) was observed in immunoprecipitation reactions 
with anti-gp69/71 serum and anti-pl5(E),pl2(E) serum (designated 
anti-pl5(E),pl2 serum in ref. 3) due to an association of these 
viral envelope polypeptides (3). The anti-pl5(E),pl2(E) serum 
was raised against a mixture of pl5(F) and pl2(E) (3); moreover, 
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it is now known that pl5(E) and pl2(E) contain common amino 
acid sequences (our unpublished results and ref. 4). To rule 
out contamination with antibodies against reverse transcriptase, 
the antisera against R-MuLV, gp69/71 and p30 were tested for 
their capacity to inhibit the enzyme activity. The sera were 
found negative in this test (not shown) and, therefore, they 
will probably not immunoprecipitate reverse transcriptase. We 
thank Dr. M. Strand and Dr. J.T. August for a generous gift of 
anti-gp69/71 serum and anti-pl5 serum (19). 
RESULTS 
Yi£y§I§EË£iÊi£_!I'BNA-activitY_of _total_golY-A_ta22§â_RNA_f rom 
¿Dië£Îê^_£ËÎi§ 
Translation of 353 RNA isolated from R-MuLV in oocytes of 
Xenopus laevis has clearly demonstrated that this RNA prepara-
tion directs the synthesis of gag-pr65 only (15). In a pre-
liminary experiment with these oocytes we observed that a 
mixture of virus-specific mRNAs of different size classes 
(14S, 22S and 35S) isolated from JLS-V9 cells infected with 
R-MuLV mediated the synthesis of the gag-gene product gag-pr65 
as well as the env-gene products env-pr82, gp69/71 and pl5(E) 
(not shown). These observations indicate that at least two 
separate mRNA functions are present among the population of 
virus-specific mRNA's: a gag-specific and an env-specific mRNA. 
To identify both mRNA activities, we repeated this experiment 
with fractionated mRNA. 
Virus-s£ecific_rnRNA3activitY_of_fractionated_mRNA 
The fractionation of mRNA from infected cells was performed 
by sucrose gradient centnfugation in the presence of formamide 
as a denaturing agent. The sedimentation pattern of virus-
specific mRNA in the gradient was determined by hybridization 
with DNA complementary to R-MuLV-RNA (Fig. 1). The results are 
essentially the same as those reported before (11) and the 
virus-specific mRNA species of 14S, 22S and 35S can be dis-
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fraction number 
Fig. 1. Sucrose gradient centnfugation of virus-specific mRNAs from JLS-V9 
cells infected with Rauscher murine leukemia viras (R-MuLV). 
Poly-A tagged TIRNA (32 ijg) isolated as described in the nethod section was 
denaturated at 56 for ì min with 85% (v/v) foriramide in 20 mM Tns-HCl 
pH 7.4, ImM EDTA ana 0 5" (w/v) NaDodSO . After dilution with one volume 
of TNE (10 mM Tns-HCl pH 7.4, ICO mM NaCl and 1 mM EDTA) the RNA preoara-
tion was layered onto an isokinetic sucrose gradient m TNL· contamino 
50% (v/v) formamde (C = j% w/v, С = 34.4% w/v, V = 12.Э ml). The tubes 
t h ir 
were spun m an SB 283 rotor (IEC) for 13 h at 4° at 41,000 rpn. RNA from 
each fraction was precipitated with ethanol after addition of 10 \iq 28 S 
RNA from calf eye-lens nboscmes as carrier. The relative amount of virus-
specific RNA was determined η each fraction by hybridization with DNA 
complementary to R-MuLV-RNA (10*. 
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Fig. 2. Radioimmunoprecipitation analysis with anti-R-MuLV serum of the vi-
rus-specific products synthesized after injection of oocytes of Xenopus lae-
vis with poly-A tagged fractionated RNA from JLS-V9 cells infected with R-MuLV. 
RNA precipitated from each fraction of the gradient shown in Fig. 1 was dis-
solved in 10 lil H O ; 0.5 \il was injected into 20 oocytes (33). The oocytes 
were incubated for 20 h at 20 with 25 yCi of L-( S)methionine (sp. act. 
329 Ci/mmol, The Radiochemical Centre, Amersham, England) and, subsequently 
homogenized in 1.25 ml of immunoprecipitation buffer (3). The homogenate 
was cleared by centrifugation for 10 min at 220,000 χ g in a ТІ50 rotor 
(Beckmann).Virus-specific polypeptides from the supernatant were analysed 
by NaDodSO Polyacrylamide gel electrophoresis (11) and scintillation auto­
radiography (34) after indirect immunoprecipitation with anti-R-MuLV serum 
(2, 3). Slot numbers 6-19 correspond with the fraction numbers of the gra­
dient shown in Fig. 1. Slot 5; immunoprecipitation analysis with anti-R-MuLV 
serum of products synthesized after injection of 0.5 μ 1 H O into 20 oocytes. 
Slot 20: virus-specific polypeptides immunoprecipitated with anti-R-MuLV 
14 
serum from infected JLS-V9 cells pulse labeled for 15 min with a C-amino 
acid mixture (3). Slot 21: the same as slot 20 except that the radioactivity 
was chased for 8 h with an excess of unlabeled amino acids. 
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tinguished. Oocytes of Xenopus laevis were injected with RNA 
from each fraction and incubated with L-( S) methionine. The 
newly synthesized virus-spccific polypeptides were separated 
from the large excess of JLS-V9-specific polypeptides and endo-
genous oocyte polypeptides by immunoprecipitation with anti-R-
MuLV serum; this serum reacts with both gag- and env-related 
products (3). The immunoprecipitates were analyzed by NaDoaSO. 
Polyacrylamide gel electrophoresis and scintillation auto-
radiography (Fig. 2). Three polypeptides, two in the 50,000 
dalton region and one with a very high molecular weight, were 
precipitated in a control experiment with oocytes injected 
with water (Fig. 2, slot 5) as well as m all other analyses 
of injected oocytes (Fig. 2, slots 6-19). Apparently these 
polypeptides are not virus-specific and, therefore, ignored in 
further discussions. A number of virus-specific polypeptides 
can be recognized which comigrate with the R-MuLV-specific pre-
cursor polypeptides or with the mature virion polypeptides 
immunoprecipitated from infected cells (Fig. 2, slots 20 and 
21) . 
The autoradiogram of virus-specific translation products 
(Fig. 2) suggests a sharp separation of virus-specific mRNA, 
which is in contrast with the diffuse hybridization pattern 
depicted in figure 1. This may be explained by the non-linear 
blackening of the film during scintillation autoradiography 
and by the unknown representation of the viral RNA m the cDNA 
probe used for hybridization. 
ïëëDïiÎi£Ëïi2Q_2Î_tbe_2ag-rriRNA 
In agreement with our previous study in which we employed 
a cell free system from reticulocytes (11), the 35S mRNA 
species (Fig. 1, fraction no. 17 and 18) directed the synthesis 
of a 65,000 dalton polypeptide (Fig. 2, slots 17 and 18). Fig. 
3, I-K, shows that the 65,000 dalton polypeptide synthesised m 
oocytes can be precipitated with anti-p30 serum as well as with 
anti-pl5 serum but not with anti-gp69/71 serum. Incidentally, 
it should be noted here that the anti-gp69/71 serum precipitates 
a polypeptide (about 32,000 aalton) from oocytes injected either 
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pr82 • 
pr75— 
cjp69/71 * 
pr65 * 
p30 
p15(E) 
pIS pl2tF) 
Fig. 3. Identification with monospecific antisera of R-MuLV-specific pro­
ducts formed in oocytes of Xenopuq laevis after infection with nRNA frac­
tions from JLS-V9 cells infected with R-MuLV. 
Lysates of oocytes injected with 14 S mRNA (fraction no. 8; C-E), 22 S mRNA 
(fraction no. 11; F-H) and 35 S mRNA (fraction no 18, I-K) were analyzed 
with monospecific antisera. Technical details and fractior numbors of nRNA 
are as described in the legend to Fig. 2. As a control, similar analyses 
were performed with oocytes injected with H O (L-N) and as a reference the 
virus-specific polypeptides from infected cells are shown (A and B). 
A: Virus-specific polypeptides imirunourecipitated with arti-R-MuLV serum 
froir lysates of JLS-VQ cells infected with R-MuLV ana pulse labeled 
14 for 15 nin with C-airino acids. 
B- The same as A except that tho radioactivity was chased for 8 η with an 
excess of unlabeled amino acids. 
C-N. analyses with the following norospecific antisola· arti-рЗС seguir (С, 
Η, I and L), anti-pl5 serum (D, J and M), anti-gp69/71 serum (E, F, К 
and N), anti-plSÌE),pl2(E) serum (G). 
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with the various RNA fractions (Fig. 3, E, F and K) or with 
water (Fig. 3, L ) , indicating that this polypeptide is an endo-
genous oocyte product. We conclude that the 65,000 dalton poly-
peptide is similar if not identical to the gag-gene product 
gag-pr65 found in infected cells. This conclusion is consistent 
with a reverse experiment carried out by Mueller-Lantzsch (20) 
showing that the polyribosomes from cells infected with Moloney 
murine leukemia virus that were immunoprecipitated with anti-
p30 serum contained 35S RNA as the main virus-specific RNA 
species. 
ïaëDÈiÎi2âti2!}_2i_ihe_env-mRNA 
The 22S mRNA fraction (Fig. 1, fraction no. 11) mediates 
the synthesis of three polypeptides (Fig. 2, slot 11) which were 
identified as the env-gene products env-pr82, gp69/71 and 
pl5(E): they comigrated with the env-genc products found m in-
fected cells (Fig. 2, slots 20 and 21); the newly synthesized 
polypeptide comigrating with env-pr82 could be immunoprecipi-
tated with anti-gp69/71 serum and anti-pl5(E),pl2(E) serum, 
whereas those comigrating with gp69/71 and pl5(E) were immuno-
precipitated with the corresponding antisera (Fig. 3, F and G ) . 
Fig. 3, H, shows that the gag-specific anti-рЗО serum does not 
precipitate translation products of 22S mRNA. 
Immunoprecipitable translation_groducts_of_the_l4S_and_2 5S 
The 45,000 dalton polypeptide formed after iniection of 
14S RNA (Fig. 1, fraction no. 8) and immunoprecipitated with 
the anti-R-4uLV serun (Fig. 2, slot 8) was not precipitated 
with the monospecific anti-рЗО, anti-pl5 or anti-gp69/7l serum 
(Fig. 3, C-E). The nature of this product remains unknown; we 
cannot exclude that it is coded for by a host 14S mRNA. Finally, 
the 25S mRNA fraction (Fig. 1, fraction no. 13) directs the 
synthesis of a minor polypeptide (85,000 - 90,000 dalton) which 
was precipitated with anti-R-MuLV serum (Fig. 2, slot 13) but 
not with anti-рЗО or anti-gp69/71 serjm (not shown). This poly­
peptide could represent a host-specific product from JLS-V9 
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cells recognized by the anti-R-MuLV serum. Some unidentified 
polypeptides in the same rango of molecular weights were pre-
cipitated by the anti-R-MuLV serum when 25-28S mRNA from in-
fected cells was translated in the reticulocyte system (11). 
DISCUSSION 
2E2D_Ën^_£-'-2s2c^_ci§ïr2DS 2n_2!222£2ËlYi£ËÎ_î?5î!Î^ 
In 1974, Baltimore (21) proposed four "genetic elements" 
for the avian sarcoma viruses: gag (for the precursor polypep-
tide of the major core protein ), env (for the major envelope 
protein), pol (for the RNA dependent DNA polymerase) and one 
(for cell transformation). He discussed them "as if they were 
genes constituting most of the genome of an RNA tumor virus". 
Since that time, all known structural polypeptides of the 
murine leukemia viruses could be assigned to either the gag-
or the env-gene. These two genes, therefore, contain "subgenes", 
their primary translation products are precursor polypeptides 
that are cleaved into subgene products. 
Our present results show that each of the two genes, gag 
and env, is expressed by translation of its own specific mRNA. 
Such virus-specific mR^'As although functionally monocistronic 
may apparently overlap other genes and, therefore, be struc-
turally polycistronic. This is obvious for the genome size 35S 
gag-mRNA and probable for the 22S env-mRNA with its estimated 
molecular weight of 1.2 χ 10 (10). Similar conclusions follow 
from hybridisation data on oncorna-viral mRNAs of different 
size classes (10, 22-24). It is tempting to speculate that as 
a rule the open (i.e. translated) cistron would be the 5'-
terminal one. Otherwise a more complicated model would be re­
quired to explain the recognition of the open initiation site. 
For the gag-mRNA, this speculation would be in agreement with 
the probable gene order proposed for the avian RNA tumor 
viruses, 5'-дад-ро1-еп -опс-ро1у-А-3' (25). Assuming the same 
gene order,the env-mRNA would then have tne structure 5'-env-
onc-poly-A-3'. 
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M^ch less is known on the expression of pol and one ; the 
latter gene although recognized by mutants of murine sarcoma 
viruses (26) is still hypothetical in the case of leukemia 
viruses. If pol and one also have separate mRNA's the model 
predicts the following structures: 5'-pol-env-onc-poly-A-3' 
and 5'-onc-poly-A-3'. 
Very_lar2e_virus3Sgecific_golYpeptides 
The concept of separate mRNAs for the gag- and the env-
gene is in accordance with data on the uncoordinate expression 
of p30 and gp69/71 in cells harboring endogenous or defective 
RNA tumor viruses (27, 28). Likewise, some recent experiments 
in which the initiation of protein synthesis was influenced 
by high salt conditions (29) indicated that different sites 
for the initiation of protein synthesis are operative in the 
expression of the gag- and the env-gene of non-defective mouse 
mammary tumor virus. From these experiments and from the re­
sults described in this paper, we conclude that translation of 
the genome of RNA tumor viruses into one giant precursor poly­
peptide (250,000-300,000 dalton) as found for picorna viruses 
(30, 31) is unlikely or, at least, is not the principal path­
way for the synthesis of the virus-specific polypeptides. Some 
authors have noticed varying amounts of very large virus-
specific polypeptides (> 100,000 dalton) in infected cells 
(8, 9); their physiological significance, however, remains 
obscure. 
SYnthesis_of the_env-_and_2a2-]3roducts_in_the_oocYte_system 
In our previous study, a 70,000 dalton polypeptide was 
synthesized in a cell free system from reticulocytes after the 
addition of 22S mRNA isolated from cells infected with R-MuLV 
(11). Presumably, this polypeptide was the protein moiety of 
the glycosylated (2) env-pr82 because a 70,000 dalton polypep­
tide was also found in infected cells when glycosylation was 
inhibited with D-2-deoxyglucose or cytochalasm В (9; van de 
Ven, unpublished results). In oocytes of Xenopus laevis, how-
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ever, the env-products were apparently glycosylated since they 
comigrated with env-pr82 and gp69/71. The synthesis of env-pr82 
was also observed in an endogenous cell free system from in-
fected cells containing polyribosomes still attached to mem-
branes (11). It is generally accepted (32) that an enzyme sys-
tem associated with the endoplasmatic reticulum recognizes 
signals for the glycosylation of nascent polypeptides. This 
enzyme system is apparently well conserved during the evolu-
tion of the vertebrates. The same seems to be true for another 
post-translational activity, the cleavage of precursor polypep-
tides, since in addition to env-pr82 the subgene products 
gp69/71 and pl5(E) are also formed in the amphibian oocytes. 
The gag-related polypeptides were less well represented in 
oocytes although in some experiments, a partial processing 
of gag-pr65 was observed (not shown). In the experiments pre-
sented here, gag-pr65 was the sole gag-specific product formed 
in the oocytes; in infected cells, we had previously identified 
a polypeptide called gag-pr75 as the immediate precursor to 
gag-pr65 (3). 
It should be noted that the independent confirmation of 
our conclusions by tryptic peptide analysis has not been under-
taken because the low amount of radioactivity that was incor-
porated in virus-specific products (approx. 500 cpm/20 oocytes). 
!î!îS_ËESD5ia£i9D_2f_14 S_RNA_in_the_oocYte_ system 
In contrast to the 45,000 dalton polypeptide synthesized 
after injection of 14S mRNA from infected cells into oocytes, 
one 30,000 and two 15,000 dalton polypeptides were produced 
in a cell free system from reticulocytes in response to the 
same mRNA fraction (11). Although it is remarkable that all 
these products (precipitable with anti-R-4jLV serum) are formed 
under the direction of an mRNA fraction that coincides with a 
small peak in the hybridization profile obtained with R-MuLV-
cDNA (Fig. 1), the origin, the nature and the possible rela-
tionship between these polypeptides are not yet clear. 
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SUMMARY 
In this thesis, a study is presented on the gene-expres-
sion of Rauscher murine leukemia virus (R-MuLV). This virus 
belongs to the group of the widely spread RNA tumor viruses. 
The tumor inducing capacity of the RNA tumor viruses corres-
ponds with a typical replication cycle: upon infection their 
RNA genome is transcribed into DNA and, subsequently, inte-
grated into the chromosomal DNA of the host. The integrated 
virus-specific genes are expressed like cellular genes via 
transcription and translation. As an introduction to our 
experimental work, these and other features of the molecular 
biology of the RNA tumor viruses are discussed in chapter I, 
with special emphasis on the murine leukemia viruses. 
Although we have not performed experimental work on murine 
sarcoma viruses, recent progress in that area will encourage 
studies on the gene expression of these viruses that will 
resemble our studies with R-MuLV. At the moment, some general 
features of the murine sarcoma viruses can be recognized, but 
a general review of the relevant literature has not yet been 
published. Therefore, we decided to present such a review in 
this thesis (chapter II). 
The genome of the RNA tumor viruses usually harbors two 
genes (gag and env) for the synthesis of the structural poly-
peptides of the virion and one gene (pol) for the synthesis 
of the reverse transcriptase. A fourth gene for cell trans-
formation (one or sarc) is recognized by mutants of the 
sarcoma viruses but still hypothetical for the murine leukemia 
viruses and absent in the genome of the avian leukemia viruses. 
We studied the expression of the gag- and env-gene of R-MuLV 
in infected cells (chapters III, IV and V) and in prot;in 
synthesizing systems programmed with virus-specific mR^ JA 
(chapters VI and VII). The low amount of virus-specific pro-
ducts synthesized in these systems and in infected cells 
demands a very sensitive method to separate them from host 
products. For this purpose, we immunoprecipitated the virus-
specific polypeptides with antisera against polypeptides of 
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R-MuLV. The solubilized precipitates were analyzed by gel 
electrophoresis and autoradiography. 
Our results showed that the mature internal and envelope 
polypeptides of R-MuLV are subgene products of the gag- and 
env-gene, respectively, since they are derived by specific 
proteolytic cleavage from the primary translation products of 
these genes (precursor polypeptides). The proteolytic cleavage 
of the precursor polypeptides coincides with the assembly of 
viral cores and envelopes. Apparently, precursor polypeptides 
help to keep polypeptides together that are assembled together 
in newly formed virions. Translation of virus-specific mRNA 
isolated from infected cells indicated that the synthesis of 
the gag- and env-gene products is mediated by different but 
partially overlapping mRNA species: a 35 S mRNA (of genome 
length) for the gag-gene products and a 22 S mRNA for the 
env-gene products. Apparently, virus-specific mRNAs contain 
open cistrons accessible to the protein synthesizing machinery 
and closed cistrons that remain silent. Our results do not 
support the idea that the viral gen products are cleaved from 
one giant precursor polypeptide. 
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SAMENVATTING 
In dit proefschrift wordt een onderzoek beschreven naar 
de gen-expressie van het Rauscher leukemievirus (R-MuLV). Dit 
virus veroorzaakt leukemie by muizen en behoort tot de groep 
van de RNA tunorvirussen. Hun vermogen om tumoren te induceren 
gaat samen met een karakteristieke replicatie-cyclus: na in-
fectie wordt het virale RNA-genoom overgeschreven m DNA en 
vervolgens geïntegreerd m het chromosomale DNA van de gast-
heer. De geïntegreerde virus-specifleke genen worden evenals 
cellulaire genen tot expressie gebracht door transcriptie 
en translatie. Als inleiding tot het experimentele werk, dat 
in dit proefschrift beschreven is, worden enkele aspecten van 
de moleculaire biologie van de RNA tumorvirussen in hoofdstuk 
I toegelicht. Speciale aandacht wordt daarbij besteed aan de 
rnui^e- leukemievirus sen. 
Ofschoon we tot nu toe zelf geen onderzoek aan de muize-
sarcomavirussen verricht hebben, lijkt het zinvol het onderzoek 
aan de gen-expressie van R-MuLV uit te breiden met een verge-
lijkbare studie van de gen-expressie van de muize-sarcomavi-
russen. De literatuur over de sarcomavirussen is echter zeer 
onoverzichtelijk. Mede gezien het ontbreken van een algemeen 
overzicht over deze virussen, hebben we in hoofdstuk II ge-
tracht de eigenschappen van het muize-sarcomavirus genoom 
samen te vatten. 
Het genoom van de RNA tumorvirussen bestaat gewoonlijk 
uit twee genen (gag en env) voor de synthese van de structu-
rele virioneiwitten en één gen (pol) voor de synthese van 
het "reverse transcriptase'. De sarcomavirussen bevatten tevens 
een gen (one of sarc) voor celtransformatie. Men beschouwt 
dit gen nog als hypothetisch voor de muize-leukeirievirussen en 
het is afwezig in het genoom van de vogel leukemievirussen. 
De gen-expressie van het gag- en env-gen van R-MuLV werd be-
studeerd in geïnfecteerae cellen (hoofdstuk III, IV en V) en 
m eiwit synthetiserende systemen waaraan virus-specifiek mRNA 
was toegevoegd (hoofdstuk VI en VII). De geringe hoeveelheid 
virus-specifleke producten die in deze systemen en in geïn-
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fecteerde cellen gesynthetiseerd werden, vereiste de toepassing 
van een gevoelige methode om de virus-specifleke eiwitten te 
onderscheiden van de gastheer-eiwitten. Daartoe werden de 
virus-specifleke eiwitten met antisera tegen R-MuLV eiwitten 
neergeslagen en na oplossen van de immuunprecipitaten geana-
lyseerd met behulp van gel-electroforese en autoradiografie. 
Onze resultaten toonden aan dat de ri^pe interne en envelope 
eiwitten van R-MuLV subgen-producten zi^n van respectievelijk 
het gag- en env-gen: zij ontstaan door proteolytische splitsing 
van de primaire translatie-producten van deze genen (procursor-
polypeptiden). De proteolytische splitsing van de presursor-
polypeptiden en de assemblage van het kerntje en de envelope 
van het virion verloopt gelijktijdig. Wellicht vervullen de 
precursor-polypeptiden een belangrijke rol bij de assemblage 
van nieuwe virusdeeltjes doordat zij de virale eiwitten van 
het kerntje of de envelope tijdens dit proces bij elkaar 
houden. 
Translatie-experimenten met virus-specifiek mRNA geïso-
leerd uit geïnfecteerde cellen toonden aan dat de synthese van 
de gag- en env-gen-producten via verschillende maar gedeelte-
lijk overlappende mRNAs verloopt: de gag-gen-producten zijn 
afkomstig van een 35 S mRNA (van genoomlengte) terwijl een 
22 S mRNA molecule verantwoordelijk is voor de synthese van de 
env-gen-producten. Blijkbaar bevatten virus-specifleke mRNAs 
naast open vertaalbare cistronen ook gesloten onvertaalbare 
cistronen. Deze resultaten maken het onwaarschijnlijk dat de 
virale gen-producten splitsingsproducten zijn van één reuze-
precursor-polypeptide. 
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